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SUMMARY OF THESIS 
Anti-CD4 induced transplant tolerance in the rat: molecular and 
cellular mechanisms
M o n o c l o n a l  a n t ib o d ie s  (mAb) directed against the C l u s t e r  o f  D if f e r e n t ia t io n  
(CD)4 molecule, expressed on the surface of T helper cells, are a potentially important 
tool for manipulating the in vivo immune response to a tissue or organ allograft. In 
rodent models of organ transplantation, administration of anti-CD4 mAb prolongs 
allograft survival and may even induce permanent transplant tolerance. However, 
clinical application of anti-CD4 mAb requires a better understanding of the molecular 
and cellular mechanisms by which anti-CD4 mAb promotes graft survival. Early 
mechanisms may include CD4 T cell depletion and impairment of residual CD4 T cell 
function by blocking interaction of CD4 with C l a ss  II M a jo r  H is t o c o m p a t ib il it y  
(MHC) antigen or disrupting T cell signalling pathways.
The experiments described in this thesis were undertaken to provide new insight into 
how one particular anti-CD4 mAb, (M e d ic a l  R e s e a r c h  C o u n c il  (MRC) O x f o r d  
U n iv e r s it y  C e l l u l a r  Im m u n o l o g y  U n it  (OX)38), prolongs graft survival in a rat 
model of cardiac transplantation. Initial studies showed that 0X38, a mouse 
Im m u n o g l o b u l in  G (IgG)2a mAb, which binds to the membrane distal domain of rat 
CD4, when given as a brief treatment preoperatively, was able to prolong survival of 
fully allogeneic Lewis (RT11) heterotopic cardiac grafts in DA (R Tla) recipients 
(M ed ia n  G r a ft  S u r v iv a l  T im e  (MST) >100 days). Moreover, recipients bearing 
long-standing heart grafts developed specific tolerance to donor alloantigen since they 
accepted a second donor graft but rejected third party grafts.
Tolerance induction following 0X38 mAb was associated with partial depletion 
(approximately 50%) of peripheral CD4 T cells. Initially, residual CD4 T cells were 
shown on the basis of phenotype, to consist of predominantly R e c e n t  T h y m ic  
E m ig r a n t  (RTE) (CD4+ve CD45RClow Thy-lhlgh), but over several weeks, peripheral 
CD4 T cell numbers recovered to near normal levels. Non-rejecting heart grafts in 
0X38 mAb treated recipients were heavily infiltrated with mononuclear cells, 
including numerous CD4 cells. Analysis of intragraft cytokine m e s s e n g e r  
R ib o n u c l e ic  A c id  (mRNA) transcripts by R e v e r s e  T r a n s c r ip t a s e -P o l y m e r a s e  
C h a in  R e a c t io n  (RT-PCR) revealed the presence of both T h e l pe r  1 (Thl) and T 
h elper  2 (Th2) cytokine mRNA in non-rejecting grafts with a pattern similar to that 
seen during unmodified rejection. Moreover, measurement of alloantibody isotypes in 
0X38 mAb treated animals did not support the view that anti-CD4 induced tolerance 
was attributable to a dominant Th2 cytokine response.
Residual CD4 T cells, following anti-CD4 mAb treatment, remained only transiently (2 
days) coated with 0X38 mAb. Encounter of CD4 T cells with alloantigen whilst they 
were still coated with mAb was not essential for tolerance induction. A small ‘window 
of opportunity’ was detected (up to 4 days following mAb treatment) during which 
cardiac transplantation failed to trigger allograft rejection. CD4+ve T cells obtained 
from 0X38 mAb treated animals during this ‘window of opportunity’, showed altered 
tyrosine phosphorylation of a 36-38 K il o  D a l t o n  (kDa) protein on subsequent 
activation in vitro with immobilised anti-T C e l l  R e c e p t o r  (TCR) mAb when 
compared with anti-TCR activated, untreated CD4 T cells. The altered phosphorylation
pattern of in vivo 0X38 mAb treated cells was similar to that seen in naive CD4 T cells 
activated with anti-TCR after in vitro 0X38 treatment. In addition, the pattern of 
phosphorylation observed in anti-CD4 treated cells was similar to that previously 
described in anergic CD4 T cells, suggesting that 0X38 mAb treated cells may be 
functionally anergic.
An unexpected role for the thymus in 0X38 mAb induced transplantation tolerance 
was identified. Anti-CD4 mAb treated recipients which had undergone thymectomy 
several weeks prior to transplantation, rapidly rejected their heart grafts, despite 0X38 
therapy. This observation suggested that CD4 T cell depletion alone was not, in itself, 
sufficient to prevent allograft rejection and that a product from the thymus was 
necessary. A role for RTE in anti-CD4 mAb induced transplantation tolerance was 
indirectly explored in experiments using immunopurified single positive (CD4+ve 
apTCR+ve) thymocytes and L y m ph  N o d e  C el l s  (LNC). In reconstitution experiments 
using thymectomised anti-CD4 treated animals, adoptive transfer of purified single 
positive thymocytes on days 2 and 4 after heart grafting, restored the ability of 0X38 
mAb to prolong allograft survival in thymectomised animals. Furthermore, in anti- 
TCR proliferation assays, single positive thymocytes were less affected by in vitro 
0X38 mAb treatment than single positive LNC and were found to produce both Thl 
and Th2 cytokine mRNA. A possible interpretation of these findings, is that in this 
experimental model, RTE may be analogous to naive T h e l p e r  0 (ThO) T cells and may 
have an essential role in tolerance induction.
By adding to current understanding of the molecular and cellular mechanisms of anti- 
CD4 induced transplantation tolerance, the above observations may provide a more 
rational basis from which to further develop strategies for using anti-CD4 mAb in 
clinical transplantation.
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Background to Thesis
I. Introduction
Human organ transplantation has blossomed since the advent of immunosuppressive drug 
therapy in the 1960's. With the increased immunosuppressive efficacy of drugs such as 
Cyclosporin A, introduced in the late 1970's, graft survival figures have shown improvement 
in many clinical trials. However, current immunosuppressive regimes still remain 
immunolologically non-specific, are often toxic, and still do not assure 100% graft survival. 
Over the years, a number of isolated anecdotal case reports have highlighted patients enjoying 
long-term graft survival following transplantation, in the absence of continuing 
immunosuppressive drug therapy. The mechanism underlying this phenomena of graft 
tolerance is the focus of intense debate and current transplantation research. A better 
understanding of the cellular and humoral effector mechanisms involved in graft rejection and 
transplant tolerance should help in achieving the long-term goal of purposeful modulation of 
the immune response with therapies which have increased immunological specificity coupled 
with reduced toxicity and better graft survival.
The principle aim of the work described in this thesis was to study the mechanism of action of 
anti-CD4 mAb pre-treatment, in a rat transplantation model using fully mismatched cardiac 
allografts. The ability of an anti-CD4 mAb (0X38) to perturb CD4 T cell function, prevent 
graft rejection and promote transplant tolerance was investigated. The introduction chapter of 
the thesis concentrates on the molecular basis of CD4 T cell allorecognition, T cell activation, 
anti-CD4 treatment and tolerance induction. Other aspects o f effector cell mechanisms in the 
context of transplantation, notably the role of lymphokines, intracellular signalling pathways 
and the role of naive precursor cells in the induction of tolerance will be addressed in more 
detail in the later chapters.
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II. Abbreviations used in Thesis
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Chapter 1-1
1. Introduction
1.1 MAJOR HISTOCOMPATIBILITY ANTIGENS (MHC)
1.1.1 Introduction
Throughout recorded history, inquisitive ‘physicians’ have been documented as having 
attempted various kinds of tissue transplantation but, until the later half of this century, these 
attempts inevitably ended in graft failure. In the early 20th century, even after the technical 
difficulties of surgical anastomosis and infection control were, to a large extent, surmounted, 
solid organ transplantation still suffered the same outcome. However, it was only after the 
technical difficulties associated with transplantation were overcome that other mechanisms 
leading to allograft failure were recognised and then studied in more detail.
The suggestion that transplant rejection may be due to “inherited factors” was first 
documented by L Loeb [1,2] at the turn of the century following the work of the geneticists 
CC Little, EE Tyzzer and colleagues. They observed that tumours taken from a strain of 
Japanese waltzing mice were, when transplanted into other mice, accepted by mice of the 
same strain but rejected by F2 generations o f waltzing mice crossed with other mouse strains. 
With considerable foresight, Tyzzer later pointed out in a review of the subject, [3] that the 
“foreignness” or “incompatibility” of the tumour in these transplantation experiments was 
dependent on “the presence of a large number of independently inherited factors”. An 
understanding of the antigenic basis of tumour allograft rejection came over 20 years later 
following work by PA Gorer who demonstrated that tumour transplantation between mice 
strains was governed by antigens present on the donor’s tissues which were absent from the 
recipient’s. [4]. Gorer named this antigen, Antigen II, and showed that it was expressed on
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blood cells and that rejection in allotransplantation experiments was secondary to the 
recipient animals making isoagglutinating antibody responses to Antigen II [5], A decade 
later, GP Snell demonstrated that a complex of dominant genes existed which determined the 
transplantability of tumours and called these the “histocompatibility antigens” [6]. With this 
important discovery, the genetic locus in mice discovered by Gorer then became known as the 
H-2 complex, and further studies by these two men and their colleagues eventually set out the 
important framework on which the development of today’s understanding of transplantation 
histocompatibility antigens has been built.
We now know that each species of animal possesses a MHC that encodes for both Class I 
(recognised by CD8 cytotoxic T cells) and Class II (recognised by CD4 T helper cells) 
antigens. The MHC is composed of a large number of highly polymorphic loci making the 
total number of inheritable antigenic combinations very large. In addition to alloantigens 
encoded by the MHC, each species also has a number of MHC independent alloantigenic loci 
which generally incite weaker alloreactive responses and have been named, collectively, the 
minor histocompatibility antigens. The major and minor histocompatibility antigens together 
are responsible for the cell-mediated and/or humoral response individuals within a species 
mount against grafts from other individuals of the same species and this immunological 
response constitutes allograft rejection.
MHC gene products are integral cell-surface proteins which are found in all higher vertebrates 
and are encoded by a similar genetic region in each species [7,8]. The main function of MHC 
gene products is to act as ‘restriction’ elements for the recognition of foreign antigens. 
Specifically, MHC molecules on the surface of A n t ig e n  P r e se n t in g  C el l s  (APC) bind 
endogenously (Class I MHC) or exogenously (Class II MHC) derived peptide antigens, and 
present the peptides in the context of ‘self MHC’ to cells (T cells) in the immune system. It is
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the ability of MHC to couple with peptide antigen which allows the host’s immunological 
system almost limitless adaptation to a constantly changing environment occupied by 
mutating and novel pathogens [9], and gives the system specificity when recognising ‘normal’ 
self from ‘altered’ self following infection or oncogenic transformation.
1.1.2 Structure and function o f MHC
The T cells responsible for initiating rejection of MHC incompatible grafts recognise and 
respond to intact allogeneic MHC molecules expressed on the surface of donor APC. This 
type of recognition is called direct allorecognition, and it is the high precursor frequency of 
alloreactive T cells for direct recognition which accounts for the exceptional high potency of 
the alloimmune response [10,11,12]. Recipient T cells may also recognise and respond to 
allogeneic MHC molecules which, like nominal protein antigens, have been enzymatically 
degraded, processed and then presented by host APCs in the peptide-binding groove of self 
MHC; this type of recognition is known as indirect allorecognition [13,14,15]. The extent to 
which T cells recognising alloantigens presented by the indirect pathway contribute to graft 
rejection is not clear but is likely to be influenced by several variables such as prior 
sensitisation of the recipient, the type of tissue transplanted, the nature of the MHC disparity, 
and the type of immunosuppressive agent used [16,17,18,19,20]. As already noted, in 
allotransplantation, the most important MHC gene products are Class I and Class II antigens.
Class I MHC molecules are expressed constitutively on the surface of most nucleated cells 
[21]. They are 45 kDa integral membrane g l y c o pr o t e in s  (gp) which comprise a short 
C a r b o x y -te r m in u s  (C-terminus) hydrophilic segment situated in the cytoplasm, a 
hydrophobic section anchoring the protein in the cell membrane, and 3 extra cellular domains,
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( a l ,  a2, and a3). The a3 domain is relatively non-polymorphic and associates non- 
covalently with the non-glycosylated and non-polymorphic 12 kDa polypeptide P2 - 
microglobulin. This domain of Class I MHC also serves as the site of recognition by CD8 
molecules [22,23]. The a l  and a2 hypervariable domains of the Class I molecule form two 
a-helices floored by a p-pleated sheet and this structure constitutes the peptide groove of the 
molecule. Uniformly folded non-polymorphic segments limit the peptide groove at either 
end, imposing physical restrictions on the size of the peptide which can be accommodated; 
Class I MHC bound peptides are between 8 and 10 amino acids in length. The a3 domain 
and p2-microglobulin of Class I MHC both display a folding pattern typical of classical 
Im m u n o g l o b u l in  (Ig) domains.
Class II MHC molecules have a much more restricted tissue distribution than Class I MHC. 
They are expressed constitutively on dendritic cells, B cells and activated macrophages and 
given the presence of appropriate cytokines, can be up-regulated and expressed on most other 
nucleated cell types. Class II MHC molecules are formed by the non-covalent association of 
a 33-34 kDa a-chain and a 28-29 kDa p-chain. Like Class I molecules, each component 
chain has a short hydrophilic cytoplasmic C a r b o x y -T er m in a l  (C-terminal) sequence, a 
hydrophobic membrane anchor, a p-sheet and a-helix domain and a classic Ig domain. The 
two sheet and helix portions of each chain align face to face to form the peptide binding 
groove. In contrast to Class I MHC, the peptide-binding groove is ‘open ended’ and can 
accommodate peptides from 13 to 25 amino acids in length. A non-polymorphic loop in the 
P chain Ig like domain (loop 3 region of p2) is the site of interaction with the CD4 molecule 
[24,25].
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1.1.3 Peptide binding to MHC
The peptides found within the peptide-binding groove of Class I MHC molecules are usually 
endogenously derived from within the cell and result from proteolytic cleavage of self 
proteins or alternately from viral proteins. Conversely, MHC Class II peptides are derived 
mainly from the enzymatic breakdown of exogenous foreign protein and/or cell-surface 
proteins [26]. The fundamental difference between Class I and Class II MHC in peptide 
binding stems from the different route of intracellular trafficking for these proteins following 
their synthesis in the E n d o pl a sm ic  R e t ic u l u m  (ER) [27]. As newly synthesised Class I 
heavy chains are first folded and assembled, they associate non-covalently with p2- 
microglobulin in the ER [26,28]. Concomitantly, cytosolic self proteins are digested by 
multi-subunit proteosomes [29] into 8-10 amino acid peptides and gain access to the ER by 
membrane bound transporters [30]. In the ER the binding of heavy chain, p2 -microglobulin 
and peptide stabilises the complex and with the help of an 88 kDa chaperone protein [31,32], 
the tri-molecular complex is transported to the cell-surface, via the Golgi apparatus, where 
glycosylation occurs. On the other hand, by temporally occupying the peptide groove of 
Class II MHC molecules [33], the invariant chain prevents Class II MHC from binding 
peptide in the ER. The invariant chain by its chaperone effect, also prevents glycosylation of 
Class II MHC molecules at the Golgi [34]. Following synthesis, Class II MHC molecules 
proceed directly from the ER to an acidic membrane bound compartment known as the 
endosome [35,36]. In the endosome, foreign proteins and the invariant chain are degraded by 
a variety of proteases which allows peptide fragments ranging from 13 to 25 amino acids in 
length to associate with Class II MHC [37]. The variation in length of Class II bound 
peptides suggests that the Class II molecule itself may play an active role in antigen selection 
by protecting bound peptide from complete degradation [38] or allowing exposed ends of
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longer peptides to be truncated or trimmed [39]. Once peptides are bound to Class II, the 
resulting complex is stabilised and transported to the cell-surface.
1.2 THE CD4 MOLECULE
1.2.1 CD4 structure and function
The CD4 molecule is a 56 kDa transmembrane protein consisting of 4 Ig like extracellular 
domains, a transmembrane domain and an intracellular C-terminus cytoplasmic portion. The 
two A m in o -t e r m in a l  (N-terminal) domains of the CD4 molecule engage the p chain of 
Class II MHC by contact sites in the C o m pl e m e n t a r it y  D e t e r m in in g  R e g io n s  (CDR)l-like 
and CDR3-like loops of the first domain, and loop 6 of the second domain [40,41]. The 
CD4-Class II MHC p domain interaction may be species specific [42], but has not been 
shown to be affected by Class II polymorphisms. The hydrophilic cytoplasmic domain of 
CD4 associates non-covalently with the 56 K ilo  D a l t o n  L y m ph o c y t e -S pec ific  T y r o sin e  
K in a se  (p56lck) via cysteine-dependent interactions [43,44,45,46,47] and probably confers the 
co-receptor function of CD4 during TCR activation (see below).
1.2.2 CD4 as a co-receptor
By physically associating with the TCR during its interaction with the Class II MHC-Peptide 
complex [48], CD4 acts as a co-receptor and leads to a 10 fold increase in TCR mediated 
lymphocyte activation [49,50,51]. The association of p56lck with the cytoplasmic tail of CD4
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permits the initiation of tyrosine kinase signalling events following TCR-Peptide-Class II 
MHC-CD4 complex engagement and is likely to be responsible for the potentiation of T cell 
activation. The observation that some T cell clones are resistant to anti-CD4 antibody 
dependent inhibition [52,53,54] suggests that the dependency of T cells on CD4 co-receptor 
function may vary depending on the lineage or activation state of the T cell. In particular, 
primed T cells may be less susceptible to anti-CD4 treatment than naive (unprimed) T cells. 
This in vitro observation is consistent with the in vivo finding that the induction of 
transplantation tolerance using anti-CD4 mAb is easier to accomplish in naive animals as 
opposed to alloantigen primed recipients [55].
1.3 ANTIGEN RECOGNITION AND SIGNAL TRANSDUCTION
1.3.1 Structure and function o f  the T cell receptor (TCR)
The TCR is a member of the Ig superfamily and consists of a dimer of non-identical a  and p 
or of y and 8 chains. Each a  and p chain has a short cytoplasmic C-terminal segment, a 
hydrophobic membrane anchor, and a large extracellular domain which resembles the Ig light 
chain. Like the Ig variable region [56], the N-terminal portion of the a  and p chains has also 
evolved hypervariability in loops 2, 3, and 6 forming CDR1, CDR2, and CDR3. The TCR a  
chain CDR1 and CDR2 engage the a  helix of the a l  domain of Class I or Class II MHC [57], 
while the same CDRs on the TCR p chain engage the other a  helix (either a2  domain of 
Class I or the pi domain of Class II). This leaves the central region of the TCR a p  dimer, 
consisting of the two CDR3s, to bind peptide antigen presented in the groove of MHC
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[58,59], The structure of the TCR y8 receptor is probably analogous to that of the aP  TCR 
but this is yet to be confirmed.
Like the Immunoglobulin D receptor on the surface of B cells, the TCR confers T 
lymphocytes with the capacity for antigen specific recognition during an immune response. 
The TCR itself does not have intrinsic signal transduction capabilities and relies instead on its 
association with other cell-surface molecules during T cell triggering and generation of the 
intracellular signals needed for T cell activation. Recent evidence, utilising chimeric TCR 
receptors [60,61,62,63], and TCR mutants [64], has shown that at least 2 molecules which 
intimately associate with TCR, CD3 8 and C, chain subunits, have signal transducing moieties. 
As discussed below, the two molecules responsible for transducing signalling events have 
highly conserved common peptide sequences within their cytoplasmic domains and these 
have been termed A n t ig e n  R ec o g n it io n  A c t iv a t io n  M o tifs  (A R A M s).
1.3.2 CD3 complex
The invariant CD3 molecule comprises an y, 8, and two 8 subunits associated with a C, chain 
existing as either a homo (CQ, or heterodimer (£r| or £y); the homodimer form is the more 
commonly found configuration [65]. Like the aP  TCR complex, the invariant CD3 molecule 
is a transmembrane protein with an Ig like extracellular domain and a hydrophobic membrane 
anchor, but unlike the TCR, which has a short cytoplasmic domain, the CD3 y, 8, and 8 chains 
have large cytoplasmic domains. Each £ chain protein has a small extracellular domain, a 
hydrophobic transmembrane anchor, and a large cytoplasmic domain. As alluded to above, a 
small percentage of TCRs have been shown to be comprised of the invariant molecule 
associated with a heterodimer of C, coupled via an r| chain which is a product of an alternated
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splicing of the C-terminal end of the C, chain [66,67,68] or complexed via the y chain of the 
M u l t i-S u b u n it  H ig h  A ffin it y  Ig E  R e c e p t o r  (FcsRIy) [69]. The y subunit o f FcsRI has 
been shown to share sequence homology with both the cytoplasmic and transmembrane 
anchor region of the C, chain [70]. Receptors containing either Qr\ or Qf can contribute to
and alter TCR function [71,72].
As mentioned above, evidence suggesting the role for £ and s chain involvement in TCR 
mediated signal transduction arises mainly from studies of two separate murine T cell 
hybridoma variants which lack complete or functional ^ chains. The first variant, which lacks 
expression of £ chain [73] was found, when reconstituted using full length £ chain, to regain 
normal TCR expression and function. However, reconstitution using C, chain with truncation 
of the cytoplasmic domain resulted in impaired antigen and superantigen induced 
In t e r l e u k in  (IL)-2 production [74]. Further experiments using this hybridoma with 
chimeric receptors consisting of the extracellular domains of CD4, CD8 or In t e r l e u k in -2  
R e c e p t o r  A lph a  C h a in  (IL-2Ra) fused to the cytoplasmic portion of £ chain which could be 
expressed independently of the other TCR subunits, gave additional support for the role of £ 
chain in TCR signalling. Antibody mediated cross-linking of CD8/^ or IL-2Ra/<^ chimeras or 
gpl20 cross-linking of CD4/<  ^(as well as CD4/r| and CD4/FcsRIy) chimeras was sufficient to 
activate biochemical and cellular events indistinguishable from those mediated by the wild- 
type multi-subunit receptor complex itself [60,61,62].
The second murine T cell hybridoma studied in this context, was devoid of cytoplasmic £ 
chain but was found to produce IL-2 in response to antigen or superantigen [75]. 
Experiments using this mutant, with a chimeric receptor consisting of the extracellular and 
transmembrane portions of the IL-2Ra chain and the cytoplasmic domain of the CD3e
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subunit (IL-2Ra/e), showed that the CD3e cytoplasmic tail was responsible for the signalling 
events and IL-2 production observed [63].
1.3.3 Antigen recognition activation motifs (ARAMs)
ARAMs are highly conserved protein sequences which are present in a variety of 
haematopoietic cell antigen receptors as well as viral plasma membrane proteins. They are 
thought to represent the structural basis for many forms of signal transduction. For example, 
the cytoplasmic domains of £ chain, CD3e, TCR r\ and FceRIy subunits share a common 
motif consisting of two 7V-TYROSINE-X-X-LEUCINE-C paired sequences separated by six 
to eight amino acids [76]. This ARAM sequence appears in triplicate in the C, chain, as a 
doublet in TCR r\, and as a single copy in CD3s and FcsRiy subunits. Chimeric receptors 
with cytoplasmic tails encompassing as few as 17 amino acids containing the isolated ARAM 
have been shown to be capable of transducing intracellular signals sufficient for the activation 
of the P r o t e i n  T y r o s i n e  K i n a s e  (P T K )  pathway and subsequent TCR-mediated effector 
functions [77,64]. Alteration in either of the two tyrosine residues of the activation motif 
using the IL-2Ra/e chimera results in a marked reduction of receptor function [63]. Loss of 
receptor function was also observed when the C-terminal leucine residue was deleted [64]. 
Thus, it would appear from these studies that the ARAM sequences encoded in the 
cytoplasmic tail of antigen receptor-associated signal transducing molecules such as the ^ 
chain and CD3s subunit plays a critical role in coupling TCR ligation to the P T K  pathway 
and to other effector molecules within the intracellular signalling cascade.
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1.3.4 Protein tyrosine kinases (PTK) and phosphatases (PTPase) introduction
The events which follow TCR ligation with antigen and lead to cytokine production, gene 
upregulation and clonal proliferation have not been fully elucidated. However, some of the 
biochemical changes following TCR ligation with antigen, superantigen, or immobilised 
antibody, as well as the changes following CD3 ligation with immobilised antibody, which 
lead to IL-2 production have been the subject of recent studies. Biochemical and genetic 
evidence implicates at least 3 cytoplasmic PTKs in TCR signal transduction, namely Lck, 
Fyn, and 70 K ilo  D a l t o n  Z e ta  C h a in  A sso c ia t e d  P r o t e in  (ZAP-70). Additionally, the 
CD45 transmembrane P r o t e in  T y r o s in e  P h o s p h a t a s e  (PTPase) has been shown to be 
quintessential in this signalling cascade, suggesting perhaps that TCR activation represents an 
alteration in the dynamic equilibrium between phosphorylated and dephosphorylated 
substrates, as orchestrated by the PTKs and PTPases.
1.3.4.1 CD45 protein tyrosine phosphatase (PTPase)
The CD45 transmembrane protein (initially identified as the leukocyte common antigen) has 
been shown to have PTPase activity and is thought to be critically involved in regulating the 
activation of a number of haematopoietic cells through their antigen receptors. As its name 
implies, CD45 is abundantly expressed on the cell-surface of all leukocytes and exists in 
several different isoforms. All isoforms of CD45 have a membrane anchor and a large 
cytoplasmic domain which is highly conserved and contains a 300 amino acid tandem repeat 
which has considerable homology to the catalytic domain of the cytosolic phosphatase-IB 
[78,79]. Unlike the cytoplasmic tail, the extracellular domain exists in several structurally 
distinct isoforms [80]. This heterogeneity arises because of alternate splicing of the several
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exons which encode the extracellular domain together with variable expression of the 
translated product. The different isoforms of CD45 have been categorised by their molecular 
weights and/or antigenic properties and may correspond to functionally distinct cell types 
[81,82].
The distinct isoforms of CD45 differentially associate with the TCR and its coreceptors, 
giving weight to the idea that the different isoforms may have discrete activation properties. 
The high molecular weight isoform of CD45 has been found to move within the cell 
membrane independently of the TCR complex on naive human [83] and mouse [84] T cells, 
while experiments using cloned activated [84,85] or “memory like” [8 6 ] T cells expressing 
the low molecular weight isoform of CD45 have found that CD45 is associated with the CD4- 
TCR and/or the CD8 -TCR complex. Interestingly, McKnight et. al. [82] have shown that rat 
T cell clones expressing high and low molecular weight CD45 isoforms secrete different 
cytokine profiles and they suggested that these isoforms may represent distinct T effector cell 
populations in the rat, analogous to the murine Thl (which secrete mainly IL-2 and 
In t e r f e r o n -G a m m a  (INF-y)) and Th2 (which secrete IL-4, IL-5, IL-6 , and IL-10) cell types 
[87]. A problem with this interpretation is that the distribution of a particular CD45 isoform 
on the surface of the T cell does not necessarily equate to a maturational end-point of that 
particular cell. For example, naive RTE CD4+ve T cells in the rat express the low molecular 
weight isoform of CD45 but are the precursors of both the high and low molecular weight 
isoforms found on more mature T cells [8 8 ]. Moreover, reconstitution of adult 
thymectomised bone marrow irradiated T cell depleted rats with high molecular weight CD45 
CD4+ve T cells results in T cells which predominantly express the low molecular weight 
CD45 isoform. [89]. In addition, reconstitution of adult congenitally athymic nude rats with 
CD4 lymphocytes expressing one or other of the isoform of CD45 results, after CD4 T cell
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repopulation, in lymphocyte populations, many of which express the reciprocal CD45 isoform 
to that of the transferred cells [90]. These results suggest that the two CD4 T cell subsets may 
have a precursor-product relationship depending on the state of antigen experience, 
activation, maturation or stage of cell division.
The earliest demonstration that CD45 might be important in TCR mediated signal 
transduction came from antibody cross linking studies. Interestingly, antibody cross linking 
of CD45 alone during TCR stimulation was found to result in either potentiation or inhibition 
of T cell activation, depending on the type of the anti-CD45 antibody used, or the nature of 
the T cell line examined [91,92,93,94,95]. However, when TCR and CD45 are co-aggregated 
by the use of cross-linking anti-TCR and anti-CD45 antibodies, inhibition of T cell activation 
is consistently observed [96]. This inhibition may occur because some forms of cross linking 
effectively inhibit the antigen receptor oligomerisation necessary for normal TCR function 
[97] but is more likely to occur as a result of antibody mediated alteration of the signalling 
activity of CD45 phosphatase.
Studies using T cell clones deficient in CD45 expression give support to the concept that 
CD45 is a positive regulator of TCR signal function since such clones display abrogation of 
TCR signal transduction. For example, a murine T cell clone lacking cell-surface expression 
of CD45 has been shown to lack the ability to proliferate or produce cytokines in response to 
antigen or anti-TCR antibodies [98]. Interestingly, this same T cell clone was still able to 
respond to exogenous IL-2, indicating that CD45 is required for TCR mediated cellular 
function but is not involved in the downstream signalling events mediated through the IL-2 
receptor. Similarly, cytotoxic T cells which are deficient in CD45 expression are unable to 
lyse target cells and to produce cytokines [99].
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Studies using Jurkat and HPB-ALL CD45 negative mutant cell lines have shown that the 
mutant cells do not undergo tyrosine phosphorylation and phosphatidylinositol hydrolysis, 
and do not increase their influx of intracellular Ca2+ following TCR ligation [100,101]. 
These deficient biochemical responses are restored following transfection of the mutant T cell 
lines with CD45 [100,102,103]. Because induction of tyrosine phosphorylation is one of the 
earliest events following TCR engagement [104,105], the lack of TCR mediated tyrosine 
phosphorylation in CD45 deficient cell lines suggests that during normal TCR induced 
signalling, CD45 is involved at a very proximal site in the signal transduction cascade.
One possible role of CD45 is to regulate the state of tyrosine phosphorylation of the tyrosine 
kinases p56lck and 59 K ilo  D a l t o n  F yn  P r o t e in  T y r o s in e  K in a se  (p59^n), both of which 
associate non-covalently with the TCR complex. Initial analysis of tyrosine phosphorylation 
patterns using CD45 deficient cell lines revealed a slight increase in the tyrosine 
phosphorylation of the lymphocyte specific protein tyrosine kinase p56lck. Peptide mapping 
revealed that p56lck was hyper-phosphorylated on it’s C-terminal tyrosine505 residue, a known 
site of negative regulation for members of the Src family of PTKs [106,107,108,109]. 
Further experiments using CD45 deficient cell lines also showed Fyn to be hyper- 
phosphorylated on it’s C-terminal tyrosine528 residue, although to a lesser degree than Lck 
[108,109]. Additional credence for the idea that Lck and Fyn, but not Src are the specific in- 
vivo substrates of CD45, is provided by the observation that CD45 is unable to de- 
phosphorylate the C-terminal tyrosine residue of Src in-vivo [108]. Analysis of Lck [109] and 
Fyn [102,109] kinase activity from CD45 positive cells has revealed a two to three fold 
increase in their in-vitro enzymatic activity when compared to CD45 negative cells, although 
this was dependent on the substrate used and specific cell examined [102,106]. Finally, the
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addition of purified CD45 to either Lck or Fyn in-vitro results in de-phosphorylation at the C- 
terminal tyrosine residues and a concomitant increase in kinase activity [1 1 0 , 1 1 1 ].
1.3.4.2 50 kilo dalton Cskprotein tyrosine kinase (p50csk)
The data outlined above suggest that the TCR signalling defect observed in CD45 deficient 
cell lines may be due to lack of dephosphorylation and activation of Lck and Fyn due to 
persistence of phosphorylation at the negative regulatory C-terminal tyrosine residue. A 
protein kinase capable of phosphorylating the C-terminal tyrosine residues of Src [112], Lck 
[113], and Fyn [114] has been identified as Csk PTK. This PTK is structurally similar to the 
Src family of PTK containing a S rc  h o m o l o g y  2 (SH2), S rc  h o m o l o g y  3 (SH3) and a 
kinase domain. However it lacks a myristylation site, an auto-phosphorylation site and a 
negative regulatory C-terminal tyrosine residue [115]. A negative regulatory role for Csk in 
TCR mediated signalling is suggested by experiments showing that a three fold increase in 
expression of Csk in CD45 positive cells resulted in a decrease in tyrosine phosphoprotein 
induction and IL-2 production [116]. Evidence that p50csk has a regulatory role on p59fyn 
enhanced TCR signalling comes from experiments using Jurkat cells expressing a 
constitutively active form of p56lck, in which the regulatory tyrosine at position 505 was 
mutated to phenylalanine and thus could not be inhibited by phosphorylation. In these 
studies, over expression of p50csk leads to attenuation of TCR induced signalling by 
inactivation of p59fyn [117]. Thus, TCR mediated signalling appears to be balanced by events 
which allow the coupling of de-phosphorylation of upstream PTKs with their downstream 
substrates and uncoupling by phosphorylation of regulatory C terminal tyrosine on these 
PTKs by Csk like molecules.
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1.3.4.3 Src and Sykfamily o f  protein tyrosine kinases
Following TCR ligation with antigen or antibody, the PTK pathway is activated and results in 
a cascade of biochemical changes within the T cell, starting with tyrosine phosphorylation of 
a variety of cellular proteins [118,119]. One of the cellular proteins that undergoes rapid 
tyrosine phosphorylation is the yl I s o f o r m  o f  P h o s p h o l i p a s e  C (PLCyl) [120,121,122]. 
Tyrosine phosphorylation of PLCyl leads to an increase in its catalytic activity which in turn 
leads to hydrolysis of p h o s p h a t i d y l i n o s i t o l  4 ,5 - b ip h o s p f ia t e  (PIP2) to I n o s i t o l  1 ,4 ,5 -  
t r i p h o s p h a t e  (IP3) and D i a c y l g l y c e r o l  (DAG) [104,123]. These bi-products act as 
second messengers within the cell and induce further changes such as the mobilisation of 
i n t r a c e l l u l a r  C a 2+ i o n s  ([Ca2+]i) and the activation of P r o t e i n  K i n a s e  C (PKC) 
[124,125].
Three PTK enzymes p56lck , p59fyn, and ZAP-70, all situated in the cytoplasm, have been 
implicated in TCR mediated signalling. P56lck and p59^n are both members of the Src family 
of protein kinases which share six common features. These are as follows, (1) a N-terminal 
myristylated glycine at residue 2  which permits membrane localisation, (2 ) a unique ~80 
amino acid N-terminal region that may dictate specific associations of the kinase, (3) a -60  
amino acid SH3 domain involved in interacting with signalling molecules with prolene rich 
regions, (4) a -100 amino acid SH2 domain that can specifically mediate the recruitment of 
tyrosine phosphoproteins, (5) a C-terminal catalytic domain, (6 ) and a C-terminal regulatory 
tyrosine residue.
In contrast, ZAP-70 belongs to the Syk family of PTKs which contain two tandemly arranged 
SH2 domains and a C-terminal kinase domain; Syk PTKs are not myristylated, do not contain 
SH3 domains and do not contain negative regulatory tyrosine residues at their C-terminal (See 
Figure 1.1 below).
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Figure 1.1 Schematic diagram of the Src and Syk family of Protein Tyrosine Kinases.
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1.3.4.4 P56lck protein tyrosine kinase
P56lck is a 56 kDa lymphoid specific PTK which non-covalently associates with the 
cytoplasmic domain of CD4 and CD8  molecules via cysteine-dependent interactions 
[43,44,45,46,47]. As mentioned earlier, the extracellular domains of CD4 and CD8  bind to 
the non-polymorphic region of Class II and Class I MHC respectively and act to stabilise the 
interaction between the T cell and the APC [126,127]. As well as serving as TCR coreceptors 
through their stabilising functions, CD4 and CD8  molecules, through their association with 
p56lck, provide signal transducing co-receptor function with TCR [128]. Experiments using 
antibody to cross-link CD4 or CD8  to CD3 have found that such cross-linking results in 
enhanced TCR mediated signalling [129,130,131,132]. The significance of CD4 and p56Ick in 
T cell induced signalling has been underscored by studies using a CD4 dependent antigen 
specific murine T cell line which lacks endogenous CD4. Transfection of this cell line with 
CD4 molecules containing mutant cytoplasmic domains, incapable of associating with p56lck, 
results in a non-functional TCR, whereas transfection with normal CD4 molecules, capable of 
associating with p56lck, restores normal TCR mediated PTK signalling [51]. Similar 
experiments using T cells expressing mutant CD8  molecules, incapable of associating with 
p56lck, also results in a non-functional TCR, further highlighting the importance of p56lck in 
CD8  T cell signalling [133].
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Experiments using genetic mutants of p56lck have helped to dissect further the role of p56lck in 
normal T cell signalling. If the mutant Jurkat leukaemic T cell line J C a M 1 . 6 ,  which lacks a 
functional p56lck, is activated via the TCR, it fails to induce tyrosine phosphorylation of 
cellular proteins, to mobilise [ C a 2 + ] j ,  or to express cell-surface activation molecules [134]. 
Reconstitution of the mutant line with wild type murine p56,ck restores normal TCR mediated 
function. Similarly, another mutant, this time an IL-2 dependent cytotoxic T cell line which 
lacks p56lck, is incapable of cytolysis until reconstituted with normal p56lck [135]. 
Interestingly, both of the above mutants have comparable levels of p59^n activity, indicating 
that other members of the src family cannot compensate for isolated p56lck deficiencies and 
that p56lck must act proximally to p59^n and other PTKs in the normal TCR signal 
transduction cascade.
1.3.4.5 FYN protein tyrosine kinase
Fyn is a 59 kDa PTK which is found predominantly in cells of neuronal and haematopoietic 
origin [136,137]. These two tissues display distinct isoforms of Fyn which differ as a result 
of alternate splicing of the several exons which encode the protein [138]. The association of 
Fyn with TCR £ chain was first demonstrated in co-immunoprecipitation experiments [139]. 
The interaction of Fyn with the cytoplasmic domain of ^  chain appears to be mediated by the 
first 10 amino acids within the unique region of Fyn and at least two regions of the 
cytoplasmic domain of £ each of which encompasses at least one ARAM sequence. The 
evidence for this comes from studies using £ chain with only one ARAM sequence capable of 
interacting with Fyn, which revealed that the two molecules failed to associate [140]. Genetic 
evidence supporting the role of Fyn in TCR mediated signalling comes from a series of
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transgenic experiments. Over-expression of wild type Fyn in the thymus of transgenic mice 
results in thymocytes that show increased levels of tyrosine phosphorylated proteins and are 
hyper-responsive with respect to TCR mediated PTK activity, when compared to thymocytes 
obtained from normal litter mates [141]. In contrast, expression of a mutant Fyn molecule 
with an inactive kinase catalytic site results in abrogation of TCR mediated proliferation and 
mobilisation of [C a 2+]j as compared to normal cells. Mice that lack Fyn as a result of 
homologous recombination have grossly normal thymocyte subsets and normal TCR Vp 
repertoires. Interestingly, these Fyn deficient mice have marked signalling abnormalities in 
the single positive thymocyte population [142,143] but have essentially normal peripheral T 
cell signalling [143], suggesting that Fyn may play a role in the later stages of thymocyte 
development and may not be required for TCR mediated proliferation in peripheral T cells.
1.3.4.6 ZAP-70 protein tyrosine kinase
Zeta-chain associated protein (ZAP-70) is a member of the Syk family of PTKs [144]. ZAP- 
70 is a 70 kDa tyrosine phosphoprotein which, as its name implies, was initially found to be 
associated with the £ chain of TCR following receptor stimulation [69]. More recently 
however, it has been shown to associate also with CD3e subunit in stimulated cells [145,146]. 
The association of ZAP-70 with the £, chain requires activation of the TCR and tyrosine 
phosphorylation of the CD3<  ^chain and ZAP-70 by p56lck. In experiments using a Jurkat cell 
line deficient in Lck, neither ZAP-70 nor £ chain were found to phosphorylate or to associate 
together when the TCR was stimulated by immobilised cross-linking anti-TCR antibodies 
[147]. In studies using chimeric receptors expressing 2 forms of £ chain, one expressed as 
part of the normal TCR and the other expressed with CD8 , stimulation of TCR results in
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association of ZAP-70 with TCR/<  ^ but not with CD8 /(^ . Conversely, stimulation of CD8  
results in association of ZAP-70 with CD8 /<^  but not TCR/^ [148]. The association of ZAP- 
70 with the £ chain has been shown to be mediated through phosphorylation of ZAP-70 SH2 
domains and £ ARAM sequences [147]. Not surprisingly, the association of ZAP-70 with 
CD3s is dependent on CD3e tyrosine phosphorylation [146,149] and is probably mediated 
through the CD3s ARAM sequence [150]. Exactly how ZAP-70 is involved in the TCR 
signalling cascade is not known. Studies using kinase inactive ZAP-70 constructs have 
reported normal phosphorylation of ZAP-70 and C, chain, with normal association of the two 
molecules but with a marked decrease in cellular tyrosine phosphorylated proteins [147]. 
Thus, it appears that ZAP-70 specifically couples Lck mediated signalling to the TCR multi­
subunit complex and is probably important in mediating signalling to downstream effector 
molecules. (See Figure 1.2 Below)
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Figure 1.2 Schematic representation of the initiating events in TCR activation. 
Adapted from Chan et. al. A nnu Rev Immunol 1994.12:555-92.
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Figure 1.2 characterises the interaction of APC with CD4 T cells. Specifically, the presentation of peptide 
antigen (Ag) with MHC Class II to the aPTCR with subsequent activation of the intracellular signalling 
pathways and generation of active intracellular substrates is illustrated. The association of CD3 with 
TCR, the co-receptor function of the CD4 molecule, and the de-phosphorylation of p56l k and subsequent 
phosphorylation of tyrosine residues on the c and chains of CD3 and ZAP-70 are also depicted.
1.4 ANTI-CD4 TREATMENT AND TOLERANCE
1.4.1 Antibody induced tolerance introduction
Studies using monoclonal antibodies directed against T cell antigens have been shown to 
inhibit T cell proliferation in vitro  [151.152.153,154,155] and to be capable o f  
immunosuppression in vivo by inhibiting the development o f  autoimmune disease 
[156,157,158,159] and by increasing allograft survival [160,161,162,163] in animal models. 
In various rodent transplantation models using vascularised cardiac allografts, different 
systemic anti-CD4 mAb treatment protocols have been employed, some o f  which lead to 
profound depletion o f  CD4 T cells and others which block CD4 T cell function, partially or
Chapter 1-22
completely spare CD4 T cell numbers. Studies using anti-CD4 in experimental transplant 
models have reported, that anti-CD4 treated animals not only enjoy increased survival of their 
cardiac allografts, compared to control animals, but additionally may develop allospecific 
tolerance when rechallenged with secondary grafts of the same strain as the original donor 
[160,162,164,165,166,167]. The mechanism of action of anti-CD4 mAb treatment in the 
development of transplantation tolerance is however, far from clear.
The first studies in which tolerance to a cardiac allograft was induced using anti-CD4 mAb, 
used anti-CD4 protocols in mice [165] or rats [162] which caused profound and long lasting 
depletion of CD4 T cell, thereby exposed the treated animals to long periods of non-specific 
immunosuppression. Although very useful in establishing models of tolerance, the almost- 
complete depletion of the CD4+ve T cell fraction, made it very difficult to determine how the 
other cell sub-populations and the re-emerging CD4+ve T cells each contributed to the 
transplant tolerance which ensued. More recent protocols of anti-CD4 treatment [164,166] 
have employed short courses of non-depleting or partially depleting anti-CD4 antibodies 
which allow for consistent monitoring of effector cell function without the need for 
experimental calculation and assumption due to the unnatural shifting of cell subsets as a 
result of depletion.
The principle mechanisms which have been proposed to explain peripheral T cell tolerance 
are clonal deletion [168,169,170], immune deviation or polarisation 
[171,172,173,174,175,176], T cell inhibition [177,178,179] and T cell anergy [180,181,182]. 
As indicated above, each individual mechanism probably represents a single facet of the 
multifaceted immune system, which when experimentally exploited, gives a false impression 
of uniqueness. It is the authors belief that transplantation tolerance using fully disparate 
MHC allografts is likely to be non-exclusive and will therefore incorporate some or all of the
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above mechanisms, perhaps working together in an active or even synergistic fashion. A 
unifying explanation for transplantation tolerance must incorporate all of the pieces of the 
‘immunological jig-saw puzzle’, explain the variation observed between experimental 
systems and hopefully predict the immune response when appropriately challenged. The 
potential mechanisms which are responsible for peripheral T cell tolerance are reviewed 
below.
1.4.2 Clonal deletion
Clonal depletion of potentially auto-reactive developing T cells within the thymus is the 
principal mechanism responsible in establishing central tolerance to potential auto-antigens. 
Clonal deletion of peripheral mature T cells, may in principle, also be partly responsible in 
the induction of tolerance following anti-CD4 mAb. In the context of anti-CD4 treatment and 
tolerance, it is believed that antibody treated cells which contact antigen, perhaps particularly 
those with the highest avidity for antigen [183], may receive inappropriate or inadequate 
intracellular signals which ultimately lead to programmed cell death or apoptosis. 
Additionally, one important element of T cell depletion by anti-CD4 antibodies appears to be 
secondary to cross-linking of the CD4 molecules on the cell-surface in the absence of TCR 
engagement and is associated with the up-regulation of Fas antigen [184,185]. The Fas 
antigen is usually only expressed on activated T cells and it is through the binding of Fas to 
its ligand (FasL) that immunoregulation through apoptosis is thought to occur. In this 
context, it is notable that mice which are deficient in either Fas or FasL expression tend to 
develop lymphoproliferative or autoimmune diseases [186].
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Several models of peripheral tolerance secondary to clonal deletion have recently been 
described. Examples include the following. Mice given bacterial superantigens display an 
early and massive T cell proliferative response followed by clonal deletion through apoptosis 
of most, but not all, of their antigen reacting T cells. When the remaining T cell pool of such 
animals are subsequently re-challenged with superantigen, the animals display classical 
immunological tolerance [187]. Another elegant example of peripheral tolerance based on 
clonal elimination was provided by Scully et. al. [188] who transplanted the thymus from a 
B10.BR mouse under the kidney capsule of adult thymectomised CBA/Ca mice which had 
been depleted of CD4+ve and CD8 +ve T cells using depleting anti-CD4 and CD8  antibodies. 
Once these animals had reconstituted their T cell pool in the presence of the new thymus, they 
were challenged with B10.BR skin grafts and were shown to be tolerant to them. However, 
the transplant tolerance observed could be broken if the transplanted mice were reconstituted 
with naive CBA/Ca T cells. Interestingly, reconstitution of unmodified naive CBA/Ca mice 
with tolerant T cells did not confer tolerance to the recipient mice. Likewise, reconstitution 
of CBA/Ca litter mates, which had been T cell depleted and thymectomised, with tolerant T 
cells did not restore graft rejection, so long as donor antigen was present in the system before 
cell transfer. This indicates that the missing cellular component in this experimental model 
was allospecific helper and/or effector cells. However, it is important to emphasise that 
clonal deletion of alloreactive T cells on its own is not the only mechanism, or indeed the 
major mechanism of tolerance induction, since, in many models of transplantation tolerance 
induced by monoclonal antibodies, restoration of allograft rejection is not achieved when 
naive immunocompetent T cells are given to the tolerant recipients [179,181,189].
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1.4.3 Immune deviation/polarisation
There is considerable evidence in the rat which suggests that the maintenance o f peripheral 
tolerance to self antigens in normal animals is mediated by regulatory CD4+ve T cells, via the 
production of cytokines such as IL-4 and IL-10 [190]. Also, Hutchings et. al. [191] found an 
increase of CD4+ve T cells producing these cytokines around the islets of Langerhans of NOD 
mice made resistant to diabetes by the administration of non-depleting anti-CD4 antibodies. 
A similar regulatory mechanism for transplantation tolerance provides an attractive 
explanation for anti-CD4 induced allograft survival. As mentioned above, CD4+ve T cells are 
a heterogeneous population and can be divided into two functionally distinct subsets, Thl and 
Th2, based, to a large extent, on their different cytokine repertoires. Thl cells, through 
release of IL-2, T u m o u r  N ec r o sis  F a c t o r -a l p h a  (TNF-a) and INF-y, are responsible for 
mediating cellular effector responses such as cytotoxicity reactions, delayed type 
hypersensitivity, and B cell help for the production of complement-fixing antibodies. In 
contrast, Th2 cells produce IL-4, IL-5, IL- 6  which provide B cell help for production of 
neutralising IgGl or anti-parasitic IgE antibodies and IL-10 which down regulates Thl cells. 
Thl and Th2 effector cells arise from a T h e l pe r  c o m m o n  p r e c u r s o r  c e l l  (Thp), and 
antigen inexperienced immature CD4+ve T cells are thought to correspond to ThO clones 
which simultaneously secrete low levels of both Thl and Th2 type cytokines. Because 
functionally distinct Thl and Th2 subsets are mutually antagonistic and because each T cell 
subset has an autocrine response to its own pattern of cytokine, as an immune response begins 
to polarise, immature T cells are thought to be recruited towards the dominant response.
Normally a balance exists in vivo between Thl and Th2 responses. Transplant rejection is 
generally associated with a strong Thl immune response. Those advocating immune 
deviation as an explanation for transplantation tolerance, suggest that in the course of
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tolerance induction, the antagonistic Th2 sub-population predominates and is responsible for 
inducing and/or maintaining the tolerant state. Several groups have shown preferential 
expression of IL-4 and/or IL-10 during the induction of tolerance to renal or cardiac allografts 
in rodents using tolerogenic strategies which include using low dose anti-CD4 antibody 
treatment [172,192]. Similarly, some investigators have been able to prevent Class II 
disparate skin graft rejection in mice by the transfer of thymocytes expressing Th2 cytokine 
repertoires [193]. However, it should be emphasised that there are a number of reports of 
tolerance induction occurring in the absence of an obvious Th2 cytokine response. For 
example, mice given rat anti-CD4 mAb to induce tolerance to skin allografts have also been 
shown to be tolerant of the rat anti-CD4 antibody itself; failure to generate a humoral 
response directed against the rat protein suggests that there is not necessarily a global bias 
towards a Th2 response in this model [189]. Also, in a similar skin allograft system but using 
both anti-CD4 and CD8  antibodies, mice which were made tolerant of Kb Class I MHC failed 
to make anti-Kb antibodies. However, such antibodies were found in high titres in untreated 
litter mates allowed to reject their grafts [194], More recently, studies using IL-4 K n o c k o u t  
(KO) mice [195] or neutralising anti-IL-10 antibody [196], have shown that mice can be 
made tolerant to oral ovalbumin in the apparent absence of any IL-4 and/or any detectable 
Th2 cytokine response. From these studies, it is clear that although Thl to Th2 immune 
deviation is an attractive explanation for peripheral tolerance in some experimental models, it 
cannot be invoked uniformly to account for anti-CD4 induced tolerance and therefore other 
potential mechanisms to explain tolerance must also be considered.
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1.4.4 T cell inhibition, suppression and/or immunoregulation
T cell inhibition as a mechanism of immunological tolerance was a popular concept in the 
early 1970s and was originally called suppression. With the failure to clearly define a distinct 
population of ‘suppressor’ T cells, the concept fell out of favour. However, in the last few 
years the concept has been revived because several groups have been able to demonstrate, by 
adoptive transfer, the presence of cells which are capable of modulating the immune response 
in vivo.
One of the best examples of suppression using mAb therapy in a transplantation model is that 
reported by Qin et. al. In 1993 [179]. They used non-depleting anti-CD4 and anti-CD8  
antibodies to induce tolerance to B10.BR multiple minor skin allografts in adult 
thymectomised CBA FI hybrid recipients, obtained after crossing normal CBA mice with 
CBA mice expressing the human CD2 transgene (hCD2+ve). After establishing tolerance, the 
authors tested for T cell suppression by transferring 5 x 107 normal spleen cells from naive 
hCD2've CBA mice back into the tolerant graft recipients. They first showed that if they 
removed the tolerant cells from the recipients at the time of spleen cell transfer, by using anti­
human CD2 antibody, then the skin grafts were be promptly rejected by the transferred 
immunocompetent cells. However, if they waited for at least two weeks after cell transfer 
before deleting the tolerant cells, then the original, and even a second B10.BR skin graft, was 
not rejected, despite the absence of any residual hCD2+ve tolerant cells. This elegant 
experiment demonstrates that the original population of lymphocytes in the tolerant animal 
were capable not only of inhibiting naive T cells, but also that, in time, the naive T cell 
population had itself become tolerant. In describing this phenomena, Waldmann’s group 
coined the term “infectious tolerance”, however, credit must go to Eardley and Gershon who 
first described infectious tolerance in 1975. Eardley and Gershon showed that tolerant cells
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could make naive cells tolerant when mixed together and called this concept “feedback 
suppression” [197]. Waldmann and collegues also showed, using their experimental model, 
that a T cell mixture taken from tolerant and naive animals could be transferred back into new 
secondary recipients who would then also display tolerance to the original antigen; moreover, 
this process could be repeated several times over, transferring transplantation tolerance from 
one new naive recipient to another. There are of course, still several important questions 
which remain unanswered in this experimental model. For example, is infectious tolerance 
one phenomena (i.e. inhibition/suppression) or does infectious tolerance also rely on multiple 
mechanisms? What type of cells are responsible for causing suppression? Do the 
“suppressor cells” actively produce cytokines which suppress other effector cells or are they 
inactive and unresponsive, and merely inhibit by interfering with a developing immune 
response by virtue of their numbers or their ability to consume important cytokines? To 
address these questions further, additional mechanisms must be considered such as T cell 
anergy.
1.4.5 Anergy
The term T cell anergy was coined by Schwartz and colleagues [198]and can be defined as the 
absence of a normal cellular response to antigen (proliferation and production of IL-2 and 
other cytokines) despite the continued presence of the cell capable of recognising the antigen 
(T helper/effector cell) and the antigen itself. Many explanations for T cell anergy have been 
proposed but it is now generally accepted that anergy in CD4+ve T cells is induced when these 
cells encounter antigen and fail to proliferate normally due to the absence of appropriate 
costimulation or cytokines. Anergy is more easily demonstrated within the Thl cell subset
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and it has been suggested that Thl cells are more susceptible than Th2 cells to the induction 
of non-responsiveness. As discussed above, the absence of an appreciable Th2 response in 
many models of Thl transplantation tolerance, suggests that Th2 cells can also be anergised, 
although direct testing for Th2 anergy in these models was not performed. Interestingly 
however, Yssel et. al. [199] showed that it is possible to induce anergy in human allergen 
specific Th2 cells by activating the cells in the absence of professional APC. The induction 
of anergy in this system was accompanied by phenotypic modulation of the cells and altered 
cytokine production upon activation.
As implied above, there has been a plethora of reports describing anergy involving Thl 
responses which date back to the mid 1980s. Jenkins & Schwartz [198] showed that T cell 
clones when stimulated with antigenic peptides bound to Class II MHC on metabolically 
inactive or non-professional APC (lacking normal costimulatory accessory surface molecules) 
did not proliferate and became unresponsive when subsequently re-challenged with antigen 
presented by professional APC. They later showed [200] that murine Thl clones stimulated 
with antigen presented by normal APC in the presence of anti-IL-2 and anti-IL-2 receptor (IL- 
2R) antibodies also became anergic. From these studies, they suggested that the lack of 
accessory molecules for costimulation is not the limiting step in the induction of anergy. 
Instead, they argued that lack of normal IL-2 production and cellular proliferation resulting 
from incomplete costimulatory activity was the critical event.
Quill et. al. [201] showed that MHC Class I restricted T-hybridoma cells could also be 
rendered anergic by using a system of antigen presentation in planar lipid membranes with or 
without Class I molecules. They showed that the T cells became unresponsive if antigen was 
presented by Class I without other accessory molecules, but remained responsive if antigen 
was presented in the lipid membranes directly without Class I. This finding suggests that
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induction of anergy, through lack of accessory costimulation, requires the engagement of the 
T cell receptor in the context of normal self MHC-CD8/CD4 complex.
T cell anergy was implicated in transplantation tolerance by Alters et. al. [182]. This group 
transplanted mouse pancreatic islets of Langerhans from A/J(IEK+ve) donors into 
streptozotocin induced diabetic C57B1/6 (IEK've) recipients under the cover of depleting anti- 
CD4 antibody treatment. They found that the recipients became tolerant of their IE disparate 
grafts, as measured by normoglycaemia for greater than 200 days. Murine TCR Vp gene 
segments which encode reactivity with Class II MHC IE antigen are found in Vp5, Vpl 1 and 
Vpl7 subsets and animals which express IE antigen generate self tolerance by depleting the 
majority of their Vp 5, 11, and 17 T cells from the periphery [202,203,204,205]. Alters et. al. 
found no evidence of Vp 5, 11, or 17 depletion in their model of anti-CD4 induced 
transplantation tolerance. Furthermore, after isolating LNCs with specific Vp subsets from 
their tolerant mice, they showed that the V p ll+ve subset proliferated poorly in response to 
immobilised anti-Vpll antibody, and that proliferation could be partially restored by adding 
exogenous recombinant IL-2. In a combination of mixing experiments using tolerant 
CD4+veV p ll+ve or CD8 +veVpl l +ve cells, the authors could not suppress naive C57B1/6 LNC 
proliferation in response to anti-Vpll antibody. These data suggest that in this particular 
model, anergy rather than clonal deletion or inhibition/suppression was responsible for 
tolerance induction. The presence of anergic cells in anti-CD4 mAb treated recipients bearing 
long-term surviving allografts has also been reported by other groups [181,189], providing 
further support for the hypothesis that anergy of peripheral CD4 T cells may be an important 
mechanism for maintaining the tolerant state.
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1.4.6 Infectious anergy
Interestingly, in all the systems discussed above, tolerance once established appears to be very 
robust and to dominate any further tendency for the immune system to respond to a new 
challenge with the same antigen. In a recent review, Cobbold et. al. [206] have introduced a 
new term, “infectious anergy”, which in part describes tolerance as being both inhibition and 
anergy working together. They have suggested [207,208] that anergic T cells might compete 
with immunocompetent T cells and, by depriving the immunocompetent cells of important 
paracrine proliferative cytokines, cause them to default to the anergic state. There is good in 
vitro data using mixing experiments with anergic and immunocompetent naive cells which 
suggests that competition between these cells for the surface of APC can induce anergy in the 
immunocompetent fraction [209]. It seems likely that competition for the APC cell-surface 
molecules required for costimulation, particularly that of either B7-1 or B7-2 with CD28 
[180] or the recently described costimulatory molecule for Thl cells [210], is involved in the 
induction of infectious anergy. It is notable that blockade of CD28-B7 interaction after 
cardiac alloantigenic challenge, has been shown to induce anergy in the Thl compartment but 
apparently spares the Th2 response [211]. There is a growing body of evidence which 
suggests that B7-2 and B7-1 may provide costimulation with some specificity for Thl and 
Th2 cells respectively [180,212]. This might explain how, if competition for ligand is 
limiting, either Thl or Th2, or both Thl and Th2 responses could be inhibited, depending on 
expression and/or level of competition for each of the ligands involved.
Cobbold et. al. [206] have proposed a model which attempts to unify the different potential 
mechanisms underlying peripheral tolerance to alloantigen. They suggest that a cellular 
collaborative unit may involve competition between non-tolerant naive ThO like cells, anergic 
tolerant Thl or Th2 CD4+ve T cells and non-tolerant CD4+ve and/or CD8 +ve T cells for the
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cell-surface of an APC. In this model, they propose that naive cells encounter antigen and 
produce low levels of Thl and Th2 cytokines. The small amount of IL-4 produced in turn 
stimulates the tolerant T cell pool to expand. During expansion, the tolerant CD4+ve T cells 
secrete INF-y and T r a n s f o r m in g  G r o w t h  F a c t o r -B e t a  (TGF-p) which further increases 
MHC expression and antigen presentation on the surface of the APC without increasing the 
APC’s expression of costimulatory molecules. This implies that it becomes more likely that 
non-tolerant CD4+ve and/or CD8 +ve T cells will contact antigen on the surface of the APC 
without receiving appropriate costimulation, which in-tum implies that they are driven 
towards the anergic state. A central element in this hypothetical model of infectious anergy, 
is the cohort of anergic T cells which are able to proliferate in response to low levels of IL-4 
and are able to secrete INF-y and TGF-p but otherwise have no direct effector cell function. 
The mechanism(s) involved in generating this initial T cell pool is not addressed in their 
model and could occur through any of the above mechanisms listed above.
1.5 AIMS AND OBJECTIVES OF THESIS
Using a full MHC mismatched rat heterotopic cardiac transplantation model, I hope to show 
that MRC 0X38 anti-CD4 mAb treatment therapy can achieve long term tolerance in treated 
recipients. I hope to also show that this treatment therapy is associated with preferential 
depletion of Thl like T effector cells and that transplantation tolerance can be achieved in 
mAb treated recipients without obvious bias to either a Thl or Th2 polarised type response.
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I hope to also show that anti-CD4 mAb treatment has an effect on the residual non-depleted T 
cell pool. To test if  treated cells are functionally capable of initiating allograft rejection, anti- 
CD4 mAb treated animals will be challenged with heart grafts at a time following mAb 
therapy when CD4 T cells are no longer coated with antibody. Additionally, following 0X38 
mAb treatment, residual CD4 T cells will be analysed to determine whether they display 
abrogated intracellular signalling in response to TCR activation. Also, the pattern of 
signalling observed in anti-CD4 mAb treated cells will be compared to the signalling pattern 
described in anergic T cells.
I also hope to demonstrate that there is an additional requirement for transplantation tolerance 
induced by MRC 0X38 mAb treatment in this experimental model. I hope to provide 
evidence that anti-CD4 induced transplantation tolerance can only be achieved is there are a 
sufficient number of RTE cells in anti-CD4 mAb treated animals. To provide a basis for the 
role of RTE in this experimental model, single positive CD4+ve thymocytes will be 
characterised in vitro using TCR activation assays and the mRNA cytokine repertoire of these 
cells will analysed by RT-PCR.
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2. Materials and Methods
2.1 ANIMALS
All animals were purchased from Harlan UK.(Harlan UK Ltd. : Shaw's Farm, Blackthorn, 
Bicester, Oxfordshire, UK) and maintained in conventional facilities at the University of 
Glasgow Department of Surgery animal house. Mice used for antibody production were FI 
(DBA/2 X BALB/c) males between 6  and 10 weeks old. Cardiac transplantation recipient 
rats were DA adult males which were between 8  and 12 weeks old at time of transplant. 
Animals used for thymectomy were DA adult males which were between 6  and 8  weeks at 
time of thymectomy. Organ and skin donor rats were all RT11 (Lewis) males which were 
between 8  and 14 weeks of age at time of sacrifice. Third party rats for skin and/or cardiac 
allografting were RT1C (PVG) adult males which were also between 8  and 14 weeks of age at 
time of sacrifice. The animals were fed using standard rodent animal feeds and were cared 
for and used in strict accordance of the Animal Scientific Procedures Act 1986.
2.2 ANTIBODIES USED
2.2.1 Hybridoma production
MRC 0X 38 [213], a mouse anti-rat IgG2a mAb, which is specific for the membrane distal 
domains of the rat CD4 molecule expressed on most rat T lymphocytes as well as some 
macrophages, was used to induce tolerance and for immunoprecipitation of CD4 bound
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p56lck. The hybridoma cell line was kindly provided by Dr. D. Mason (MRC Cellular 
Immunology Unit, Oxford, England).
R73 [214], a mouse IgGl anti-rat mAb specific for the constant determinant of the rat 
apTCR receptor was used for T cell staining and T cell activation experiments. The 
hybridoma cell line was kindly provided the European Collection of Animal Cell Cultures 
(ECACC) (Portondown, Wilkshire, UK).
The hybridomas for both 0X38 and R73 were grown using standard tissue culture techniques 
(see below). When sufficient cell numbers were available, they were injected 
In t r a p e r it o n e a l l y  (IP) into (DBA/2 X BALB/c) FI mice (2 x 106 cells/animal) (Harlan 
Olac) which had been primed 7 days earlier with 0.2mls of pristane injected IP. Seven to 
fourteen days after IP injection of hybridoma cells, 2-5mls of ascitic fluid was harvested from 
each mouse, pooled and allowed to clot. The clotted ascities was then centrifuged in a 
Minifuge GL Centrifuge (Heraeus-Christ Centrifuge : Osterode, Germany) at 200g for 10 
M in u te s  (Min) at room temperature (r.t.). The supemate was saved, further clarified by 
centrifuging at 1500g for 10 Min at r.t. in the same centrifuge and then filtering using 
millipore GS 0.22pm filters (Millipore S. A. : 67120 Molsheim, France) into sterile 50ml 
polypropylene tubes. Ascities samples were stored at -20°C until further purification.
2.2.2 Other antibodies used
MRC OX8  [215], a mouse anti-rat IgGl mAb which binds to rat CD8  expressed on rat T 
cytotoxic/suppressor lymphocytes as well as some rat NK cells and MRC 0X 12 [216] a 
mouse IgG2a mAb which binds to rat Ig k chains, expressed on B-lymphocytes, were used in
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the purification of rat CD4+ve T lymphocytes and thymocytes. These mAb were kindly 
provided by Dr. D. Mason (MRC Cellular Immunology Unit, Sir William Dunn School of 
Pathology, Oxford, England).
As well as R73 (previous page), polyclonal R a b b i t  a n t i - M o u s e  a n t i b o d y  (RaMo) IgG 
(Serotec Ltd.) was used in preparation of anti-TCR coated plates and cytometer tubes (see 
below), but was also used in conjunction with 0X38 in inhibition assays when it was 
employed as a cross-linking second antibody.
RC-20 (Affinity Research Products : Nottingham UK), a construct incorporating the 
hypervariable binding domain of an anti-phosphotyrosine antibody conjugated to H o r s e  
R a d i s h  P e r o x i d a s e  (H R P ) ,  polyclonal rabbit anti-human p56lck and polyclonal rabbit 
anti-human ZAP-70 were both purchased from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology : Santa Cruz, Ca ), and polyclonal goat anti-rabbit HRP (DAKO A/S : 
Dakopatts Produktionsvet 42, P. O. Box 1359, DK-2600, Glostrup, Denmark) were all used 
in Western blotting.
MRC 0X 39 [217], is a mouse IgGl mAb specific for the 50,000 kDa induceable IL-2Ra 
chain which is present on activated rat CD4+ve T cells, MRC 0X 1 [218], a mouse IgGl mAb 
which binds to the rat leukocyte common antigen, MRC 0X 22 [219], mouse IgGl mAb 
which binds to the high molecular weight isoform of the leukocyte common antigen 
(CD45RC antigen) and MRC 0X21 [220], a mouse IgGl mAb specific for the human C3b 
inactivator (which was used as a control antibody) were kindly provided by Dr. D. Mason 
(MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, Oxford, England), 
W3/25 [215], a mouse IgGl mAb which also labels the membrane distal domain o f rat CD4, 
was a kind gift from Dr. E. Bell (Dept of Immunology, Manchester School of Medicine,
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Manchester, UK), EDI [221] (Serotec Ltd) a mouse IgGl mAb which labels most rat tissue 
macrophages, monocytes and dendritic cells were used in immunohistochemical staining of 
cardiac tissue, PBL, LNC, thymocytes, and spleen cells and MRC 0X 7 [88] a mouse IgGl 
mAb which binds to the rat Thy 1.1 antigen expressed by thymocytes and by newly exported 
functionally naive CD4 T cells was used in flow cytometric analysis.
Other antibodies used for fluorescent staining included P h y c o e r y t h r in  (P E )  conjugated 
0X8 and W3/25; F l u o r e s c e in  I s o t h io c y a n a t e  (FITC) conjugated R73, P E  and FITC 
conjugated 0X22, FITC conjugated mouse anti-rat IgM, IgGl, IgG2a, IgG2b, and IgG2c (All 
from Serotec Ltd.), as well as FITC c o n ju g a t e d  p o l y c l o n a l  R a b b it  a n t i- M o u s e  
a n t ib o d y  (RaMo-FITC) (both from DAKO A/S). A summary of the antibodies used in this 
thesis are provided in Table 2.1 below.
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Table 2.1
mAb Species Ig Class Specificity Reference
0X38 Mouse IgG2a Membrane distal domain rat CD4 [213]
R73 Mouse IgGl Rat apTCR [214]
0X8 Mouse IgGl Rat CD8 [215]
0X12 Mouse IgG2a Rat Ig Kappa chain expressed on B cells [216]
0X39 Mouse IgGl Inducible Rat IL-2 Receptor a  chain [217]
0X1 Mouse IgGl Rat leukocyte common antigen [218]
0X22 Mouse IgGl Rat high molecular weight isoform of the 
leukocyte common antigen (CD45RC+ve)
[219]
0X21 Mouse IgGl Human C3b inactivator [220]
W3/25 Mouse IgGl Membrane distal domain rat CD4 [215]
EDI Mouse IgGl Rat macrophages, monocytes and dendritic 
cells
[221]
0X7 Mouse IgGl Rat Thy 1.1 antigen [88]
2.2.3 Prosep-A affinity purification o f  0X38 mAb from mouse ascitic flu id
Ascitic fluid was thawed, diluted 1:2 in l.OM glycine, 0.3M NaCl pH 8.6 buffer, and applied 
to a Protein-A affinity column (PROSEP-A High Capacity Bioprocessing Ltd. : 1 Industrial 
Estate Consett Co, Durham, England) as recommended by the manufacturer. Briefly, aliquots 
of the diluted ascities were added to a 10ml PROSEP-A column which was equilibrated in 
l.OM glycine, 0.15M NaCl pH 8.6 buffer and the bound protein fraction eluted using a pH 6 
to 3 gradient of 0.1 M citrate buffer. All effluents passed through a single wave length in-line
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spectrophotometer (Single Path Monitor UV1, Pharmacia-LKB Biotechnology AB : 
Bjorkgatan. S-75182, Uppsala, Sweden) and peak fractions collected in a Frac-100
Pharmacia fraction collector. See Figure 2.1 below.
Figure 2.1 Affinity purification of 0X38 ascities
9 OD 280
7
5
3
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Frac t io n  N u m b e r
This figure illustrates that as the PROSEP-A column elution buffer pH was reduced, protein (as 
determined by absorption of light at an OPTICAL DLNSITY (O D ) 280rim  wavelength) was eluted and 
collected by fraction from the column.
Pooled peak fractions were dialysed using Visking size 2-18/32" tubing (Medicell 
International Ltd. : 239 Liverpool Road. London) into Phosphate Buffered Saline pH 7.4 
Dulbecco 'A', (PBS) and were stored at -20°C  until use.
2.2.4 Radial immune diffusion (RID) determination o f  antibody concentration
The IgG2a concentration in each o f  the two pooled peaks obtained by PROSEP-A affinity 
purification (described above), were determined by Radial Immune Diffusion assay using a 
commercially available kit (Serotec IgG2a RID Kit, Serotec Ltd.).
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2.3 SODIUM DODYCYL SULFATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE)
The starting ascities, unbound non-absorbed protein fraction from the PROSEP-A column, 
and pooled elution peaks from the same column, as well as TCR-activated CD4 T cell lysates 
or immunoprecipitates were analysed by SDS-PAGE on 10% gels as described by Laemmli,
[222], The Molecular Mass o f  protein bands were determined by running standard protein 
markers on each gel (Gibco BRT : Life Technologies Ltd. P. O. Box 35, Trident House, 
Renfrew Road. Paisley, UK). See Figure 2.2 below.
Figure 2.2 10% SDS-PAGE of affinity purified monoclonal antibodies
S tanda rd  0X 38  R73I---------------- 1-----I---------------- 1
M W  kDa + 0Mlr ♦PM1- - 0MF. + 0MF pME
As dem onstrated by 10% SDS-PAGE, this figure illustrates the purity of both 0X 38 and R73 mAb. The 
polyacrylamide gel was stained with 1% Coomassie blue dye for 30 Min and de-stained in 10% 
methanol/acetic acid overnight. The single lane on the left shows standard molecular weight protein 
m arkers, while the lanes on the right show 5pg protein samples of affinity purified 0X 38 and R73 run in 
the presence and absence of PME.
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2.4 HETEROTOPIC CARDIAC TRANSPLANTATION
2.4.1 Donor animals
Rat heterotopic cardiac transplantation was performed as described by Ono and Lindsey
[223]. Briefly, using sterile technique and halothane/oxygen inhalation anaesthesia, donor 
animals were heparinised using 100 In t e r n a t io n a l  U n it s  (IU ) Heparin In t r a v e n o u s l y  
(IV ) (Leo Laboratories Ltd. : Princes Risbourgh, Bucks., England) and were exsanguinated. 
Thoracotomy was performed and the heart immediately chilled with topical 4°C normal saline 
and ice. The right and left superior vena cavae, inferior vena cava, and pulmonary venous 
trunk were individually ligated using 6.0 silk ties and transected. All other venous and 
arterial branches, except the pulmonary artery and aorta, were ligated en-mass using a single 
6.0 silk tie. The heart was excised and the donor organ immediately placed in cold (4°C) 
sterile saline until required for transplantation. Cold ischaemic time (i.e. the time in cold 
sterile saline after removal of the heart from the donor until the anastomosis was started in the 
recipient) varied from 5 to 45 Min in total.
2.4.2 Recipient animals
Using sterile technique and halothane/oxygen inhalation anaesthesia, recipient animals had 
laparotomy performed on heated operating plates. The infra-renal abdominal aorta and vena 
cava were identified and isolated. Lumbar vessels were ligated using 8.0 silk ties. Two 
microsurgical vascular occlusion clamps were placed 1.5 cm apart across the aorta and vena 
cava together and arterotomy and venotomy performed. Using standard microsurgical 
techniques, the donor heart aorta and pulmonary artery were anastomosed, in an end to side 
fashion, onto the recipient aorta and vena cava respectively using a continuous 9.0 prolene
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running sutures. Reperfusion of the donor organ occurred on average after a 15 to 25 Min 
warm anastomosis time (i.e. the time from removal of the donor organ from cold saline until 
reperfusion with recipient blood occurred) with the removal of the vascular occlusion clamps. 
The peritoneum-abdominal muscles, and skin were closed separately using a continuous 4.0 
dexon running suture. Overall, donor organ retrieval and recipient transplantation took 
between 30 and 60 Min to perform. Graft function was checked daily by direct abdominal 
palpation of the donor organ.
2.5 ORTHOTOPIC RENAL TRANSPLANTATION
2.5.1 Donor animal
Briefly, using sterile technique and halothane/oxygen inhalation anaesthesia, donor animals 
were heparinised using 100 IU Heparin IV (Leo Laboratories Ltd. : Princes Risbourgh, 
Bucks., England). The left renal vein, artery and ureter were divided and the animal 
exsanguinated. The kidney was perfused with 5 mis of cold (4°C) saline by direct cannulation 
of the renal artery using a 25 gauge needle and 5 ml syringe, and placed directly into the 
recipient for immediate transplantation.
2.5.2 Recipient animals
Using sterile technique and halothane/oxygen inhalation anaesthesia, after opening the 
abdomen using a midline incision, the native left renal vein and artery were isolated and
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occluded using fine vascular clamps and then each was transected distal to the occlusion 
clamp. The left ureter was then divided near the lower pole of the native left kidney which 
was removed so that the donor kidney could be placed in an orthotopic position for 
transplantation. The donor renal artery and vein were anastomosed in an end to end fashion 
using the recipients renal artery and vein respectively using interrupted 10.0 prolene sutures. 
Reperfusion of the donor organ occurred on average after a 15 to 25 Min warm anastomosis 
time (i.e. the time from after perfusion of the donor kidney with cold saline until reperfusion 
with recipient blood occurred) with the removal of the vascular occlusion clamps. The donor 
ureter was then anastomosed to the recipients left ureteric stump using interrupted 10.0 
prolene sutures. The peritoneum-abdominal muscles, and skin were closed separately using a 
continuous 4.0 dexon running suture. Overall, donor organ retrieval and recipient 
transplantation took between 30 and 60 Min to perform. Seven days after transplantation, 
using halothane/oxygen inhalation anaesthesia, through a separate posterior-retroperitoneal 
loin incision, the recipients right kidney was removed after mass ligation of the vascular and 
ureteric pedicle using a single 6.0 silk tie. The muscle and skin wound was closed en-mass 
using a 4.0 dexon running suture. The animals which were left to survive on the transplanted 
kidney alone, were assessed daily for clinical signs of uraemia and were bleed by tail tipping 
at regular intervals for serum creatinine and urea measurements.
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2.6 SKIN GRAFTING
2.6.1 Donor animals
Donor animals were sacrificed so that skin from over the abdominal region which was shaved
of fur and cleaned with 70% ethanol could be obtained for grafting. Once removed, skin
samples were cut into 2 cm patches and were used immediately for grafting.
2.6.2 Recipient animals
On the back between the fore legs (front shoulder region), recipient animals were shaved of 
fur and cleaned with 70% ethanol. Using sterile technique and halothane/oxygen inhalation 
anaesthesia, a 2 cm2 patch of native skin was excised from the prepared area and was replaced 
with a similar sized portion of donor skin. The donor skin was sutured in place along the 
edges, using interrupted 4.0 dexon sutures. Animals were assessed daily for evidence of skin 
graft rejection, which was defined as the day that the skin graft sloughed off completely.
2.7 THYMECTOMY
Thymectomy of R T la (DA) male rats (6 to 8 week old) was performed using sterile technique 
and halothane/oxygen inhalation anaesthesia. Briefly, with the rat prone and the neck 
hyperextended, a 10mm longitudinal skin incision was made over the sternal notch and 
proximal sternum. A 3-5 mm sternotomy was then performed by scissor dissection of the 
manubrium, taking care to avoid the external jugular and brachiocephalic veins. The
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sternotomy was widened using blunt dissection until the thymus was easily visualised with 
the aid of an operating microscope (x 15 magnification). Sharp dissection of the connective 
tissue surrounding the thymic capsule was then performed until the thymus could be removed 
in one piece from the superior mediastinum and delivered through the skin wound. The 
sternotomy and skin wounds were then closed using continuous catgut suture and the rats 
given one to two breaths of positive pressure ventilation to expand their lungs by gently 
blowing through a 2.5 ml syringe barrel which was held over the rats nose and mouth.
2.8 TISSUE CULTURE
All tissue culture work, except centrifugation, was performed using standard tissue culture 
techniques in a Gelaire BSB 40 laminar flow hood (Flow Laboratories Ltd. : Woodcock Hill, 
Harefield Road, Rickmansworth, Herts., England). All centrifugation was performed at 4°C 
for 8 Min at 200g in a Minifuge GL Centrifuge. Washes were performed by addition of 
lOmls medium to resuspended cell pellets, debris was allowed to settle, and suspended cells 
transferred to clean tubes with plastic Pasteur pipettes. Tissue culture medium, unless 
otherwise stated, was R o sw e l l  P a r k  M e m o r ia l  In st it u t e  (RPMI) 1640 with Penicillin (10 
IU/ml), Streptomycin (lOpg/ml), Glutamine (2mM) with or without 10% F o e t a l  C a lf  
S e r u m  (FCS) and/or 2 x 10’5 M 2-Mercaptoethanol (Gibco BRL). Cell cultures were grown 
in 5% CCVair mix at 37°C in a FLOW LABORATORY 210 incubator (Flow Laboratories 
Ltd.).
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2.9 MIXED LYMPHOCYTE REACTION (MLR) ASSAY
2.9.1 Spleen cells (Stimulator and target cells)
Spleens were obtained, using sterile technique, from sacrificed Lewis rats and placed into 
50ml petri dishes containing standard RPMI culture medium (RPMI 1640, with 10 IU/ml 
penicillin, lOpg/ml streptomycin, 2mM glutamine, Gibco BRL) with 10% FCS added. As 
described above, all work except centrifugation and cell irradiation was performed using 
standard tissue culture techniques. Splenocytes were obtained by gently crushing the splenic 
capsule with disposable sterile plastic forceps releasing the cells into the tissue culture 
medium. The cells were triturated free of clumps by using 5ml plastic Pasteur pipettes and 
were then transferred to 10ml conical centrifuge tubes for centrifugation at 200g for 8 Min at 
4°C. The supemate was discarded, the cell pellet resuspended in lOmls of medium, 
transferred to a fresh 10ml conical tube and the centrifugation repeated. Erythrocytes were 
lysed by resuspending the washed cell pellets in 5mls sterile water immediately followed by 
5mls of sterile 0.3M NaCl. Cells were washed a further 3 times by centrifugation and 
resuspended in 5mls medium. The cells were then irradiated, (3000 Rads over 10 Min), 
washed twice by centrifugation and finally resuspended at the desired concentration in 
medium with 10% FCS and 2 x 10"5 M 2-Mercaptoethanol.
C o n c a n a v a l in - A  (Con-A) (Sigma Chemicals Ltd.) transformed splenic blasts were prepared 
using standard tissue culture conditions after adding 50pg sterile Con-A to 2.5 x 107 Lewis 
splenocytes in lOmls RPMI with 10% FCS and incubating for 72 h o u r s  (hr).
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2.9.2 Lymph node cells (LNC : Responder cells)
Cervical and mesenteric lymph nodes were obtained using sterile technique from sacrificed 
DA rats. Peri-lymphatic fat and connective tissue was dissected away from the lymph nodes 
which were then placed in 50ml petri dishes containing culture medium. Using standard 
tissue culture techniques, lymphocytes were obtained by teasing the lymph nodes through a 
sterile stainless steel tea strainer with the rubber end of a 2ml syringe plunger. The cells were 
washed twice by centrifugation (as described above) and were resuspended at the desired 
concentration in medium with 10% FCS and 2 x 10'5 M 2-Mercaptoethanol.
2.9.3 MLR assay
MLR assay were performed in U bottomed 96 well microtitre plates (Nunclon Microwell 
Plates, Nunclon Intermed : Denmark). 0.1ml of irradiated stimulator (1 x 106/ml) and 
responder (0.5 x 106/ml) cells were used per well. Responder and stimulator cells were 
incubated at 37°C in 5% COi/air mix. On days 3, 4, and 5, culture wells were pulsed with 
0.010ml (0.001 mci) of TRK 418 T r it ia t e d -T h y m id in e  (3H-Thymidine) (Amersham 
International Pic. : Lincoln Place, Green End, Aylesbury, Bucks., England). Eighteen hrs 
after pulsing, cells were harvested onto microtitration filter paper (ICN Flow Biomedicals 
Ltd. : Eagle House, Peregrine Business Park, Gomm Road, High Wycombe, Bucks., England) 
using a Microtiter Dynatech Automash II harvester (DYNEX Technologies : Billingshurst, 
West Sussex, England). Filter paper-cell circles were placed into 5ml polypropylene tubes 
and mixed with 3mls Ecoscint A scintillation fluid (National Diagnostics : 1013-1017 
Kennedy Blvd., Manville, N. J., USA). 3H-Thymidine uptake was determined by counting
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samples on a 1209 Rank Beta Liquid Scintillation counter (LKB Wallac : Wallac OY, P. O. 
Box 10, 20101 Turku, Finland).
2.10 OTHER CELL PREPARATION / PURIFICATION
2.10.1 Thymocyte preparation
Thymus glands were obtained using sterile technique from sacrificed DA rats. Peri-thymic 
fat and connective tissue were dissected away from the glands which were placed in 50ml 
petri dishes containing standard culture medium. Using standard tissue culture techniques, 
thymocytes were obtained by teasing the thymic tissue through a sterile stainless steel tea 
strainer as described above. Cells were washed twice by centrifugation and resuspended at 
the desired concentration in Phosphate Buffered Saline (PBS).
2.10.2 Peripheral blood lymphocyte (PBL) enrichment
PBL were obtained using sterile technique by bleeding DA rats, by direct cardiac puncture, 
into syringes pre-loaded with 50 IU of heparin. The heparinised blood was then mixed with 
an equal volume of PBS. Five mis of diluted blood-PBS mix was layered on 5 mis o f percol 
(q = 1.088) and centrifuged at 400g for 20 Min at 22°C. Following centrifugation, PBL were 
harvested from the interface and washed twice by centrifugation at 200g for 8 Min at 4°C in 
PBS and were resuspended at the desired concentration in standard medium or PBS.
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2.10.3 CD4 T cell and thymocyte purification
CD4 +ve T cells were obtained by negative selection using immunomagnetic cell separation. 
Purified LNC and Thymocytes, obtained as outlined above, were resuspended in PBS + 0.2% 
B o v in e  S e r u m  A l b u m in  (BSA) (Ultra Pure, Sigma Chemical Co. : P. O . Box 14508, St. 
Louis, Mo., USA), and 50pl of 0X8 and 0X12 mAb were added per 109 cells. The cells 
were incubated for 30 Min at 4°C and were then triple washed by centrifugation, as described 
above, and resuspended in 1ml of standard medium. The cells were counted using a standard 
haemocytometre, 1ml of goat anti-mouse IgG coated magnetic beads (Biomag, Advanced 
Magnetics Inc. : UK) was added per 108 cells. After incubation for 30 Min at 4°C, the cells 
were pelleted, using a magnetic stand as recommended by the manufacturer. The supemate 
was added to a second portion of Bio Mag beads and the purification process repeated. CD4 
enriched cells were then washed twice by centrifugation, counted and resuspended at the 
desired concentration in either medium or PBS. In subsequent discussion, CD4 enriched 
LNC are referred to as ‘purified CD4 T cells’ whereas CD4 enriched thymocytes are referred 
to as ‘purified CD4 thymocytes’.
The purity of CD4 T cells obtained after negative selection immunomagnetic cell separation 
was routinely checked by double label flow cytometric analysis and a typical result is depicted 
in Figure 2.3 below. Here LNCs were stained directly using anti-apTCR-FITC (y-axis) and 
either anti-CD8-PE (left panels, x-axis) or anti-CD4-PE (right panels, x-axis). Cells were 
stained both before (upper panels) and after (lower panels) negative selection of CD4 T cells. 
In all experiments to be described, the purity of CD4 preparations from LNC and thymocytes 
was always greater than 93 and 80% respectively.
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Figure 2.3 Lymph node cell purity as determined by double label flow cytometry
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Cells were resuspended at 1.4 x 106 / ml in PBS containing 0.2% BSA. The first 10,000 cells were 
analysed using an EPICS XL^analyser (Coulter : Luton, UK), see above for detailed protocol. (A) 0X 8- 
PE vs. R73-FITC before beads. (B) W3/25-PE vs. R73-FITC before beads. (C) OX8-PE vs. R73-FITC 
after beads. (D) W3/25-PE vs. R73-FITC after beads.
2.11 ANTI-TCR ACTIVATION EXPERIMENTS
2.11.1 Preparation o f  culture p lates with a p  TCR mAb fo r  proliferation and cell signalling  
experiments
For proliferation and cell signalling studies, CD4 T cells were activated by cross-linking o f  
a p T C R  in culture plates containing immobilised R73 mAb. Using sterile tissue culture 
techniques, 0.2ml o f  polyclonal RaMo IgG (Serotec Ltd.) diluted to lOpg/ml in 0.1M 
N aH C03  pH 8.2 was added to each well o f  a U 96 Nunclon Microwell Plates (Nunclon
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Intermed) and incubated for 2 hrs at 37°C. The plates were triple washed with excess PBS, 
blotted dry, and 0.2ml of R73 mAb diluted to 5pg/ml in PBS added to each well. The plates 
were then incubated at 4°C until ready to be used. Prior to use, the wells of the plate were 
triple washed with excess PBS and ‘blocked’ by addition to each well of 0.2ml of 1% 
N o r m a l  M o u se  S e r u m  (NMS) diluted in PBS and incubating for 1 hr at 4°C. Finally the 
wells were triple washed with excess PBS and blotted dry ready for addition of CD4 T cells. 
Plates prepared in this way are subsequently referred to as ‘standard TCR plates’.
2.11.2 Preparation o f  tubes with ap  TCR mAb fo r use in Ca2+ signalling experiments
Polystyrene flow cytometer tubes (Coulter) were preincubated with 3mis of 50% ethanol for 1 
hr at 22°C. The ethanol was then removed and the tubes allowed to dry. 2ml of polyclonal 
RaMo IgG (Serotec Ltd.) diluted to lOpg/ml in 0.1 M NaHC0 3  pH 8.2 was added to each tube 
and the tubes incubated for 2 hrs at 37°C. After the tubes had been triple washed with excess 
PBS and blotted dry, 2mls of R73 mAb diluted to 5pg/ml in PBS was added to each tube and 
incubated at 4°C until ready to be used. Prior to use, each tube was triple washed with excess 
PBS and ‘blocked’ by addition of 2ml of 1% NMS diluted in PBS and incubating for 1 hr at 
4°C. Finally, the tubes were triple washed with excess PBS and blotted dry ready for addition 
of CD4 T cells. Flow cytometer tubes prepared in this way are subsequently referred to as 
‘standard TCR coated cytometer tubes’.
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2.11.3 TCR proliferation assays
Purified CD4 T cells (or thymocytes) were prepared at 1 x 106/ml in standard medium with 
10% FCS and 2 x 10'5 M 2-Mercaptoethanol and 0.1 ml added to each well of standard TCR 
plates. For proliferation assays, the plates were incubated at 37°C in 5% C02/air mix. On 
days 2, 3, and 4 of culture, the wells were pulsed with 0.010ml (0.001 mci) of TRK 418 3H- 
Thymidine (Amersham International Pic.). Eighteen hrs after pulsing, cells were harvested 
onto microtitration filter paper (ICN Flow Biomedicals Ltd.) using a Microtiter Dynatech 
Automash II harvester (DYNEX Technologies). Filter paper-cell circles were placed into 5ml 
polypropylene tubes and mixed with 3mls Ecoscint A scintillation fluid (National 
Diagnostics). 3H-Thymidine uptake was determined by counting samples on a 1209 Rank 
Beta Liquid Scintillation counter (LKB Wallac).
2.11.4 TCR cell signalling experiments : Whole cell lysate preparation
Purified CD4 T cells were prepared at 1-2.5 x 107/ml in PBS and 0.1 ml of cells were added 
to each well of standard TCR plates. Plates were incubated for 0, 0.5, 2, 5, and 30 Min at 
22°C. At each time-point, T cell activation was arrested by the addition of 50pl of triple 
concentrated Laemmli S o d iu m  D o d e c y l  S u lfa te  (SDS) Sample Buffer. The samples were 
then transferred to 0.5ml polypropylene microfuge tubes containing 15pl of lOmM Na 
Vanadate, lOOmM Na Fluoride, lOOmM Na Pyrophosphate and boiled for 5 Min. 15pl of 
each sample was then loaded on a 10% polyacrylamide gel as described above.
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2.11.5 TCR cell signalling experiments : Immunoprecipitation
Purified CD4 T cells were prepared at 1-8 x 107/ml in PBS and 0.08ml of cells was added to 
20 j l x 1 of 10 times concentrated lysis buffer which contained 5% NP-40, 0.5M NaCl, 250mM 
Tris pH 8.3, 50mM Na pyrophosphate (Sigma Chemicals), 5mM Na ortho-Vanadate (Sigma 
Chemicals), 50mM Na Fluoride (Sigma Chemicals), lOpg/ml Leupeptin (Sigma Chemicals), 
lOpg/ml Aprotinin (Sigma Chemicals), 20pg/ml Pepstatin A (Sigma Chemicals), 0.8mM 
EDTA, and lOmM p-nitrophenylnitrophosphate (Sigma Chemicals). Ten pi of appropriate 
antibody (diluted to 1 mg/ml in lysis buffer) was then added to each sample which was 
incubated for 30 Min at 4°C. Following incubation, lOpl protein-A Sepharose (Sigma 
Chemicals), pre washed with PBS (at 20mg Protein-A/ml beads) was added and incubated for 
10 Min at 4°C. The samples were pelleted by centrifuging for 5 Min using a MSE Micro 
Centaur microfuge (Fischer Scientific UK : Bishop Meadow Road, Loughborough, UK), the 
supemate removed and the pellet triple washed by resuspending in 0.5ml of lysis buffer and 
recentrifuging as above. The washed pellet was then resuspended in 0.1ml of Laemmli SDS 
sample buffer and boiled for 5 Min. Fifteen pi of each supemate was then loaded on a 10% 
polyacrylamide gel as described above.
2.11.6 TCR cell signalling experiments : Anti-phosphotyrosine and anti-p56lck signalling 
Following activation of purified CD4 T cells using standard TCR plates, proteins lysates and 
immunoprecipitates were separated by 10% SDS-PAGE and transferred to nitrocellulose 
(Hybond, ECL : Amersham, Buckinghamshire, UK) using the Sartoblot (Sartorius Ltd. : 
Blenheim Road, Epson, Surrey, UK) semi-dry blotting method as described by the 
manufacturer. Blotting efficiency was tested by staining pre and post-transfer SDS gels as
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well as post-transfer nitrocellulose paper with coomassie blue stain as shown in Figure 2.4 
below.
Figure 2.4 Blotting efficiency as tested by Coomassie blue staining
SD S G els N itrocellu lose Paper
P r e -  P ost-T ran sfer  P ost-T ran sfer
• 4 x 105 whole cell lysates run per lane
• Nitrocellulose transfer performed by semi-dry western blotting at 4 mAmp/cm2
• Gels and nitrocellulose stained with 1% Coomassie blue for 30 Min and de-stained in 10% 
methanol/acetic acid overnight
The nitrocellulose transfers were then blocked for lhr at r.t. in affinity wash buffer (0.1M 
Tris-Base, 0.1M NaCl, 0.1% Tween. pH 7.5) containing 5% BSA. To stain for 
phosphotyrosine containing proteins, a 1:2500 dilution o f  RC-20 (Affinity Research Products) 
in affinity wash buffer + 0.5%BSA was incubated at r.t. for lh r or overnight at 4°C. To stain 
for p56kk, a two stage procedure was employed. (1) A 1:1000 dilution o f  anti- p56,Lk 
antibody (Santa Cruz Biotechnology : Santa Cruz, California. USA ) (pre-absorbed with 
NMS) in affinity wash buffer + 0.5%BSA was incubated at r.t. for lhr followed by washing 
twice with affinity wash buffer. (2) Addition o f  a 1:1700 dilution o f  a HRP coupled goat 
anti-rabbit antibody (DAKO A/S) (pre-absorbed with NMS) in affinity wash buffer + 0.5% 
BSA + 5% N o r m a l  G o a t  S e r u m  (NGS) for lhr at r.t.. After staining, blots were washed
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three times in affinity wash buffer and the staining detected by chemoluminescence- 
autoradiography system as described by the manufacturer (Hybond, ECL) using X-OMAT O 
film (Eastman Kodak Co. : Rochester, NY)
2.11.7 TCR cell signalling experiments : Calcium signalling
One ml of purified CD4 T cells at 1 x 107/ml in standard RPMI, (RPMI 1640 with 10 IU/ml 
penicillin, lOpg/ml streptomycin, 2mM glutamine, Gibco BRL) containing 2.5mM of Ca2+ 
(signalling medium) was incubated with 5pM of Fluo-3 (Molecular Probes - Cambridge 
BioScience : Cambridge, UK) dissolved in 25% Pluronic F-127 (Molecular Probes - 
Cambridge BioScience) in Anhydrous DMSO (Sigma Chemicals) for 15 Min at 37°C. The 
cells were then diluted 1:2 using signalling medium and were ready for activation 
experiments using standard TCR coated cytometer tubes as outlined above. All activation 
experiments were performed at r.t. using the EPICS XL®cytometer (Coulter) analysing 
between 600-1000 cells/second. Total Flou-3 florescence was determined by adding 2pM of 
ionomycin (Sigma Chemicals) to each sample.
2.12 IL-2 CYTOKINE ASSAY
Supernates from MLR were assayed for IL-2 by bioassay using the IL-2 dependent cell line 
CTLL (kindly provided by Dr. C. Lawrence University of Glasgow School of Veterinary 
Medicine, Glasgow, UK). Doubling dilutions of supemate were incubated with 5 x 103
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CTLL in U 96 Nunclon Micro well Plates (Nunclon Intermed) for 24 hrs at 37°C. Cells were 
then pulsed with 0.001 mci 3H-Thymidine (Amersham International Pic) and Thymidine 
incorporation measured by counting samples on a 1209 Rank Beta Liquid Scintillation 
counter (LKB Wallac) as outlined above. An IL-2 standard curve was generated for each 
experiment by using recombinant human IL-2 (Galaxo : Geneva, Switzerland).
2.13 IMMUNOHISTOCHEMISTRY
2.13.1 Tissue preparation
Cardiac tissue was snap frozen in liquid nitrogen and cryostat sections of 5 pm were cut at 
-20°C onto gelatinised slides. A range of mAb were used to label tissue sections using an 
indirect immunoperoxidase technique [224]. Briefly, Cryostat sections were rehydrated in 
PBS then incubated with optimal dilutions of mouse mAb directed against rat leukocyte 
subpopulations for 30-60 Min at r.t.. After triple washing in PBS, a peroxidase-conjugated 
polyclonal RaMo-antibody (DAKO A/S) (which was pre-cleared using 10% Normal Rat 
Serum to prevent non-specific binding) was added at 1:40 dilution and incubated at r.t. for 30 
Min. Sections were then triple washed in PBS and then incubated with substrate : 0.6mg/ml 
3,3’-diaminobenzidine tetrahydrochloride (Sigma Chemicals) in PBS with 0.01% H y d r o g e n  
P e r o x id e  (H2O2) for 5 Min at r.t. until the brown reaction product appeared. After further 
washing in PBS, sections were briefly counter stained in Harris’s hematoxylin (BDH Ltd. - 
Merck Ltd. : Lutterworth, Leicester, UK), rinsed in H2O, dehydrated in ethanol, cleared in 
xylene, then mounted in DPX mountant (BDH Ltd. - Merck Ltd.). A portion of each heart
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graft was also fixed in formalin, embedded in paraffin wax, sectioned and stained with 
H e m a t o x y l in  a n d  E o sin  (H & E ).
2.13.2 Morphometric analysis o f  cellular infiltrating cells
The mononuclear cell infiltrate of cardiac tissue was assessed by counting the number of 
positively stained cells per high powered field [400x magnification] using a microscope 
eyepiece graticule bearing a counting grid. Ten consecutive high power fields per section 
were counted and the results represented by the mean +/- S ta n d a r d  D e v ia t io n  (sd) for each 
section.
2.14 FLUORESCENT ACTIVATED FLOW CYTOMETRY
Mesenteric and cervical LNC, PBL, Thymocytes or purified CD4 T cells or purified CD4 
thymocytes were obtained as outlined above and were resuspended in PBS made with 0.2% 
BSA (Ultra Pure, Sigma Chemical Co.). 1 x 106 cells in 0.1ml were incubated for 1 hr at 4°C 
with 0.01ml of purified antibody conjugate (Serotec Ltd) or 0X38 diluted 1:10 with PBS with 
0.2% BSA. Cells were then washed twice by centrifugation and the 0X38 cell pellets 
resuspended in 0.020ml of RaMo IgG (diluted 1:20 in 10% Normal Rat Serum) conjugated 
with FITC (DAKO A/S) and incubated for 30 Min at 4°C. The fluorochrome labelled cells 
were washed a further two times by centrifugation and were finally resuspended in 0.7mls of
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PBS with 0.2% BSA. A total of 10,000 cells were then analysed on a EPICS XL® analyser 
(Coulter).
2.15 ANTIBODY MEDIATED CYTOTOXICITY ASSAYS
Serum taken from transplanted DA recipients was heat inactivated for 30 Min at 56°C and 
tested for alloantigen-specific cytotoxicity using a standard 5ICr-release assay. Briefly, 5Mbq 
51Cr (Amersham) was incubated for 90 Min at 37°C with Lewis (Donor Strain) Con A- 
transformed splenic blast cells. After excess 51Cr was removed from the blasts by 
centrifugation, 1 x 105 target cells in standard RPMI with lOmM Hepes and 5% FCS, were 
added to 50pl of serial diluted test sera in 96 well U-bottomed microtitre plates (Nunclon 
Intermed). The plates were incubated with the sera for 30 Min at 37°C. Then, lOOpl of 
guinea pig complement (Serotec Ltd) was added to each well and the plates incubated for a 
further 60 Min at 37°C. Plates were then centrifuged for 5 Min at 200g at r.t., lOOpl of 
supemate recovered and transferred to separate tubes for counting released 51Cr on a LKB 
Compu-gamma counter (LKB Wallac). Specific 51 Cr release was calculated by the formula: 
Percent specific release = 100 x [(experimental release - spontaneous release) / (Maximum 
release - spontaneous release).
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2.16 ALLOANTIBODY ISOTYPE DETERMINATION
Lewis LNC (1 x 106 cells in 0.1 ml PBS with 0.2% BSA) were incubated with tripling 
dilutions of heat inactivated serum obtained from test and control animals for 30 Min at 4°C. 
Following incubation, the cells were washed twice by centrifugation in PBS with 0.2% BSA 
and cell pellets were resuspended using FITC-conjugated anti-isotype antibody (Serotec Ltd.) 
at the manufacture’s recommended dilution. The target cells were incubated for a further 30 
Min at 4°C, washed twice by centrifugation, resuspended in 0.5mls PBS with 0.2% BSA and 
analysed on a EPICS XL® analyser (Coulter).
2.17 REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-
PCR)
2.17.1 Ribonucleic Acid (RNA) isolation from cardiac samples
Three hundred to 400 mg of cardiac tissue was homogenised in 3ml of TRIzol (Gibco BRL) 
using a sterile Teflon pestle and glass homogenisation tubes for 1-2 Min at 4°C. The 
homogenised sample was incubated a further 5 Min at 4°C to permit the complete 
dissociation of nucleoprotein complexes. Two ml of the homogenate was added to 0.2ml of 
chloroform and after mixing by vortexing, the preparation was incubated at r.t. for 3 Min. 
The samples were then centrifuged at 12,000g for 15 Min at 4°C using a SIGMA-2K15 
centrifuge (SIGMA-Aldrich Co Ltd. : Fancy Road, Poole, Dorset, UK) to pellet the 
R ib o n u c l e ic  A cid  (RNA). Each RNA pellet was then washed in 1ml of 75% Ethanol and 
re-centrifuged at 7,500g for 5 Min at 4°C. Each pellet was resuspended in 100pl o f D ieth y l
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P y r o c a r b o n a t e  (DEPC) - H2O by repeated trituration of the sample using a micro-pipette 
and was incubated at 60°C for 10 Min. The OD of each sample was determined at both 260 
and 280r|m wavelengths using a Pye Unichem SP8-100 spectrophotometer (Philips Unichem 
: York Street, Cambridge, UK) to calculate, respectively, the quantity of RNA and the relative 
contamination with protein.
2.17.2 RNA isolation using DyNABEADS mRNA direct kit
Purified CD4 T cells or thymocytes (1-5 x 106), from TCR activation experiments were 
pelleted by spinning in the microfiige for 5 Min at r.t. and were either stored at -20°C or used 
immediately for each experiment. 1ml of lysis/binding buffer (lOOmM Tris-HCl, pH 8.0, 
500mM LiCl, lOmM EDTA, 1% LiDS, 5mM D it h io t h r e it o l  (DTT)) was added to each 
pellet and lysis was performed by repeated trituration firstly through a micro pipette followed 
by a 21 gauge stainless steel needle. 0.25ml ofDynabeads® (DYNAL A.S. : Oslo, Norway) 
Oligo (dT)25 were washed into 0.20mls of lysis/binding buffer by magnetic transfer and were 
added to the cell lysates and were annealed for 5 Min at r.t.. The magnetic beads were then 
washed twice using 0.5ml washing buffer (lOmM Tris-HCl, pH 8.0, 0.15M LiCl, ImM 
EDTA) with 0.1% LiDS added and triple washed in 0.5ml washing buffer alone by magnetic 
transfer. The mRNA was then displaced from the magnetic beads by adding 30pl DEPC-H2 O 
and incubating at 65°C for 2 Min.
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2.17.3 Complementary Deoxyribonucleic Acid (cDNA) synthesis
Twenty-four pi of RNA (representing lOpg of total RNA obtained from Cardiac tissue, or 
undiluted mRNA obtained from the Dynabead isolation method) was incubated with 2pl 
(lpg) oligo (dT)i2 -i8 primer (Boehringer-Mannheim UK : Bell Lane, Lewes, East Sussex) at 
70°C for 10 Min then cooled to 4°C for 5 Min. lOpl of 5x reverse transcriptase buffer (Gibco 
BRL), 4pl (lOOmM) DTT, 2pl (lOmM) dNTPs (Boehringer-Mannheim UK) was added and 
incubated at 37°C for 2 Min. Finally 2pl (400U) of Superscript Rnase H Reverse 
Transcriptase (Gibco BRL) was added and c o m pl e m e n t a r y  D e o x y r ib o n u c l e ic  A cid  
(cDNA) synthesised using the Cetus 480 (Perkin-Elmer Ltd. : Maxwell Road, Beaconsfield, 
Bucks, UK) automated temperature cycling machine.
2.17.4 Reverse Transcriptase-Polymerase chain reaction (RT-PCR)
P-Actin, IL-2, IL-5, INF-y, IL-10, IL-13, IL-2Ra and IL-2RP (+) and (-) specific primers were 
obtained from Cruachem (Cruachem Ltd. : Todd Campus, West of Scotland Science Park, 
Acre Road, Glasgow). All primers were used at a final concentration of 0.2pM except P- 
Actin which was used at 0.1 pM. RT-PCR was performed using a Geneamp 9600 (Perkin- 
Elmer Ltd.) automated temperature cycling machine after mixing 0.1 pi (0.5 units) Taq 
polymerase (Gibco BRL), 0.4pl (lOmM) dNTPs (Boehringer-Mannheim UK), 0.75pl 
(50mM) Mg2+ (Gibco BRL) (except when IL-4 primers were used and 1.25 pi (50mM) Mg2+ 
was added instead), 2.5pl lOx PCR buffer (Gibco BRL), 5.0pl (+) and (-) primer mix, 5pl 
cDNA, and DEPC-H2O to make 25pl reaction volume in Rnase free sterile PCR tubes 
(Perkin-Elmer Ltd.). Primer sequences used in RT-PCR are summarised in Table 2.2 below.
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Table 2.2
Cytokine Sequence Reference
P actin sense (+) 5’ ATGCCATCCTGCGTCTGGACCTGGC 3’ Nudel et. al. Nucleic 
Acids Research
P actin antisense (-) 5’ AGC ATTT C GGGT GC AC GAT GG AGGG 3’ 1983.11:1759
IL-2 sense (+) 5’ CATGTACAGCATGCAGCTCGCATCC 3’ M°Knight et. al. 
1mm unogenetics
IL-2 antisense (-) 5’ CC ACC AC AGTT GCTGGCT CAT CAT C 3’ 1989.30:145
INF-y sense (+) 
INF-y antisense (-)
5’ ATGAGTGCTACACGCCGCCTCTTGG 3’ 
5’ G AGTT C ATT G AC AGCTTT GT GCT GG 3’
Dijkema et. al. EMBO 
Journal 1985.4:761
IL-2Ra sense (+) 5’ GTGGGGAGATAAGGTGGACGCAT 3’ Page and Dallman Eur 
J  Immunol
IL-2Ra antisense (-) 5’ GATCGAAAGGAGACAGGCACCC 3’ 1991.21:2133
IL-2RP sense (+) 5’ TACTGGTCCTCGGCTGCTTCTTTG 3’ Page and Dallman Eur 
J  Immunol
IL-2RP antisense (-) 5’ GTGAAAGGCAGCAGAGGTGGGA 3’ 1991.21:2133
IL-4 sense (+) 
IL-4 antisense (-)
5’ TGATGGGTCTCAGCCCCCACCTTGC 3’ 
5’ CTTTCAGTGTTGTGAGCGTGGACTC 3’
McKnight et. al. Eur J  
Immunol 1991.21:1187
IL-10 sense (+) 5’ GT G A AG ACTTT CTTTC A AA 3’ Feng et. al. Biochem 
Biophys Res Commun
IL-10 antisense (-) 5’ T GAT G A AG AT GTC A A ACTC 3’ 1993.192:452
IL-13 sense (+) 5’ CAGGGAGCTTATCGAGGAGC 3’ Lakkis and Cruet
Biochem Biophys Res
IL-13 antisense (-) 5’ A AGTT GCTT GG AGT A ATT G AGC 3’ Commun 1993.197:612
IL-5 sense (+) 
IL-5 antisense (-)
5’ TTCTAACTCTCAGCTGTGTCTGGGC 3’ 
5’ AATGCCCACTCTGTACTCATCACGC 3’
Uberla et. al. Cytokine 
1991.3:72
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3. Effect of 0X38 anti-CD4 monoclonal antibody on the CD4 T cell pool
3.1 INTRODUCTION
Following clinical organ transplantation, currently available anti-rejection treatment regimens 
are immunologically non-selective, need to be given long-term, and are associated with a 
variety of side effects and long-term hazards, such as increased susceptibility to infection and 
malignancy. CD4+ve T cells play a central role in initiating and amplifying the diverse effector 
mechanisms responsible for graft rejection. Adoptive transfer studies using congenitally 
athymic T cell deficient rats have clearly demonstrated that CD4 T cells alone are sufficient to 
initiate rejection of fully allogeneic grafts, whereas CD8 T cells are neither necessary, nor by 
themselves, sufficient to mediate rejection, even in high responder rat strain combinations 
[225,226,227,228,229,230]. In exceptional circumstances, notably mouse skin grafts bearing 
a mutant Class I MHC disparity, CD8 T cells alone appear able to mediate graft rejection 
autonomously, but in most other circumstances CD4 T cells play an essential role, [231]. The 
central role of CD4 T cells in graft rejection can be attributed to their ability to function 
effectively as T helper cells, releasing the necessary cytokines for orchestrating the various 
effector pathways, including cytotoxic T cell-mediated lysis [232,233], delayed type 
hypersensitivity responses [232,234] and B cell activation and humoral immunity [226,230]. 
The CD4 molecule is therefore an obvious target molecule for prevention of graft rejection 
and mAb therapies directed against CD4 T cells provide an attractive tool with which to 
manipulate the alloimmune response with the aim of promoting long-term graft survival.
The use of anti-CD4 mAb to perturb the function of CD4 T cells has been shown to be an 
effective strategy for prolonging the survival of skin and vascularised organ allografts in 
various rodent models of transplantation [160,161,162,163]. Moreover, in some animal
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models, anti-CD4 therapy has been shown to induce a state of permanent and specific 
tolerance, such that treated recipients accept further grafts of the original donor strain but 
promptly reject those from unrelated strains [160,162,164,165,166,167]. Early studies 
employing anti-CD4 mAb used antibody treatment protocols which resulted in profound and 
prolonged depletion of CD4 T cells. More recent studies however, have focused on the use of 
partially depleting or non-depleting anti-CD4 regimes and have shown that complete 
elimination of CD4 T cells is not an essential prerequisite for prolongation of allograft 
survival. Since non-depleting or partially depleting protocols are likely to be associated with 
a considerably shorter period of non-specific immunosuppression than depleting protocols, 
they are likely to be of greater clinical value.
The central aim of this thesis was to investigate the possible mechanisms involved in the 
induction and maintenance of transplantation tolerance resulting from administration of a 
partially depleting pre-operative course of the mouse mAb MRC 0X38 [213] which is 
directed against the rat CD4 molecule. Previous studies using MRC 0X38 have shown that 
transplantation tolerance, which is dependent on the presence in the recipient of an intact 
thymus gland, can be induced in ACI (R Tla) rats receiving Lewis heart allografts [160]. For 
the present studies, the same low responder strain combination was employed in a heterotopic 
cardiac allograft model. In the experiments described in this chapter, the depletion of CD4 T 
cells and their subsets was determined at various time-points following antibody treatment 
and cardiac transplantation and the ability of the residual T cells to proliferate and produce 
IL-2, when re-challenged in vitro with alloantigen, was analysed. To seek evidence for 
polarisation of the alloimmune response to either a Thl or Th2 response, the cytokine mRNA 
profile within rejecting and tolerant heart allografts was assessed using RT-PCR. 
Furthermore, to provide additional information as to whether a dominant Thl or Th2 response
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was evident in the tolerant recipients, the isotype of the alloantibody response was 
determined.
3.2 RESULTS
3.2.1 Protocol fo r  all in vivo pre-treatment o f  animals using MRC 0X38 mAb
For all of the studies in this thesis, unless otherwise stated, the anti-CD4 mAb 0X38 was 
administered IP at a dose of 10 mg/kg on day minus 3, and 2 mg/kg on days minus 2, minus 
1, and 0 (relative to the day of transplant). This treatment protocol of 0X38 mAb was based 
on that found by Shizuru et. al. [162] to promote tolerance of Lewis (RT11) hearts in ACI 
(R Tla) rats. For convenience, this protocol of 0X38 mAb treatment is subsequently referred 
to as the ‘standard protocol’. For all of the studies described in this thesis, 0X38 mAb was 
affinity purified. In addition, unless otherwise stated, all studies were performed in adult 
male DA rats.
3.2.1.1 Pre-treatment o f  DA recipients with MRC 0X38 mAb results in long-term acceptance 
o f Lewis cardiac allografts
An initial study was performed to confirm that the standard treatment protocol of 0X38 was 
able to prolong the survival of Lewis heart grafts in fully allogeneic DA recipients. The 
results are shown in Table 3.1. The control group received MRC 0X21 mAb [220] instead of 
0X38. Although 0X21 is an IgGl mAb whereas 0X38 is an IgG2a subclass mAb, it was
Chapter 3-66
readily available in the laboratory and it was decided that it would be an acceptable control 
antibody.
Table 3.1
Group M onoclonal Antibody Treatment (mAb)* n Graft Survival (days) MST (days)
1 0X21 (Control Antibody) 7 8 ,9 ,10x2 ,11 ,14x2  10
2 0X 38 7 8,>100 x 6 >100
*mAb was administered by IP injection at a dose o f lOmg/kg (day -3 ) ,  and 2m g/kg (days -2 ,  -1 ,  0). DA  
recipient animals received a Lewis cardiac allograft on day 0. 0X 21  (Control Antibody) is a mouse mAb 
which is directed against human C3b inactivator. Graft rejection was defined as complete cessation of 
ventricular contraction.
As expected, all animals receiving the control mAb, OX21, rejected their cardiac allografts 
rapidly with a MST of 10 days. In contrast, although one animal given anti-CD4 mAb 0X38 
rejected its heart graft promptly at 8 days, the other 6 animals treated with 0X38 showed 
long-term allograft survival and had readily palpable beating allografts for greater than 100 
days following transplant (the duration of the experiment).
3.2.1.2 Following transplantation using 0X38 pre-treatment, DA animals display 
allospecific, but not tissue specific tolerance
To test if  DA animals with long-term Lewis heart allografts after pre-transplant 0X38 
treatment were tolerant to donor alloantigen, four animals with functioning primary cardiac 
allografts at greater than 100 days were challenged with both a PVG (RT1°, third party) and a 
Lewis (RT11, allospecific) skin allograft. In addition, the four animals received a Lewis 
orthotopic renal allograft and underwent contralateral nephrectomy 7 days later, leaving their
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survival dependent on the function of the transplanted kidney. The transplanted animals were 
examined daily and the end point for rejection of the individual skin grafts was taken as the 
day on which complete graft destruction had occurred. Table 3.2 summarises the graft 
survival data from this experiment. It can be seen that all recipients rejected third party PVG 
skin grafts whereas Lewis skin and kidney allografts were accepted indefinitely (>100days). 
However, it is notable that the rejection times of the PVG skin grafts (MST 26 days) are 
longer than might have been expected in a normal DA rat.
Table 3.2
Group Recipient* Strain and type o f 2nd n Graft Survival MST (days)
donor allograft (days)
1 DA* PVG Skin (3rd party) 4 21 ,26x3  26
2 DA* Lewis Skin (Donor Specific) 4 > 1 0 0 x 4  >100
3 DA* Lewis Kidney (Donor Specific) 4 > 1 0 0 x 4  >100
* AH recipients were 0 X 3 8  treated DA rats bearing a long-standing (>100 days) prim ary Lewis cardiac 
allograft.
Sequential serum samples were also obtained from the four transplant recipients following 
renal allograft transplantation to determine urea and creatinine levels as an index of kidney 
allograft function. The results are shown in Figure 3.1.
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Figure 3.1 Measurement of renal function of transplanted RT11 (Lewis) kidneys
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It can be seen from Figure 3.1 that, following kidney transplantation, recipients with a long 
standing heart allograft maintained normal renal function, indicating that the kidney grafts did 
not suffer from significant graft rejection. From previous studies in the laboratory it was 
known that unmodified allograft recipients which reject renal allografts usually die o f  gross 
renal failure within 2 days o f  contralateral nephrectomy and develop serum urea levels o f  
greater than 50 mMol/L and creatinine levels o f  greater than 1000 pM/L (Data not shown; 
Personal communication Mr. J Tweedle Dept o f  Surgery, Western Infirmary, Glasgow).
Chapter 3-69
Taken together, these data indicate that animals with long-term cardiac allograft survival 
following pre-operative 0X38 mAb, display donor specific but not tissue specific tolerance.
3.2.2 Following treatment with 0X38, the mAb, is quickly cleared from the serum
The observation that pre-transplant 0X38 mAb treatment led to long-term impairment of 
allograft rejection, raises the question as to how long the administered mAb persists in treated 
animals. To determine the extent to which administered 0X38 mAb persisted in the serum of 
treated rats, animals given the standard protocol of 0X38 were bled serially from the tail vein 
to obtain serum samples at 2, 18, 48, and 72 hrs after the last injection of anti-CD4 antibody. 
The serum samples were then used to stain normal LNCs in vitro in order to determine 
whether they contained residual 0X38 mAb. Briefly, the serum samples were heat 
inactivated and then incubated neat with DA LNCs for 30 Min at 4 °C. The target cells were 
washed three times by centrifugation and were then incubated with RaMo-FITC and analysed 
by flow cytometry using an EPICS XL® fluorescent cell sorter (Coulter, Luton, UK), to detect 
bound 0X38 mAb. As a negative control, serum from normal DA rats was used and as a 
positive control, a saturating dose of 0X38 mAb was added to the serum from normal DA 
rats. The results of this experiment are shown in Figure 3.2. It can be seen that there is no 
evidence of residual 0X38 mAb in serum samples taken at 72 hrs and that even by 18 hrs, 
only low amounts of residual 0X38 mAb were present which were insufficient to saturate 
CD4 binding sites on the target cells. Thus, 0X38 antibody is rapidly cleared from the serum 
of treated animals.
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Figure 3.2 Ability of serum obtained from 0X38 treated animals to label normal 
CD4 T cells in vitro
□  Control
□  0X38 Treated
Pre-Tx C 2 18 48 72
Time After 0X38 Treatm ent (Hours)
DA LNC target cells were stained with serum which was obtained from animals prior to 0X 38 treatment 
(Pre-Tx) and at times indicated, following the last dose of the standard in vivo anti-CD4 treatment 
protocol.
Control (C) is LNC staining using pre-treatment serum to which a saturating dose of 0X38 had been 
added in vitro .
3.2.3 In-vivo treatment with 0 X 3 8  causes modest levels o f  modulation o f  CD4 molecules 
and the mAh is no longer detected on the surface o f  PBL or LN C by 72 hrs after 
treatment
Having shown that 0 X 38  mAh persists for a relatively short time in the serum o f  treated 
animals, studies were then performed to determine how long 0 X 38  persists on the surface o f  
CD4 T cells in the peripheral blood and lymph nodes o f  anti-CD4 treated animals. In 
addition, evidence for modulation o f  CD4 molecules following 0 X 3 8  treatment was sought. 
Determination o f  cell-surface CD4 expression was measured after sacrificing treated and/or
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transplanted animals (a minimum of four animals in each group) at various time-points and 
analysing fluorochrome labelled cells. Each antibody employed in the analysis was used at a 
saturating concentration pre-determined using PBL and LNCs taken from control untreated 
animals (data not shown).
PBL and LNC were obtained from animals at 2, 48, 72 and 96 hrs after the last injection of 
0X38 mAb. They were then stained in vitro with RaMo-FITC to determine residual 0X38 
labelling. In addition, a saturating amount of 0X38 mAb was added to the cells in vitro and 
they were then stained with RaMo-FITC to provide a measurement of total 0X38 binding 
sites. Figures 3.3 and 3.4 show representative results of single label flow-cytometry analysis 
from this experiment. The figures show labelling of cells from a control untreated animal 
(left panels) and labelling of cells obtained 2 hrs following the last injection of mAb using the 
standard protocol of 0X38 pre-treatment (right panels). Residual (upper panels), and total 
0X38 labelling (lower panels) of PBL and LNC are shown. The horizontal gating in this 
analysis shows the relative % of cells in each area of the profile. The y-axis shows the cell 
count and the x-axis shows the Logio of the FITC signal and is indicative of the intensity of 
the signal. The results illustrated are typical of the results obtained from several other 
experiments.
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Figure 3.3 Residual and total binding of 0X38 to PBL following in vivo anti-CD4 
treatm ent
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Typical single colour fluorescence analysis. Cell number (Count) is depicted on y-axis and the Log10 of 
the FITC fluorescence is depicted on the x-axis. Left panels (A) and (C) are PBL cells from a control 
naive untreated animal whereas the right panels (B) and (D) are PBL cells from a Day 0 (2 hr after last 
treatment) 0X 38 mAb treated animal. Upper panels (A) and (B) show the profiles using FITC- 
conjugated rabbit-anti-mouse antibody alone and the lower panels (C) and (D) depict the cell staining 
when a saturating amount of 0X38 mAb was added exogenously to the cells prior to FITC-RaMo.
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Figure 3.4 Residual and total binding of 0X38 to LNC following in vivo anti-CD4 
treatm ent
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Typical single colour fluorescence analysis. Cell number (Count) is depicted on y-axis and the Log,0 of 
the FITC fluorescence is depicted on the x-axis. Left panels (A) and (C) are LNC from a control naive 
untreated animal whereas the right panels (B) and (D) are LNC from a Day 0 (2 hr after last treatment) 
0X 38 mAb treated animal. Upper panels (A) and (B) show the profiles using FITC-conjugated rabbit- 
anti-mouse antibody alone and the lower panels (C) and (D) depict the cell staining when a saturating 
amount of 0X 38 mAb was added exogenously to the cells prior to FITC-RaMo.
Figure 3.5 shows the in vivo labelling and CD4 molecule modulation following the treatment 
o f  DA recipients with the standard in vivo protocol o f  0 X 3 8  mAb treatment. In this figure, 
the results o f  several flow cytometric analysis are combined and expressed as a bar chart. 
100% maximum fluorescent intensity refers to the value obtained when normal LNC or PBL 
are labelled with a saturating amount o f  0 X 3 8  mAb followed by RaMo-FITC. Values below 
the 100% level, indicate an increasing degree o f  CD4 molecule modulation from the
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lymphocyte cell-surface. The unfilled portion o f  each bar in this figure, represents the 
residual in vivo labelling with 0X 38 , whereas the filled portion represents additional CD4 
molecules which are labelled when exogenous 0 X 3 8  mAb is added in vitro to the cell 
population (i.e. total CD4 labelling).
Figure 3.5 In vivo labelling and modulation of PBL and LNC CD4 molecules 
following 0X38 treatm ent
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Results are expressed as the mean number (from a minimum of 4 animals in each group) of the % 
maximum fluorescence intensity of PBL and LNC following staining with RaMo-FITC (residual in vivo 
0X38 labelling) or 0X38 then RaMo-FITC (total CD4 binding sites). Open columns represent in vivo 
labelling and fdled columns represent total CD4 binding. A drop down from % 100 Max Fluorescence 
Intensity represents the degree of modulation of CD4 molecules. Control untreated naive animal cells are 
represented by (C) whereas the 0X38 treated animal cells at each point are represented by the time in hrs 
after last injection of mAb. Upper panel are from PBL and lower panel are LNCs.
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Overall, the data from this analysis show that the 0X38 treatment protocol used in these 
studies results in partial modulation of CD4 molecules at 2 hrs post treatment. The CD4 
modulation observed was slightly more pronounced in PBL than in LNC. However, it is 
evident that significant CD4 modulation was no longer detected at 48 hrs after in vivo 
treatment with 0X38 mAb. The data also show that 2 hrs after the last dose of 0X38 mAb, 
CD4 molecules on lymphocytes from PBL were saturated with the 0X38 mAb but only 60% 
of CD4 T cells from LNC had bound 0X38 still detectable on their cell-surface. The loss of 
anti-CD4 mAb from the surface of both PBL and LNC lymphocytes by 72 hrs after the last in 
vivo treatment with 0X38 mAb is consistent with the lack of residual 0X38 mAb in the 
serum of treated animals at this time-point.
3.2.4 0X38 mAb treatment partially depletes both PBL and LNC CD4 T cells
The extent to which 0X38 mAb treatment depleted aPTCR+ve CD4+ve lymphocytes was 
determined by double label Flow Cytometric analysis using directly conjugated fluorochrome 
labelled antibodies against the CD4 and apTCR molecules. In each experiment, several 
internal controls, including labelling for other cell-surface antigens in combination with either 
anti-apTCR or anti-CD4, were included and cells from normal animals which had not 
received 0X38 mAb were also analysed for comparison. In each analysis, therefore, the 
absolute number of double positive (CD4+ve apTCR+ve) cells could be compared to the 
number of CD4+ve or apTCR+ve cells determined indirectly.
To determine the effect of 0X38 treatment on depletion of CD4 T cells, animals were 
sacrificed on days 0, 2, 4, 7, 21 and 100 following 0X38 mAb treatment and/or 
transplantation. Both PBL and LNC were labelled with R73-FITC and 0X38 + RaMo-PE
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(day 0 animals) or W3/25-PE (days 2, 4. 7, 21, 100 animals). The mAb W3/25 labels the rat 
CD4 molecule and competes for the same binding site as 0 X 3 8  mAb [215]. Figure 3.6 
summarises the results o f  this analysis. Each column represents the mean ± SD for a 
minimum o f  4 animals. The results show that on the day o f  transplant (day 0), the CD 4+ve 
a p T C R +' e cell fraction had fallen from 53% to 20% in PBL and from 52% to 27% in LNC. 
By day 4 after transplant, there appeared to be some recovery o f  CD4 T cell numbers in both 
peripheral blood and lymph nodes. Interestingly. CD4 T cell numbers never recovered 
completely, but by day 100, had returned to near pre-operative levels.
Figure 3.6 Residual CD4 T cells in PBL and LNC following 0X38 treatm ent and 
cardiac allograft transplant
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PBL and LNC were double labelled to detect CD4 and apTC R  cells (minimum of 4 animals in each 
group). Results are expressed as the % mean cell number ± SD. Control untreated naive animals cells 
are represented by filled columns (C) whereas the 0X38 treated animals are represented by open 
columns. Upper panel (A) are PBL and lower panel (B) are LNCs.
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3.2.5 The depletion o f  CD4 T cells following 0X38 mAb treatment is more pronounced in 
the CD45RC*ve (MRC O X 2 tigh)  subset than in the CD45RCve (MRC OX22low) subset
Rat CD4 T cells can be subdivided according to their expression of the high molecular 
isoform of the leukocyte common antigen, CD45RC, by their reactivity with the mAb MRC 
0X22 [219]. Although the CD45 molecule is found on the cell-surface of all leukocytes, the 
0X22 determinant is restricted to rat B cells, non-activated CD8 T cells, N a t u r a l  K iller  
(NK) cells, some bone marrow cells, 2% of thymocytes and two-thirds of CD4 T cells [235]. 
Rat leukocytes expressing the high molecular weight isoform of CD45 (CD45RC+ve) labelled 
with 0X22 are typically described as OX22+ve, OX22hlgh or OX22bright, whereas cells 
expressing the low molecular weight isoforms are typically described as OX22've, OX22low or 
OX22dul]. As a result of the profile continuum on flow-cytometric analysis due to differential 
expression of CD45RC antigen and binding of 0X22 mAb, the distinction between the CD4 
T cell subsets is probably best described by the terms high and low. Consequently, CD4 T 
cells labelled with 0X22 in the studies described in this thesis are referred to using the 
nomenclature of OX22hlgh and OX22low. The observation that functional heterogeneity exists 
between the OX22hlgh and OX22low CD4 T cell subsets, namely the ability of the OX22hlgh 
CD4 T cell subset to induce G r a ft  V er su s  H o s t  D ise a se  (GVH) [219] and restore allograft 
rejection and normal T cell effector mechanisms in CD4 T cell deficient nude rats [236], lead 
me to explore the possibility that 0X38 mAb treatment may preferentially affect one, or the 
other o f the CD4 T cell subsets.
To analyse the effect of 0X38 mAb treatment on the two CD4 T cell subsets, peripheral 
blood and LNCs from treated animals were labelled using 0X22 mAb. To exclude the 
possibility of analysis bias, the flow cytometric gates were standardised for each experiment 
and were identical for each cell sample. Figure 3.7 show typical two colour flow cytometric
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profiles obtained after labelling PBL (upper panels) and LNC (lower panels) o f  control (left 
panels) and 0 X 3 8  treated animals (right panels) with the 0 X 2 2  mAb. As an internal control, 
each experiment included labelling the cells for CD4 and apT C R . The number o f  double 
positive cells (CD4+NC a p T C R +ve) was compared with the number o f  C D 4+NL OX22hlgh + l0" 
cells and in each experiment, the percentage o f  cells labelled was found to be very similar, 
indicating that flow cytometric gating and cell staining was uniform for each experiment.
Figure 3.7 Labelling for CD45RC antigen and for CD4 using 2 colour Flow 
Cytometric analysis
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Typical two colour fluorescent analysis using FlTC-conjugated anti-CD45RC y-axis (Log,0 FITC signal) 
and PE-conjugated anti-CD4 x-axis (Log,0 PE signal). Left panels (A) and (C) represent cells from a 
control naive untreated animal whereas the right panels (B) and (D) are from a Day 4 0X38 treated and 
transplanted animal. Upper panels (A) and (B) shows the staining for PBL and the lower panels (C) and 
(D) depict the staining for LNC.
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Figure 3.8 shows the results of several different flow cytometric analysis experiments 
expressed as a bar chart. This figure shows the percentage of CD4+ve OX22hlgh (left panels) 
and CD4+ve OX22low (right panels) obtained after labelling PBL (upper panels) and LNC 
(lower panels) from control and 0X38 treated animals on days 0, 2, 4, 7, 21, and 100 after 
0X38 treatment and/or cardiac allograft transplant. It can bee seen that the depletion of CD4 
lymphocytes following 0X38 treatment was associated with preferential loss of the OX22hlgh 
fraction of CD4+ve T cells. There was almost complete sparing of the OX22low fraction. This 
observation can be interpreted as either preferential depletion of the OX22hlgh subset by 0X38 
mAb, or CD4 depletion associated with isotype switching to the low molecular weight form 
of the residual CD4 T cells.
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Figure 3.8 Preferential depletion of the CD45RC+' c CD4 T cell subset following 
0X 38 treatm ent and cardiac allograft transplant
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Results are expressed as the % mean cell num ber ± SD of PBL and LNC staining double positive for CD4 
and CD45RC(+ve and ve) from a minimum of 4 animals in each group. Control untreated naive animals are 
represented by filled columns (C) whereas the 0X 38  treated animals are represented by open columns. 
Panels (A) and (C) represent the proportion of cells labelling positive for CD4 and CD45RC+ve. Panels 
(B) and (D) represent the proportion of cells which labelled CD4 positive but were CD45RC"ve. Upper 
panels (A) and (B) are from PBL and lower panels (C) and (D) are LNCs.
3.2.6 A bility  o f  LN C  fro m  0 X 3 8  mAb treated graft recipients to proliferate and  produce IL- 
2 in the M LR
Although 0X38 mAb treatment made DA recipients tolerant to a Lewis cardiac allograft, it 
was apparent from the preceding studies that significant numbers of CD4 T cells remained 
after 0X38 treatment, and that T cell depletion was no longer apparent by day 100 after 
transplant. It was therefore of interest to determine the ability of LNC from such 0X38 
treated animals to proliferate and produce IL-2 when restimulated in vitro  with irradiated
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donor strain (i.e. Lewis) stimulator cells in a one way MLR. A feature of MLR which can 
make assays performed on separate days difficult to compare, is that there can be wide 
experiment to experiment variation in the levels of proliferation observed, despite careful 
standardisation of the assay system. Therefore, because MLR experiments were performed 
on several different days, each experiment was “standardised” by including a measurement of 
the proliferation of naive control cells to alloantigen in each assay and designating the 
proliferation observed as 100%. The ability of LNC harvested at different time-points from 
0X38 mAb treated heart graft recipients to proliferate in vitro is shown in Figure 3.9. In the 
figure, the mean proliferation (using a minimum of 4 animal per group), has been divided by 
the control proliferation for that particular experiment and then multiplied by 100 to give a 
value relative to the 100% control value. Supemates from proliferating cells were obtained 
on the day of maximum proliferation and were tested for IL-2 activity using an IL-2 
dependent cell line as described in the Materials and Methods (Section 2.12). To test the 
ability of cells taken from 0X38 treated DA animals to proliferate in vitro in response to 
alloantigen, LNCs were obtained from animals at 2, 4, 7, 21 and 100 days post transplant and 
were challenged in vitro using Lewis irradiated spleen cells. Untreated DA animals bearing a 
rejecting Lewis heart graft were used as a comparison at 2, 4, and 7 days following 
transplantation. Day 0, 0X38 treated and naive untreated untransplanted animal cells were 
also used and have been plotted in the figure. The bar graph in Figure 3.9 shows the peak 
proliferation (day 3 MLR) results, while the line plot shows IL-2 production measured from 
the supemates of the proliferating cells from each sample.
As shown in Figure 3.9, the proliferation of cells from 0X38 treated animals at day 0 is only 
50% that of the naive cells. This reduction in proliferation is in keeping with the observation 
that 0X38 can inhibit LNC proliferation in MLR when added exogenously in vitro since at
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day 0, the CD4 T cells obtained from anti-CD4 treated animals are still coated with mAb. At 
days 4, 7 and 100, 0X38 treated animals show allospecific sensitisation and proliferate more 
than cells obtained from normal animals. Interestingly, the sensitisation which occurred in 
the 0X38 treated animals was not as marked as that observed in untreated animals which 
rejected their allografts where proliferation was two fold greater than that observed in 0X38 
treated heart graft recipients.
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igure 3.9 Mixed lymphocyte proliferation and IL-2 production of LNC from control
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LNC from unmodified DA animals with rejecting Lewis heart grafts are represented by filled boxes and 
columns (Control) whereas responses from LNC taken from the 0X38 treated animals at each point are 
represented by open diamonds and columns (0X38). Results are expressed as mean number from 4 
animals at each of the time-points, of Day 3 LNC proliferation and IL-2 production from an MLR using 
DA responder cells cultured with irradiated Lewis stimulator cells. Cell cultures were pulsed with 3H- 
Thymidine, harvested 18 hrs later onto microtitration filter paper, and analysed using a Beta Liquid 
Scintillation counter. Supemates from proliferating cells were used in an IL-2 bioassay as described in 
the Materials and Methods Section 2.12. The proliferative response of untreated naive control animal 
cells (Day 0) is taken as a proliferation index of 100%. Proliferation results are expressed as a Bar chart 
(Left y-axis) whereas the IL-2 results are expressed as a Line chart (Right y-axis).
When analysing the IL-2 data, it is interesting to note that even when LNC from 0 X 3 8  treated 
animals (on days 4, 7, and 100) proliferated in excess to LNC from normal animals (day 0) 
and control rejecting (day 2) cells, the IL-2 production from the 0 X 3 8  treated animals was
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less than that seen in cells from normal animals and never reached 50% of the peak IL-2 
observed in the control rejecting cells on day 2.
3.2.7 0X38 mAb treated heart graft recipients show a delayed alloantibody response
After observing that LNC from 0X38 mAb treated heart graft recipients displayed differences 
in IL-2 production in the one way MLR when compared with untreated control LNC, further 
evidence for abrogated effector function in anti-CD4 treated recipients was sought. In 
particular, the ability of 0X38 treated and unmodified heart graft recipients to mount a 
cytotoxic alloantibody response was determined as another measure of CD4 T helper cell 
function. Serum samples were obtained from graft recipients on days 0, 4, 7, 21 (0X38 
treated) and 100 (0X38 treated) and tested for the presence of cytotoxic antibody against 
donor strain (Lewis) target cells in a standard complement dependent cytotoxicity assay using 
guinea pig complement as a source of complement. The results are depicted in Figure 3.10 
which shows the cytotoxic antibody titre, expressed as Log2 of the reciprocal dilution of 
serum which gave >50% specific release of 5lCr from the target cells.
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Figure 3.10 Cytotoxic alloantibody response of control rejecting and 0X38 mAb 
treated tolerant animals
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Ser um samples from control rejecting (filled boxes) and 0X38 treated (open boxes) DA recipients of a 
Lewis heart allograft were assessed for cytotoxic alloantibody levels against MC r labelled Lewis Con-A 
blasts. Results shown are mean number ± SD of 4 animals per group. The y-axis represents Log2 of the 
reciprocal dilution of serum and the x-axis is the day follow ing heart transplantation on w hich serum was 
collected.
As expected, cytotoxic antibody levels were initially low in both groups o f  animals. They 
rose to a maximum titre o f  1:64 at day 7 in unmodified recipients bearing rejecting heart 
allografts. The 0 X 3 8  mAb treated graft recipients showed a delayed cytotoxic alloantibody 
response, but by day 100 the levels o f  cytotoxic alloantibody observed were comparable to 
those observed at day 7 in the unmodified graft recipients.
To determine the antibody isotype o f  alloantibody in serum taken from DA recipients o f  
Lewis cardiac allografts, target LNC from normal Lewis rats were incubated with serum 
samples obtained from unmodified and from 0X 38  mAb treated DA rats bearing Lewis 
cardiac allografts. The target cells were then stained with fluorescent conjugated mouse anti-
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IgM, IgG l, IgG2a, IgG2b, or IgG2c antibodies. T h e M f.a n  C h a n n e l . F l u o r e s c e n c e  (MCF) 
was then determined after analysing the fluorochrome labelled target cells. The results o f  this 
antibody isotype analysis are shown in Figure 3.11. It can be seen that at day 7 all isotypes o f  
alloantibody were respectively low in both groups o f  animals, despite the previously noted 
cytotoxic alloantibody found at day 7 in unmodified recipients bearing a rejecting heart 
allograft. By day 21, the 0 X 3 8  treated group showed a rise in the IgM, IgG2b and IgG2c 
alloantibody levels and by day 100, all alloantibody isotypes were increased. In retrospect, it 
would have been interesting to determine both cytotoxic alloantibody and alloantibody 
isotypes in unmodified graft recipients at days 21 and 100, but unfortunately these animals 
were sacrificed after they had rejected their grafts.
Figure 3.1! Class and subclass of alloantibody response in unmodified and 0X38 
mAb treated DA recipients of a Lewis cardiac allograft
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DA recipients of a Lewis cardiac allograft were assessed for alloantibody isotypes against Lewis LNC. 
Serum samples from control rejecting Day 7 animals are represented in the first group, whereas the 
0X 38 treated Days 7, 21, and 100 animals are represented in the second group. The results are the mean 
+ SD of the mean channel fluorescence. (Minimum of 4 animals in each group at each time-point).
Day 100 ,
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3.2.8 Non-rejecting cardiac allografts in 0X38 mAb treated recipients are heavily 
infiltrated by mononuclear cells
As the humoral effector response appeared intact in 0X38 mAb treated DA recipients bearing 
Lewis cardiac allografts, evidence for impaired cellular infiltration of heart allografts was 
sought. The cellular infiltrates in rejecting cardiac allografts from unmodified recipients and 
from non-rejecting heart allografts in 0X38 treated recipients were assessed by immuno- 
histochemistry to determine the magnitude and phenotype of the graft infiltrate. Cryostat 
sections of heart grafts were stained with a panel of monoclonal antibodies and a quantitative 
assessment of the infiltrate made. Figure 3.12 shows the cellular infiltrate of heart grafts from 
both unmodified and anti-CD4 treated animals at day 7, and of grafts from anti-CD4 treated 
animals at days 21 and 100 after transplantation. Both rejecting and non-rejecting cardiac 
allografts were, by day 7, heavily infiltrated by mononuclear cells. In all heart grafts there 
were large numbers of CD8+ve (0X8), CD4+ve (W3/25) and otpTCR+ve (R73) cells, as well as 
heavy infiltrates of macrophages (EDI) and IL-2 receptor-a (0X39) positive cells. The 
infiltrate in non-rejecting heart grafts from 0X38 treated recipients declined by day 21 and at 
day 100 and only occasional mononuclear cells were present. These were predominately 
ED l+ve macrophages. This data shows that tolerance induction using anti-CD4 mAb does not 
prevent the early infiltration of cardiac allografts by mononuclear cells, even those which are 
CD4 positive. However, with time, the mononuclear cell infiltrate in tolerant allografts 
declines.
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Figure 3.12 Infiltration of Lewis cardiac allografts in control rejecting and 0X38 mAb 
treated DA recipient rats
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Lewis cardiac allografts obtained from DA recipients were assessed for mononuclear cell infiltration by 
immunoperoxidase staining. Cardiac allograft samples from control rejecting Day 7 animals are 
represented in the first group, whereas the 0X38 treated Days 7, 21, and 100 animal allograft samples are 
represented in the second group. The results are expressed as cells per high power field. Heart sections 
from 4 animals in each group were examined and results are depicted as mean + SD.
3.2.9 Rejecting cardiac allografts from  unm odified recipients and tolerant allografts from  
0 X 3 8  mAh treated recipients show sim ilar mRNA cytokine transcripts
As both rejecting and tolerant cardiac allografts were initially heavily infiltrated with 
mononuclear cells, it was therefore o f  interest to assess whether there were differences in the 
cytokines present in rejecting and non-rejecting cardiac allografts. To determine the cytokine 
activity associated with the graft infiltrates, cytokine mRNA transcripts were assessed semi- 
quantitatively in rejecting and non-rejecting hearts using the polymerase chain reaction (RT- 
PCR). Primers specific for IL-2. INF-y, IL-2Ra, IL-2Rp. IL-4, IL-10, IL-13, and IL-5 were
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used (see Materials and Methods Section 2.17 for details). The results obtained for heart 
grafts from both control rejecting and anti-CD4 treated animals on days 2, 4, and 7 after 
transplantation are displayed in Figures 3.13, 3.14, and 3.15 respectively. The results 
obtained for heart grafts from anti-CD4 treated animals at day 21 and day 100 after 
transplantation are shown in Figure 3.16. For each of the time-points after transplantation, 4 
individual cardiac allografts from each experimental group were examined and these are 
labelled (a) to (h) in each of the figures. RT-PCR reactions were stopped at five different 
cycle numbers and the RT-PCR product was analysed after electrophoresis using 1% agarose 
gels which were stained with Ethidium Bromide. The presence of visible PCR product after 
ultra-violet illumination is indicated by a “+“ for each sample. To ensure that an equal 
amount of starting material was used for each comparison, the cDNA from each heart graft 
was analysed at 3 different dilution’s, (1/100, 1/10, and neat) and material at each dilution 
was analysed at 3 different cycle numbers, using the housekeeping gene primer, p-actin. A 
representative Polaroid photographic image of the gels from each experiment and for each 
cytokine have been included in the figures and in each case these were obtained from the 
cardiac allograft which had the most intense staining; it should be pointed out that the 
presence of visible PCR product by naked eye examination of the ultra violet illuminated gel 
(on which the scoring of RT-PCR product was based) did not necessarily equate to visible 
reproduction of the PCR product on the photographic image.
The cytokine profiles of rejecting heart allografts obtained 2 days after transplant from 
unmodified recipients and non-rejecting day 2 heart grafts from 0X38 mAb treated recipients 
are compared in Figures 3.13. It can be seen that there were similar amounts of cytokine 
message in heart grafts from the two experimental groups for all primers used, with exception 
of those for IL-10. Message for IL-10 was present in reduced amount in the heart grafts from
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0X38 treated recipients than grafts from unmodified recipients. Figures 3.14 and 3.15, 
compare day 4 and day 7 rejecting and 0X38 treated non-rejecting cardiac allografts 
respectively and demonstrate that there was no major difference in the level of cytokine 
message between the two experimental groups. The cytokine profiles from day 21 and day 
100 cardiac allografts in the 0X38 treated recipients are depicted in Figure 3.16. This figure 
shows that day 21 and day 100 cytokine profiles are similar to the day 4 and day 7 graft 
profiles, with the exception that increased levels of IL-13 were detected in both the day 21 
and 100 hearts grafts. Additionally, very little cytokine message for IL-10 was detected in the 
day 100 heart allografts obtained from 0X38 mAb treated recipients.
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Figure 3.13 Cytokine PCR from Day 2 rejecting and 0X38 treated cardiac allografts
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Figure 3.14 Cytokine PCR from Day 4 rejecting and 0X38 treated cardiac allografts
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for the house keeping gene P-actin, a typical gel depicting this analy sis is show n at the top o f  the figure.
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Figure 3.15 Cytokine PCR from Day 7 rejecting and 0X 38 treated cardiac allografts
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Figure 3.16 Cytokine PCR from Days 21 and 100 0X38 treated cardiac allografts
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3.3 DISCUSSION
The initial results described in this chapter confirmed the observation [160] that a brief period 
of treatment with the anti-CD4 mAb, MRC 0X38, at the time of heart transplantation, leads 
to donor specific transplant tolerance in the fully allogeneic Lewis (RT11) to DA (R Tla) rat 
strain combination. In order to gain insight into the possible mechanisms whereby anti-CD4 
mAb could promote graft survival and tolerance induction in this experimental model, a 
detailed phenotypic analysis of the lymphocyte populations of the antibody treated 
transplanted animals was made, followed by an analysis of the cellular and humoral responses 
of the graft recipients to donor strain alloantigens.
The results of the flow cytometric analysis to determine the duration of 0X38 binding to 
residual CD4 T cells and the assessment of CD4 modulation were o f particular interest. 
Following 0X38 treatment, residual CD4 T cells in the blood and lymph nodes remained only 
transiently coated with anti-CD4 mAb and the residual CD4 cells showed no detectable in 
vivo labelling 72 hrs after transplant. The short period of residual CD4 T cell coating with 
mAb contrasts sharply with similar studies in the mouse [167] in which the antibody persisted 
for several weeks. The 0X38 mAb pre-treatment protocol resulted, initially, in partial 
modulation of CD4 molecules from residual cells in both blood and LNC. However the CD4 
modulation observed was short lived and expression of surface CD4 molecules recovered by 
48 hrs in both compartments. Additionally, the anti-CD4 treatment protocol saturated all 
available CD4 molecules on the surface of PBL, but not LNC. These results imply that 
modulation of CD4 from the T cell-surface is unlikely to play a major role in the induction of 
tolerance observed in this experimental model. This finding contrasts with those from 
models of anti-CD4 induced transplantation tolerance in which either non-depleting or 
depleting anti-CD4 protocols were found to cause profound and long lasting modulation of
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CD4 molecules from the T cell-surface [167,237]. The CD4 modulation observed in these 
studies, may, however, not be a critical event in the perturbation of T cell function, but, 
rather, may be one step in a cascade which involves other molecular mechanisms. These may 
include interruption of downstream intracellular signalling events within the T cell resulting 
in T cell inhibition and subsequent tolerance induction.
The number of T cells required to initiate and effect allograft rejection is relatively small, for 
example transfer of 5 x 106 purified T cells is sufficient to cause rejection of fully allogeneic 
kidney allografts in the rat [225]. Consequently, T cell depletion is not likely to be the 
principal mechanism involved in 0X38 mAb induced transplantation tolerance. Analysis of 
CD4 T cell numbers in the peripheral blood and lymph nodes of 0X38 treated animals 
revealed that the mAb treatment produced approximately 50-60% CD4 T cell depletion 
around the time of heart transplantation. CD4 T cell numbers gradually recovered thereafter 
and were near normal by 100 days. Additional results, to be described in Chapter 5, provide 
further support for the view that CD4 T cell depletion is not the sole reason for induction of 
tolerance after 0X38 mAb. These results show that 0X38 mAb treated animals which have 
been thymectomised as adults before anti-CD4 treatment, reject their heart allografts 
promptly with kinetics similar to unmodified control animals.
Interestingly, when the phenotype of the residual CD4 T cells in 0X38 treated animals was 
examined, there was apparent sparing of the CD4+ve OX22low fraction, suggesting preferential 
depletion of the CD4+ve OX22hlgh T cell subset in these animals. It has been suggested that 
the rat OX22hlgh CD4 T cell subset may be equivalent to murine Thl cells because of the 
ability of these cells to initiate GVH [219], provide B cell help in antibody production 
[89,238] and because of the Thl like cytokine profile of OX22hlgh cells in response to 
mitogenic and allogeneic stimulation in vitro [238]. Additionally, Bell and colleagues have
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shown that reconstitution of congenitally athymic RT1C (PVG) nude rats with OX22hlgh CD4 
T cells, obtained from euthymic naive RT1C (PVG) donors, restores normal peripheral T cell 
function to the nude recipients which develop normal GVH responses, allograft rejection and 
thymus-dependent antibody production [236]. In contrast, reconstitution of nude rats with 
OX22low T cells does not restore peripheral T effector cell function.
The apparent preferential depletion of the CD4+ve OX22hlgh T cell subset in the present 
experimental model, is consistent with the recent observations of Stumbles and Mason [239]. 
They found that activation of rat CD4 T cells in vitro, in the presence of a non-depleting anti- 
CD4 antibody (W3/25), led to a preferential Th2 type cytokine response by the CD4 T cells. 
Stumbles and Mason suggested that this was due to preferential inhibition of the Thl CD4 T 
cells by the anti-CD4 mAb. This observation is also consistent with the results of Goedert 
and colleagues [240], who showed that anti-CD4 mAb selectively inhibited the differentiation 
in vitro of Thl like, but not Th2 like, CD4+ve T cells.
Another explanation for the present observation is that after 0X38 mAb treatment, CD45 
isotype switching from the CD4+ve OX22hlgh to the CD4+ve OX22low isoform may have 
occurred. However, as will be seen later, analysis of the CD4+ve OX22low fraction, (discussed 
fully in Chapter 5), revealed that this particular subset was made up predominantly of Thy- 
l +ve T cells. The Thy-1 antigen in the rat is expressed by immature thymocytes and RTE cells 
and it is unlikely, therefore, that isotypic switching may have occurred. Why preferential 
depletion of the CD4+ve OX22hlgh T cell subset should occur after 0X38 mAb treatment is not 
known. One possibility is that this subset of CD4 T cells is more likely to apoptose, either as 
a result of cross linking with bivalent anti-CD4 mAb or after contacting alloantigen whilst 
coated with anti-CD4 mAb. Functional differences between CD4+ve OX22hlgh and CD4+ve 
OX22low cells regarding cytoplasmic expression of protein tyrosine phosphatase (PTPase) and
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their intracellular signalling capabilities have been described [241]. Differential depletion 
may be a result of the differential intracellular signalling capabilities of these cells, because 
alternate intracellular signalling pathways are utilised following CD4 ligation with mAb. If 
so, it is reasonable to speculate that this may lead to differential up-regulation of CD95 (Fas) 
and hence apoptosis in the CD4+ve OX22hlgh T cell subset, but not in the CD4+ve OX22low T 
cells.
Addition of anti-CD4 mAb to rat T cells in vitro prevents them from proliferating to 
allogeneic stimulators and impairs their ability to produce IL-2 [239]. It was of interest, 
therefore, to examine whether LNC from tolerant anti-CD4 treated recipients were able to 
proliferate and produce IL-2 in vitro in a one way MLR. As described, CD4 T cells from 
anti-CD4 treated and transplanted animals showed allospecific sensitisation and proliferated 
to a greater extent than LNC obtained from normal DA rats. However, when the supernatants 
from the proliferating LNC were tested for IL-2 activity, using an IL-2 dependent cell line, 
0X38 mAb treated animals showed less IL-2 activity, compared to samples obtained from 
naive LNC. It should be noted, however, that interpreting measurements of IL-2 production 
in the MLR is potentially problematic. For example, low levels of IL-2 in the supemates may 
be attributable to reduced production of IL-2 by the responding T cell population, but could 
also arise if the responding T cell population consumes the IL-2 after it has been released. 
Another point to note is that in the MLR experiments, an equal number of responder LNC 
was used for each well. Therefore, when cells were obtained from 0X38 treated animals, at 
the early time-points, the fraction of CD4+ve T cells in each MLR well was proportionally less 
than the number of CD4+ve T cells obtained from rejecting control animals. Nevertheless, IL- 
2 production in vitro was still reduced when cells were obtained from tolerant 0X38 treated 
animals 100 days after transplantation where the proportion of CD4+ve cells in LNC was
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similar to that found in control animals. Despite reduced IL-2 production, T cells obtained 
from 0X38 mAb treated tolerant animals responded vigorously in MLR to donor alloantigen. 
This T cell proliferation could, in principle, have been due to a T cell growth factor other than 
IL-2. Unfortunately, after testing for IL-2, there was not sufficient supemate to allow testing 
for other pro-proliferative cytokines, such as IL-4.
Initial assessment of mononuclear cell infiltration of the Lewis cardiac allografts obtained 
from unmodified and from anti-CD4 treated DA recipients, showed that grafts from both 
experimental groups were heavily infiltrated with CD8+ve, CD4+ve, ocPTCR+ve and IL-2Ra+ve 
cells and cells of the macrophage lineage with no apparent difference between the 
experimental groups. To determine whether there was evidence for a shift from one type of T 
helper response to another, cardiac allografts were also assessed for the presence of Thl and 
Th2 cytokine message. Intragraft mRNA transcripts for IL-2, INF-y, IL-2Ra, IL-2Rp and IL- 
4 were readily detectable by RT-PCR to a similar extent in both tolerant and rejecting heart 
grafts. The amount of IL-10 message was greater in rejecting heart grafts at day 2 and was 
almost undetectable in tolerant grafts at day 100. At days 2,4 and 7 following transplantation, 
IL-13 levels were detectable to a similar extent in both rejecting and non-rejecting grafts. The 
preliminary cytokine mRNA data, therefore, provided no support for the suggestion that 
transplant tolerance in this particular experimental model was associated with a Thl to Th2 
cytokine shift. A degree of caution is, however, required in interpretation of the cytokine 
mRNA data in terms of the Thl/Th2 paradigm. The presence of mRNA for IL-4, IL-10 and 
IL-13 in rejecting heart allografts does not necessarily equate with the presence of Th2 
CD4+ve T cells, as non-lymphoid cells may, under certain circumstances, also produce IL-10 
[242], and cells of the mast cell and basophil lineage may produce IL-4 [243], Interestingly, 
message for the Th2 cytokine IL-13 was present to a similar extent in both tolerant and
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rejecting animal grafts early on, and appeared to be increased in heart grafts obtained from 
tolerant animals at days 21 and 100. The gene for rat IL-13 has only recently been cloned 
[244] and while human IL-13 shares many of the properties of IL-4, including B cell 
stimulation and Ig isotype switching [245], it is not yet clear to what extent rat B cells 
respond to IL-13.
Split tolerance (i.e. the ability of cells from tolerant animals to respond to donor alloantigen in 
vitro) is well recognised in a variety of experimental models where tolerance is induced by 
various means such as D o n o r  S pe c ific  B l o o d  T r a n s f u s io n  (DST) [246], anti-CD4 
treatment [162], neonatal inoculation of antigen [247,248] and Cyclosporin A treatment 
[249]. A recent report in which non-depleting anti-CD4 treatment was used to prolong 
survival of rat heterotopic cardiac allografts, noted that cells obtained during the induction 
phase of tolerance showed normal proliferation to donor antigen in a one way MLR but cells 
obtained from the long-term tolerant animals showed diminished proliferation in vitro [250]. 
In this experimental system the authors suggested that lack of T cell proliferation in the 
established tolerant state was due to inhibition of CD4 T cell help by the anti-CD4 mAb but 
they failed to explain why this phenomenon took several months to develop. The authors 
suggested that the emergence of stable tolerance was associated with a dominant polarised 
Th2 state and inferred that reduced T cell help was due to diminished IL-2 production.
Dallman et al [251] originally showed that tolerance induction, using a model of DST in rats, 
was associated with reduced IL-2 mRNA transcripts in the grafts of tolerant animals and that 
transplant tolerance in this experimental model could be overcome by the administration of 
exogenous IL-2 at the time of tolerance induction. On the basis of the Thl/Th2 paradigm, it 
seemed reasonable to assume that if tolerance was associated with a diminished Thl 
response, then Th2 cytokines might be enhanced and contribute to tolerance, and several
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groups involved in transplantation research rushed to find the evidence for Th2 dominance 
using a plethora of experimental models. Decreased Thl associated cytokines, with sparing 
of Th2 cytokines, has now been observed in several other transplantation models where organ 
graft survival was observed, including induction therapies using CTLA4-Ig [211] and non­
depleting anti-CD4 monoclonal antibodies [252,253]. Although there is a suspicion that 
immune deviation to a Th2 pattern of response in a model of Thl mediated graft rejection 
may be permissive for long-term engraftment, a Th2 type of alloimmune response may, 
paradoxically, support the development of chronic rejection in the longer term [211]. This 
suggestion is supported by some studies which have utilised immune modulating therapies 
aimed at polarising the alloimmune response towards a Th2 response. While this strategy has 
resulted in prevention of Thl mediated early rejection, grafts were lost in the longer term 
[254,255,256]. This data suggests that simply inhibiting a Thl response and enhancing a Th2 
response, is unlikely to be the panacea for preventing allograft rejection. Additional evidence 
also suggests that a polarised Th2 response does not necessarily confer transplant tolerance in 
some models of transplantation. Interestingly, liver transplantation in the same low responder 
rat strain combination which was utilised for the work in this thesis, (Lewis to DA), results in 
spontaneous tolerance of some allografts, whereas transplantation in the reciprocal high 
responder strain combination, (DA to Lewis), results in prompt rejection. When graft 
infiltrating cells were analysed by semi-quantitative RT-PCR following liver transplantation, 
the immune response in both strain combinations was found to be remarkably similar, the 
only difference being reduced mRNA expression of IL-4 in cells from the low responder 
tolerant group [257]. Moreover, using IL-2 KO mice in a pancreatic islet transplantation 
model, Steiger et. al. [258] were able to demonstrate that IL-2 was not required for allograft 
rejection and that the presence of IL-4 and IL-10 expression in the absence of IL-2 did not 
result in transplant tolerance - all transplants were rejected, albeit in a slower fashion than
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grafts in control animals. A potential problem with this and other cytokine KO mice is, as the 
authors themselves point out, that KO mice are not ‘normal’ animals with a single cytokine 
deficiency. One can imagine that as the immune system in KO animals develops, cells not 
dependent on the missing cytokine for growth or differentiation are positively selected for, 
and that other cytokines whose function overlaps with the missing cytokine, may also play an 
increased role within what is undoubtedly a highly redundant biological system.
In the present studies, the assessment of the alloantibody response in unmodified and anti- 
CD4 treated animals gave further insight into the nature of the T helper response. In the rat, 
on the basis of the selective effects of IL-12 on IgG isotype alloantibody responses, 
alloantibodies of the IgG2b and IgG2c subclass appear to be Thl mediated, and IgGl subclass 
antibodies are of Th2 T helper dependent isotypes [259]. The experiments in this chapter 
revealed a weak cytotoxic alloantibody response which was present in both rejecting and anti- 
CD4 treated tolerant animals. However, in the anti-CD4 treated recipients, the cytotoxic 
antibody response was slower to develop. The alloantibody isotype data confirms that early 
antibody responses in this model are relatively weak with only modest levels of alloantibody 
detected early on. Alloantibody levels were substantially higher in the long-term tolerant 
recipients but there was no evidence for dominance of any particular antibody isotype and 
hence no support, for the suggestion that tolerance in this particular experimental model is 
associated with a Thl to Th2 cytokine shift.
In the context of transplantation rejection and tolerance, the Thl/Th2 paradigm cannot be 
invoked universally to explain whether graft rejection or tolerance will result. A large 
number of studies have been published with contrasting results, some supporting and some 
negating the hypothesis. The apparent discrepancy between the results using different 
experimental systems, is perhaps, not surprising if one considers that the immune system in
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mammals has evolved by developing strategies to match the variation imposed by the 
pathogens it faces. Some experimental models may only exploit one facet of the immune 
response and with such a constraint the response may be skewed in one way or the other. For 
example, if an antigen which only generates a Thl or Th2 response is chosen to challenge the 
immune response and one manipulates the response and induces tolerance, it may not be 
surprising to find an intact opposing Th2 or Thl compartment (which could be interpreted as 
the important mechanism in tolerance induction). In allograft transplantation, it seems clear 
that immune responses dominated by both cell-mediated or humoral effector mechanisms 
may be detrimental to organ graft survival and depending on the species used, the strain 
combination tested, the influence of the immunosuppressive protocol employed and the time 
frame examined, domination of either cell-mediated or humoral effector mechanisms may be 
apparent. It remains to be determined whether manipulating the cytokine repertoire from one 
T helper response to the other will result in long-term allograft survival and tolerance 
induction.
If polarisation from one type of T helper response to another is not the explanation for 
transplantation tolerance then what other mechanism may be responsible? Cobbold et. al. 
[206] and Strom et. al. [260] who recently reviewed the mechanisms of peripheral tolerance 
and the Thl/Th2 paradigm respectively, have implied in their reviews, that the local autocrine 
effect of cytokines on T cell growth and differentiation in the milieu of an immune response 
modified by some form of immunosuppression (e.g. altering cytokine production, reducing 
critical T cell mass, blocking necessary T cell-costimulation and perturbing T cell signalling) 
may have a certain hierarchy and if appropriately manipulated initially away from the 
dominant T helper response responsible for rejection, (i.e. away from a Thl response if Thl 
mechanisms are principally responsible for rejection, or away from a Th2 response if Th2
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mechanisms are dominant) then tolerance may be induced. This understanding allows the 
important point that once “non-rejection” occurs, perhaps with other constraints being met 
and maintained, then tolerance can be generated without the need for polarisation to the 
alternate type of T helper response.
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3.4 KEY POINTS
• Pre-operative anti-CD4 (0X38) treatment results in allospecific (but not tissue 
specific) tolerance in the Lewis to DA model of heterotopic cardiac transplantation.
• Following treatment, anti-CD4 mAb is cleared rapidly from the lymphocyte cell- 
surface of PBL and LNC and is not detectable in the serum at 72 hrs.
• The anti-CD4 treatment protocol employed, results in partial depletion of CD4 T 
cells with preferential sparing of the CD45RC've T cell subset.
• Lymph node cells taken from tolerant animals display ‘split tolerance’ when re­
stimulated in vitro in standard one way MLR (i.e. show allospecific sensitisation) but 
produce reduced amounts of IL-2 compared to normal LNC.
• Alloantibody responses and cellular infiltration in cardiac allografts are similar in 
tolerant and unmodified heart graft recipients.
• RT-PCR analysis of cardiac allografts obtained from tolerant and unmodified graft 
recipients at days 2, 4, 7, 21 and 100 provided no evidence for a Thl to Th2 cytokine 
shift with tolerance.
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4. Effect of 0X38 monoclonal antibody on intracellular signalling events
4.1 INTRODUCTION
Ligation of the a(3T cell receptor with peptide antigen presented in the grove of MHC Class II 
triggers an intracellular signalling response, the nature of which is common to that which is 
seen in other cells of haemopoietic origin following their activation. The signalling response 
involves the activation of PTKs and a cascade of tyrosine phosphorylation of intracellular 
proteins, including components of the antigen receptor itself. During T cell -  APC 
interaction, the membrane glycoprotein CD4 coaggregates with TCR - CD3 - MHC Class II 
complex [48] and enhances antigen mediated activation of Class II MHC restricted T cells 
[49,50,51]. This positive effect of CD4 in the T cell activation process has been attributed to 
its non-covalent association [43,44] with the PTK p56lck, which becomes activated upon CD4 
aggregation [128]. As discussed earlier, activation of p56lck probably involves 
dephosphorylation at the negative regulatory C-terminal tyrosine505 site by CD45 phosphatase 
and auto phosphorylation at the positive regulatory tyrosine394 site. Once activated, p56lck 
potentiates signal transduction by phosphorylating and activating downstream substrates 
including PTKs such as ZAP-70.
An additional means by which CD4 associated p56lck may enhance downstream tyrosine 
protein phosphorylation is through a mechanism unrelated to its tyrosine kinase activity, but 
relying instead on its SH2 sequence [261]. Xu and Littman observed that the SH2 domain of 
p56lck is able to recruit other phosphotyrosine containing signalling molecules or, 
alternatively, protect tyrosine phosphorylated substrate sequences from the action of 
phosphatases, thus complexing and stabilising tyrosine phosphorylated CD3 £ chains, ZAP- 
70, and possibly other molecules, with CD4 and TCR.
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In the recent years significant progress has been made in identifying the T cell proteins which 
serve as targets for p56lck during TCR induced T cell activation. As discussed earlier, several 
components of the CD3 complex, including the c and £ chains [76,146,149,262], 
phospholipase-Cyl (PLCyl) [120,121], and ZAP-70 [144,145,148] undergo rapid tyrosine 
phosphorylation during T cell activation and may recruit and/or phosphorylate other down 
stream effector molecules in the signalling cascade. For example, following activation by 
phosphorylation, activated PLCyl mediates, in turn, the hydrolysis of PIP2 to IP3 and DAG 
[263,264]. The latter molecules are ultimately responsible for increasing the concentration of 
cytoplasmic calcium and activating PKC [265,266]. Other proteins which undergo 
phosphorylation during T cell activation are Vav, a 95 kDa polypeptide which is thought to 
possess guanine nucleotide exchange activity towards low molecular weight G-proteins, 
[267,268,269], She, a 46-52 kDa protein which once phosphorylated may interact with £ 
chain [270] and become involved in recruitment of Grb-mSos complex to the plasma 
membrane [271], and a 36-38 kDa protein [272] which may also complex with Grb2. 
Through their action on the G u a n o sin e  T r ip h o s p h a t e  (GTP) binding protein, p21ras, these 
proteins may have an important regulatory function in TCR mediated activation and 
proliferation although this remains to be fully clarified. Ras proteins cycle between an 
inactive, G u a n o s in e  D ip h o s ph a t e  (GDP) bound state and an active GTP bound form 
[273,274,275]. Hydrolysis of bound GTP is accelerated by G T P a se  A c t iv a t in g  P ro t ein s  
(GAPs) which inactivate ras [276] whereas G u a n in e  N u c l e o t id e  R e l e a s in g  F a c t o r s  
(GRFs) exchange GDP for GTP which activate ras [277]. An elegant series of transfection 
experiments using mutant and wild type p2 1 ras protein genes has underscored the importance 
of p21ras in expansion of effector T cells. In these studies, the expression of a dominant 
negative p21ras protein resulted in suppression of IL-2 gene induction, whereas expression of
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active p21ras resulted in activation of transcriptional factors, such as AP-1, and increased IL-2 
production [278,279]. Although the mechanism and role of p21ras in T cells activation has yet 
to be fully elucidated, activation of p21ras in T cells occurs in both a PKC dependent [280] 
and a PKC independent [281] manner. The PKC independent pathway is the one which 
appears to involve the 36-38 kDa p21ras binding protein [272].
In several studies using a diverse range of T cells, including immortalised human T cell 
clones [282], normal human PBL’s [283] and murine LNC’s [284] treatment with anti-CD4 
mAb has been shown to alter the intracellular signalling cascade which is orchestrated 
through CD4 and p56lck. From these studies, it seemed reasonable to hypothesise that anti- 
CD4 (0X38 mAb) pre-treatment in the rat experimental model which forms the basis of this 
thesis, may also lead to differences in T cell function as a result of altered intracellular 
signalling. This possibility was therefore investigated using an in vitro activation system 
employing immobilised anti-apTCR mAb to activate rat CD4 T cells. Anti-TCR induced 
activation was chosen instead of activation in response to alloantigen because it avoids the 
possibility of introducing additional phosphorylated proteins into the system by the use of 
allogeneic stimulator cells. In the studies performed, attention was focused particularly on 
the 36-38 kDa protein because lack of tyrosine phosphorylation of this protein has been 
shown to correlate with the development of T cell anergy [285,286]. Consequently, the SDS- 
PAGE system used in the experiments described was optimised using 10% gels to maximise 
separation of proteins in the 20 to 70 kDa range. As a result, it was accepted that changes in 
tyrosine phosphorylation of other activation proteins may have been over looked under 
experimental conditions used.
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4.2 RESULTS
4.2.1 Effect o f  anti-CD 4 treatment on the normal T cell intracellular signalling cascade
In principle, anti-CD4 mAb treatment may abrogate T cell activation either by sterically 
interfering with the interaction o f  CD4 on the T cell and MHC Class II on the APC, and/or by 
perturbing the normal T cell signalling cascade. The two mechanisms, which are not 
mutually exclusive, are depicted schematically in Figure 4.1 below.
Figure 4.1 Possible mechanisms whereby anti-CD4 mAb may interfere with T cell 
activation
A) Inhibition of CD4/MHC B) Perturbation of CD4
class II interaction intracellular signalling
A g/M H C  IIAg/.MHC II
CD4
C D 3/T C R C D 3/T C R
PK PK
p56 PLC
IP3 DAG IP3 DAG
The figure illustrates two mechanisms whereby anti-CD4 mAb may interfere with T cell activation
A). Anti-CD4 mAb may by binding to the CD4 molecule, form a physical barrier which interferes with 
the normal interaction of the CD4 molecule with the non-polvmorphic region of the MHC Class II 
molecule;
B). Anti-CD4 mAb may perturbate the normal intracellular signalling mechanisms invoked by CD4 
through its interaction with p56lck or other cytoplasmic kinases.
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4.2.2 Delaying cardiac transplantation until after anti-CD4 mAb has been cleared from  
treated animals still results in prolonged allograft survival
To investigate the possibility that anti-CD4 mAb may perturb T cell signalling and to exclude 
CD4+ve apTCR+ve T cell depletion as an exclusive mechanism for tolerance induction in this 
experimental model, advantage was taken of the finding, discussed earlier in Chapter 3, that 
in 0X38 mAb treated animals, the anti-CD4 mAb is rapidly cleared from the blood of treated 
animals and remains only transiently detectable on the lymphocyte surface. In contrast, 
following 0X38 mAb, the CD4 T cell depletion observed was relatively slow to recover and 
the level of CD4 depletion observed was similar at days 0, 4 and 7 following in vivo 0X38 
treatment. Based on these observations, it was decided to delay heart transplantation from 
day 0 until either day 4 or day 7 following the last dose of 0X38 mAb. Table 4.1 shows the 
heart graft survival data for the different experimental groups.
Table 4.1
Group Day of Transplant (relative to mAb) mAb* n Graft Survival (days) MST (days)
1 0 0X21 7 8,9 ,10x2,11 ,14x2 10
2 0 0X38 7 8 > 1 0 0 x 6 >100
3 +4 0X38 7 8,14,>100 x 5 >100
4 +7 0X38 6 9,12 x 2,18,>100 x 2 15
*mAb was administered by IP injection at a dose of lOmg/kg (day -3 ) , and 2m g/kg (days -2 ,  -1 ,  0). DA  
recipient animals received a Lewis cardiac allograft on days 0, plus 4 and plus 7 relative to last treatment.
Experimental Groups 1 and 2 received anti-CD4 mAb (0X38) according to the standard 
protocol (lOmg/kg on days -3, 2 mg/kg on days -2 , - 1 , and 0 the day of transplant). Group 1 
received a control mAb 0X21 and this group had a MST of 10 days. Group 2 received 0X38
Chapter 4-111
mAb and, as already noted in Chapter 3, had a MST of greater than 100 days. Groups 3 and 4 
also received 0X38 mAb and were then transplanted with cardiac allografts either 4 or 7 days 
after the last dose of anti-CD4. The MST in Group 3 was >100 days and the MST in Group 4 
was 15 days. Since the level of CD4 T cell depletion after anti-CD4 mAb was similar on 
days 0, 4, and 7 after treatment, but residual labelling of CD4 T cells was no longer detectable 
at day 4, these data are consistent with the idea that anti-CD4 mAb treatment may impart 
some degree of ‘negative’ signalling to the T cell. If so, this process is partially reversed by 
seven days after the last dose of anti-CD4. This observation suggests a ‘window of 
opportunity’ exists (up to day 4), in which to seek evidence for functional and biochemical 
differences in anti-CD4 treated cells at a time when they are no longer coated with anti-CD4 
mAb but before they have regained normal in vivo function.
4.2.3 TCR activation is associated with changes in intracellular tyrosine phosphorylation 
The CD4 molecule is intimately associated with p56lck tyrosine kinase and it was therefore of 
interest to look for evidence of tyrosine phosphorylation following ligation of the apTCR 
using immobilised anti-apTCR mAb. It can be seen from the upper panel of Figure 4.2, 
which shows tyrosine phosphorylation patterns, that the most striking observation was the 
phosphorylation of a 36-38 kDa protein which was most apparent after activation of CD4 T 
cells for a period of 30 seconds. This protein subsequently became partially 
dephosphorylated at the 30 Min time-point. In order to ensure that the differences observed 
in tyrosine phosphorylation, in this and subsequent experiments, were not due to differences 
in the amount of cell lysate loaded on to the sample lanes, the same nitrocellulose blots were 
stripped and re-stained using anti-ZAP 70 and/or anti-p56lck antibodies. The results of
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staining this western blot with anti-ZAP 70 and anti-p56kk antibodies is displayed in the 
lower two panels o f  Figure 4.2. It can be seen in the bottom two panels o f  this figure, that the 
same magnitude o f  staining for p56kk and ZAP-70 was observed for all sample, with 
exception o f  the 30 Min time-point sample, which stained less heavily with both antibodies.
Figure 4.2 TCR activation dependent ty rosine phosphorylation of CD4 T cells
O’ 0.5’ 2’ 5’ 30’ Time TCR Activation
Anti-Phosphotyrosine
Anti-ZAP-70
Anti-p56lck
Immunopurified CD4 ' e T cells were activated in vitro using immobilised anti-aPTCR mAb. Assays were 
quenched by the addition of SDS sample buffer after 0, 0.5, 2, 5 and 30 Min of activation. Cell lysates 
were then analysed by 10% SDS-PAGE and proteins transferred to nitrocellulose paper by western 
blotting. Specific staining of proteins was performed using antibody mediated chemoluminescence and 
autoradiography. The top panel shows the anti-phosphotyrosine staining. The bottom two panels 
represent the anti-ZAP-70 and anti-p56lck staining of the same western blot. The time of activation is 
indicated on the top of the figure for each lane in Min.
Chapter 4-113
4.2.4 Addition o f  0X38 mAb to CD4 T cells alters the tyrosine phosphorylation pattern o f  
cytoplasmic proteins
To determine the effect of in vitro 0X38 mAb treatment on immunopurified CD4+ve T cells 
using the anti-apTCR activation system described above, purified CD4 T cells were activated 
after pre-treatment with either PBS (Control), 0X38 mAb, or 0X38 which was then cross- 
linked by the addition of RaMo-antibody. It has been observed in previous studies that when 
using anti-CD4 antibodies to inhibit CD4 T cell activation, valence of the anti-CD4 antibody 
is critical and that polyvalent, but not monovalent antibody, inhibited normal intracellular 
signalling pathways [287] and also that IgM was more effective than IgG in inhibiting TCR 
induced activation [154] (and reviewed by Janeway [81]). It was therefore, reasonable to 
assume that cross-linking 0X38 mAb with RaMo-antibody would ensure polyvalent 
attachment and clustering of CD4 molecules on the lymphocyte cell-surface and may lead to 
alteration in T cell activation induced intracellular signalling.
A representative autoradiograph from one experiment is shown in Figure 4.3. The 
autoradiographs obtained in this, and similar experiments, were also analysed using a BioRad 
Gel Doc 1000 soft laser densitometer and image analysis software system. The OD of the 36- 
38 kDa band and p56lck is displayed within brackets for each sample below the lanes of 
Figure 4.3. It can be seen from Figure 4.3 (lower panel), that anti-phosphotyrosine antibody 
chemoluminescence staining revealed a two fold or greater increase in the phosphorylation of 
the 36-38 kDa protein upon activation of control CD4 T cells at the 2 Min time-point, as 
detected by OD. It was notable, however, that there was no appreciable change in the 
phosphorylation of the 36-38 kDa protein upon T cell activation in the presence o f either 
0X38 mAb or 0X38 mAb cross-linked by RaMo-antibody. The top panels of Figure 4.3 
show the staining of anti-p56lck in this experiment using the same western blot. Although the
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density o f  the p56lck bands are three times higher in the control CD4 T cells when compared 
to the 0 X 38  mAb treated samples, the important observation is that the relative amount o f  
p56kk within each experimental group is similar. This indicates that any changes observed in 
the phosphorylation o f  the 36-38 kDa band within a group was not an artefact caused by 
unequal loading o f  lysate in that sample.
Overall, the data from these experiments suggests that in vitro pre-treatment o f  CD 4+' e T cells 
with the anti-CD4 mAb 0 X 3 8  leads to an impairment o f  the normal intracellular signalling 
cascade which occurs following TCR activation. This is evident as a reduction in the 
phosphorylation o f  a 36-38 kDa protein in 0 X 38  mAb treated cells when compared to 
untreated control CD4 T cells.
Figure 4.3 Inhibition of TCR activation-dependent tyrosine phosphory lation in CD4 
T cells by in vitro 0X38 mAb treatm ent
Anti-p56lek
Anti-PT
Control
O' 2’ 30'
(1246) (1255) (1259)
O '
0X38
2' 30'
(406) (375) (568)
   M.........
OX38-XL
(029) (059) (033) (0 0 2 ) (0 0 1 ) (0 0 2 )
0 ’ 2 ’ 3 0 ’ TCR Activation
m m mm < 56k Da
(399) (423) (216) (O.D.)
y.-.,
36-38kDa
(002) (001) (002) (O.D.)
Immunopurified CD4 ' 1 T cells pre-treated with PBS (Control, left panels) 0X 38 (middle panels), or 
0X38 which was cross-linked using Rabbit anti-Mouse antibody (right panels), were activated using 
immobilised anti-a(3TCR mAb. Assays were quenched by the addition of SDS sample buffer after 0, 2 
and 30 Min of T cell activation. Cell lysates were analysed by 10% SDS-PAGE and proteins transferred 
to nitrocellulose paper by western blotting. Specific staining of proteins was performed using antibody 
mediated chemoluminescence and autoradiography. The lower 3 panels depict the typical tyrosine 
phosphorylation patterns observed using anti-phosphotyrosine antibody staining. The upper 3 panels 
represent staining of the same gel using anti-p56lck antibody. The optical density (O.D.) of the 36-38 kDa 
protein band and p56lck are shown below each lane for each gel.
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4.2.5 Anti-CD4 treatment o f  CD4 T cells is associated with inhibition o f TCR mediated 
activation in vitro
To determine whether the alteration in intracellular signalling brought about by anti-CD4 
mAb treatment correlated with any functional differences in anti-CD4 treated cells, the 
proliferative response of CD4 T cells to immobilised R73 antibody was assessed by 3H- 
Thymidine incorporation at 24 and 48 hrs after T cell activation. Briefly, in the experiment 
shown, CD4 T cells were treated, prior to activation, with PBS (Control), 0X38 mAb or 
0X38 mAb which was cross linked by RaMo-antibody. The CD4 T cells were added to 
culture wells in which anti-apTCR mAb (R73) had been bound to the plate. Cells were then
• 3 • • 3pulsed with H-Thymidine, harvested onto microtitration filter paper and H-Thymidine 
uptake determined by counting samples on a beta liquid scintillation counter. The results of 
this experiment are shown in Figure 4.4. It can be seen that anti-CD4 mAb treatment reduced 
the ability of CD4 T cells to proliferate in response to TCR cross-linking and that inhibition 
was more pronounced when the anti-CD4 mAb was cross-linked on the T cell-surface by 
RaMo-antibody.
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Figure 4.4 Ability of 0X38 to inhibit CD4 LNC activation by immobilised anti-TCR 
antibodies
□ Control
□ 0X38 
HOX38-XL
CD4LNC 
T cells
10000
24 48
Hours After H3-Thymidine
Immunopurified CD4 ve T cells were treated in vitro with PBS (Control, lightly fdled columns), 0X38 
mAb (0X38, open columns), and 0X38 mAb which was then cross-linked using Rabbit anti-Mouse 
antibody (OX38-XL, darker filled columns) and were activated using immobilised anti-a(3TCR mAb. Cell 
cultures were pulsed with H-Thymidine after 24 and 48 hrs, and were harvested 18 hrs later onto 
microtitration filter paper. Thymidine uptake was analysed using a Beta Liquid Scintillation counter. 
The y-axis represents the COUNT P e r  Mini IE (CPM) of iH-Thymidine, and the x-axis shows the time in 
hrs of cell culture.
4.2.6 CD4 T cells obtained from  animals treated with 0 X 3 8  mAh in vivo display signalling  
defects identical to those observed in CD4 T cells treated in vitro with 0X 3 8
Following the observation that in vitro 0 X 38  mAb treatment o f  CD4 T cells leads to altered 
intracellular signalling in these cells, studies were performed on CD4 T cells treated with 
0 X 3 8  mAb using the standard in vivo treatment protocol. Specifically, these studies were 
designed to determine whether the perturbation o f  CD4 T cell function responsible for the 
increased cardiac allograft survival in recipients given a heart allograft 4 days after the last
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dose o f 0X38 mAb, was associated with alteration in the normal biochemical signalling 
cascade. CD4 T cells were obtained from animals at various time-points following the 
standard in vivo 0X38 treatment protocol and then tested in vitro using the same immobilised 
anti-apTCR activation system described above. Figure 4.5 shows the results of one such 
experiment and the results obtained in this experiment were typical of replicate experiments 
performed using the same conditions.
The format of Figure 4.5, is identically to that used previously for Figure 4.3, but the CD4 T 
cells used for this study were obtained from animals treated with 0X38 mAb in vivo and were 
harvested after 0, 4 and 7 days following the last dose of anti-CD4 mAb.
Interestingly, the phosphorylation of the 36-38 kDa protein observed after activation of 
normal CD4 T cells was not observed in CD4 T cells obtained from the animals on day 0 or 
day 4 after 0X38 mAb treatment. However, a marked increase in phosphorylation of this 
protein was apparent after 2 Min of T cell activation in the CD4 T cells obtained from 
animals 7 days after 0X38 mAb treatment (OD 005 compared to 065 at 0 and 2 Min TCR 
activation respectively). It is notable that the difference observed in protein phosphorylation 
could not be accounted for by differences in the quantity of lysate loaded onto the gel. The 
top panel of Figure 4.5 confirms that within each group the OD of the p56lck staining is 
similar for the different lysate samples loaded on the gel.
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Figure 4.5
Anti-p56lck
Anti-PT
Immunopurified CD4 ' e T cells were obtained from animals treated with the standard in vivo 0X38 mAb 
protocol. CD4 T cells were obtained on Day 0 (left panels), Day 4 (middle panels) and Day 7 (right 
panels) after 0X38 mAb treatment and were activated using immobilised anti-aPTCR mAb. Assays were 
quenched by the addition of SDS sample buffer after 0, 2 and 30 Min of activation. Cell lysates were 
analysed bv 10% SDS-PAGE and proteins transferred to nitrocellulose paper by western blotting. 
Specific staining of proteins was performed using antibody mediated chemoluminescence and 
autoradiography. The lower 3 panels show the typical tyrosine phosphorylation patterns observed using 
anti-phosphotyrosine antibody staining. The upper 3 panels represent staining of the same gel using anti- 
p56lfk antibody. The optical density (O.D.) of the 36-38 kDa protein band and p56lk are shown below 
each lane.
The data from this experiment suggest that the alteration in intracellular signalling observed 
after in vitro pre-treatment o f  CD4 ne T cells with the mAb 0 X 38  is also observed in CD4 T 
cells from animals treated with 0 X 3 8  in vivo. However, the impairment in CD4 T cell 
signalling after in vivo 0 X 3 8  mAb appears to be transient and/or reversible, as CD4 T cells 
obtained from animals 7 days following the last dose o f  0 X 3 8  mAb have signalling patterns 
identical to those seen in normal CD4 T cells. As noted already, the signalling defect 
observed in the CD4 T cell obtained from in vivo 0 X 3 8  mAb treated recipients correlates 
with a functional impairment in the animals since those transplanted with an allogeneic
Inhibition of TCR activation-dependent tyrosine phosphorylation of CD4 
T cells by in vivo 0X38 mAb treatm ent
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cardiac allograft on day 4 after 0X38 mAb treatment do not reject their heart grafts, whereas 
those transplanted on day 7 following 0X38 are able to mediate heart allograft rejection.
4.2.7 Analysis o f  CD4 immunoprecipitates fo r evidence o f  dissociation ofp56Ick
A possible mechanism for altered intracellular signalling in 0X38 mAb treated CD4 T cells is 
the dissociation of p56lck from the cytoplasmic tail of the CD4 molecule following anti-CD4 
mAb binding. To determine whether evidence for this could be found in the present 
experimental system, in vitro 0X38 treated CD4 T cells and CD4 T cells from 0X38 treated 
animals were lysed in non-ionic buffer and the CD4 immunoprecipitated using anti-CD4 and 
Staph Protein A. Immunoprecipitates were then analysed by SDS-PAGE -nitrocellulose 
western blotting and were stained directly using anti-p56lck. The results of this experiment 
are depicted in Figure 4.6. The left panel (A) of Figure 4.6, shows the staining pattern of 
CD4 immunoprecipitated p56lck which was observed in cell lysates from CD4 T cells after in 
vitro pre-treatment with PBS, 0X38 and 0X38 cross-linked with RaMo-antibody. It can be 
seen that 0X38 treatment results in only partial dissociation o f p56lck from the CD4 molecule 
and this dissociation is most marked when 0X38 mAb is cross-linked by RaMo-antibody.
When CD4 T cells were obtained from animals on days 0, 4 and 7 following the last dose of 
in vivo anti-CD4 treatment, using the standard 0X38 treatment protocol, and analysed in the 
same fashion as the in vitro 0X38 treated cells, no change in the staining pattern of CD4 
immunoprecipitated p56lck was observed. The results from this experiment are displayed in 
the right panel (B) of Figure 4.6. This latter observation argues against the idea that the 
altered intracellular signalling which occurs after anti-CD4 treatment can be attributed wholly 
to dissociation of p56lck from the CD4 molecule.
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Figure 4.6 CD4 associated p56kk following in vitro and in vivo 0X 38 pre-treatm ent
A C ontrol 0 X 3 8  O X 38-X L B Day 0 Day 4 Day 7
Anti-p56,ck
in vitro 0X38 Treatm ent in vivo 0X38 Treatm ent
Immunopurifled C D 4 'e T cells were obtained from naive untreated animals and pre-treated in vitro with 
PBS (Control, panel A left), 0X38 (0X38 Treated, panel A centre) and 0X 38 which was cross-linked 
using Rabbit anti-IMouse antibody (OX38-XL, panel A right) or were obtained on day 0 (Day 0 panel B 
left), on day 4 (Day 4 panel B centre) and day 7 (Day 7 panel B right) from animals treated with in vivo 
0X 38 mAb (Standard Protocol). CD4 T cells were lysed using non-ionic buffer and immunoprecipitated 
using anti-CD4 antibody and staph protein A sepharose. Immunoprecipitated pellets were solubilised in 
SDS sample buffer and analysed by 10% SDS-PAGE. Proteins were transferred to nitrocellulose paper 
by western blotting and specific staining performed using anti-p56llk antibody mediated 
chemoluminescence and autoradiography.
4.2.8 Effect o f 0 X 3 8  on intracellular Ca~ influx fo llow ing  anti-TCR induced activation
In view o f  the observed differences in the phosphotyrosine labelling pattern o f  CD4 T cells 
after in vitro and in vivo 0 X 38  mAb treatment, it was decided to determine if the same 0 X 38  
mAb therapy also abrogated downstream signalling events, such as influx o f  intracellular 
calcium, which normally follow ligation o f  the apT C R . After TCR activation, the level of  
intracellular Ca2' increases, due to the activation o f  Phospholipase C which cleaves PIP2 to 
produce IP3. The latter molecule mediates Ca“ release from intracellular Ca2+ vesicles and 
initiates an influx o f  Ca2 from the extracellular milieu. This rapid and sustained increase in 
intracellular Ca2 is then thought to influence Ca2+ / calmodulin -dependent events which are 
essential for the production o f  key cytokines such as IL-2 [288,289,290,291].
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To test the integrity of the intracellular signalling pathway distal to the PTKs, changes in 
intracellular Ca2+ were measured indirectly by pre-loading immuno-magnetically enriched 
CD4+ve T cells with the calcium dependent dye Fluo-3. Fluo-3 requires active cell 
metabolism for loading and therefore only labels living cells. CD4 T cells were obtained 
from naive animals and pre-treated in vitro with PBS (Control) or 0X38 mAb. Alternatively, 
CD4 T cells were obtained from animals 4 days after the last dose of 0X38 mAb using the 
standard in vivo treatment protocol. All CD4 T cells were activated in vitro using 
immobilised R73 mAb and continuous assessment of cell fluorescence was performed using 
the flow cytometer. The results of such an experiment are depicted in Figure 4.7. It can be 
seen that there is an increase in Fluo-3 fluorescence with time after TCR activation in Control 
CD4 T cells. However, the increase in fluorescence is abrogated in CD4 T cells after in vitro 
0X38 mAb treatment and in CD4 T cells obtained on Day 4 after in vivo 0X38 mAb 
treatment. After addition of the calcium ionophore, ionomycin, to each of the different cell 
populations, maximum Fluo-3 fluorescence was observed and was equivalent in each of the 
samples. The latter finding confirms that loading of the intracellular dye was comparable in 
the different experimental groups and that lack of fluorescence after activation in the 0X38 
treated T cells was not due, therefore, to absence of Fluo-3 dye. It can be seen from Figure
4.7 that the width of the fluorescent band is slightly broader in the analysis of CD4 T cells 
from anti-CD4 treated animals. This is probably attributable to a slightly higher cell number 
in the sample of this particular experiment.
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Figure 4.7 Inhibition of apTCR-activated calcium-dependent fluorescence by in vitro
and in vivo 0X38 mAb pre-treatm ent
F lu o -3
F lu o r e s c e n c e
0 X 3 8  T r e a te dC o n tr o l
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D a y  4  a fte r  in-vivo 0 X 3 8
Ionom ycin
T im e  T C R  A ctivation  (Seconds)
CD4 T Cells were obtained from naive animals and pre-treated in vitro with PBS (Control, left panel), or 
0X 38 (0X38 Treated, centre panel) or were obtained from animals 4 days after using the standard in 
vivo 0X 38 treatment protocol (Day 4 after in vivo 0X38, right panel). CD4 T cells were activated using 
immobilised R73 mAb while assessing the change in fluorescence of the calcium dependent dye Fluo-3, 
using an EPICS XL Flow cytometer (Coulter, Luton, UK). The y-axis represents the Log,0 of Fluo-3 
fluorescence and the x-axis represents the time in seconds after initiation of TCR activation.
4.3 DISCUSSION
CD4 T cell inhibition by anti-CD4 mAb therapy may be mediated by at least three non­
exclusive mechanisms. Firstly, by binding to the CD4 molecule, the mAb may cause steric 
inhibition o f  the interaction o f  the CD4 molecule with the non-polymorphic region o f  the p 
chain o f  MHC II (Loop 3 p2). Secondly, after binding to the CD4 molecule, the mAb may 
sequester or ‘cap' cell-surface CD4 molecules to a particular region on the cell-surface so that 
association o f  CD4 with MHC Class II - TCR - CD3 is not able to readily occur. Third, by
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binding to CD4 molecule, the anti-CD4 mAb may "‘stimulate’ or ‘inhibit’ the normal 
intracellular signalling mechanism in such a way that once the CD4 - TCR - MHC Class II 
complex is formed, the CD4 T cells are not able to undergo normal activation. This latter 
process has been collectively called “negative signalling”. Previous studies have shown that 
0X38 mAb can inhibit CD4 T cell function both in vivo and in vitro but have not sought 
evidence for negative intracellular signalling.
The results reported in this chapter demonstrate that anti-CD4 mAb inhibits normal CD4 T 
cell function and is associated with an alteration in tyrosine phosphorylation pattern which 
follows apTCR activation. The perturbation of CD4 T cell function caused by CD4 ligation 
with 0X38 mAb, outlasted the physical interaction between antibody and ligand, suggesting 
that the antibody pre-treatment did result in some form of “negative signalling” within the 
CD4 T cell itself. This observation has not previously been reported. Negatively signalled 
CD4 T cells were, when challenged in vivo with alloantigen in the form of a full MHC 
mismatched vascularised cardiac graft, unable to mediate allograft rejection, and when 
challenged in vitro, using immobilised anti-apTCR antibody, failed to phosphorylate the 36- 
38 kDa protein and failed to mobilise intracellular Ca2+ stores. The alteration in intracellular 
signalling could not be attributed to dissociation of p56lck from CD4, as no appreciable 
differences were detected between normal CD4 T cells and anti-CD4 treated CD4 T cells in 
this experimental system.
* Stimulation of p56lck when it is juxtaposed to inappropriate substrate could result in the generation of negative 
signals.
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Following TCR activation, tyrosine phosphorylation of cytoplasmic T cell proteins is a 
necessary prerequisite for induction of IL-2 synthesis [212,292]. Using an activation system 
employing immobilised cross-linked anti-a[3TCR mAb, an increase in the tyrosine 
phosphorylation of a 36-38 kDa protein band over time was observed. Additionally, in cells 
which had been treated with 0X38 mAb, in vitro or in vivo, phosphorylation of this protein 
was inhibited in this experimental system. Other published studies using Thl T cell clones 
[285] or naive LNC [286] have also shown TCR activation-dependent phosphorylation of a 
38 and a 75 kDa T cell protein. Interestingly, in these studies when the Thl clones were 
rendered anergic in vitro or when the normal T cells were made unresponsive to 
superantigens using an in vivo anergy protocol, there was a reduction in the phosphorylation 
of these two proteins following T cell activation. In addition, these studies found that the 
alteration in protein phosphorylation was associated with a concomitant defect in both IL-2 
production and utilisation, suggesting that the two proteins may, in part, be involved in IL-2 
production and/or up-regulation. The defect in tyrosine phosphorylation observed in the 
present studies correlated with a functional defect in CD4 T cells, as demonstrated by 
decreased T cell proliferation in vitro and by lack of cardiac allograft rejection in vivo (when 
transplantation was delayed to day 4 following last 0X38 mAb treatment). Furthermore, the 
anti-CD4 treated T cells displayed additional functional defects consistent with abnormalities 
in IL-2 production. In preliminary experiments, when in vitro or in vivo anti-CD4 treated T 
cells were analysed for TCR activation-dependent calcium mobilisation, the anti-CD4 treated 
T cells did not, in contrast to normal cells, release intracellular calcium freely into the 
cytoplasm.
Active p21ras has been shown to be important in the induction of the IL-2 gene in T cells 
[278,279]. Moreover, as mentioned earlier, the PKC independent p21ras activating pathway
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appears to involve the participation o f a 36-38 kDa protein which phosphorylates following 
TCR activation [272] but which fails to phosphorylate in anergic T cells. It is reasonable to 
suggest that the 36-38 kDa protein which has been the focus of attention in this chapter, may 
be a p21ras activating protein or an early down stream substrate of active p21ras which is 
necessary for normal IL-2 production. Further characterisation of the 36-38 kDa protein is 
necessary to elucidate the relationship between this protein and p21ras. To provide evidence 
for association of the 36-38 kDa protein with p21ras, immunoprecipitation- 
immunochemoluminescence experiments using antibodies raised against these proteins would 
be helpful. Additionally, once the 36-38 kDa protein has been further characterised, 
examination of tyrosine phosphorylation and IL-2 production using CD4 T cells from 36-38 
kDa KO animals would provide further insight into the role and relationship between the 36- 
38 kDa protein with p21ras and with IL-2 production.
One possible mechanism by which anti-CD4 mAb therapy may result in altered intracellular 
signalling events is by modulation of p56lck from the cytoplasmic tail of the CD4 molecule. 
Anti-CD4 mAb treatment has been shown to lead to a reduction in the CD4 bound p56lck 
fraction in Herpes saimiri virus immortalised human T cell clones and to cause a concomitant 
reduction in total p56lck kinase activity [282]. In another study using murine lymph node T 
cells, dissociation of CD4 from p56,ck after anti-CD4 mAb pre-treatment was also noted 
[284]. However the latter study, when comparing anti-CD4 treated and untreated control T 
cells following anti-a(3TCR stimulation, failed to demonstrate any detectable differences in
' Vi  # 9 9
the early tyrosine phosphorylation pattern or Ca mobilisation. A ten fold inhibition of 
D e o x y r ib o n u c l e ic  A cid  (DNA) synthesis in the anti-CD4 treated group was, however 
noted. Both of the above studies suggested that the alteration in T cell activation observed 
after anti-CD4 mAb, was a consequence of dissociation of p56lck from the CD4 molecule,
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thus removing effective kinase activity from the TCR and other downstream targets. 
However, not all studies using protocols which demonstrate altered intracellular signalling 
have been able to show dissociation of p56lck from CD4. For example, a study which 
examined the effect of humanised mouse anti-CD4 antibody on resting and activated human 
CD4 T cells, found qualitative differences between the mAb treated and untreated T cells and 
showed partial modulation of the CD4 molecule associated with reduced tyrosine 
phosphorylation of cytoplasmic proteins following anti-CD4 antibody pre-treatment. 
However, when remaining CD4 molecules were isolated by immunoprecipitation, this study 
found no measurable dissociation of p56lck from CD4 [283]. Interestingly, treatment of CD4 
T cells with phorbol esters and anti-CD3 antibodies [293] and ligation of CD2 in Jurkat cells 
[294] have been shown to provoke dissociation of p56lck from CD4. Treatment with phorbol 
esters, mitogenic lectins, and stimulation via the antigen receptor complex also causes marked 
phosphorylation of p56lck at N-terminal serine residues and this is associated with reduced 
autophosphorylation and p56lck activity [295]. It is also associated with retardation in the 
electrophoretic mobility in SDS-PAGE, increasing the apparent molecular weight of the 
molecule to 59-60 kDa and is likely to change the interactions of p56lck with a subset of its 
regulators, including CD4 itself [296,297], Both of the studies discussed above, showing 
dissociation of p56lck from CD4 following anti-CD4 antibody treatment, found that the p56lck 
which was lost from the pelleted immunoprecipitate was the heavier of a protein doublet 
fraction and the possibility remains that the altered signal transduction and observed 
dissociation may have been due to serine phosphorylation provoked by the anti-CD4 pre­
treatment or some other factor unique to the individual experimental design in these studies. 
In the experiments described in this chapter, immunoprecipitation using non-activated 
immunopurified CD4+ve LNCs treated with anti-CD4, administered either in vivo or in vitro, 
failed to demonstrate appreciable dissociation of p56lck from CD4. A prerequisite for p56lck
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dissociation from CD4 may be modulation of CD4 with subsequent degradation of one or 
both components in the lysosomal compartment of the cell [298]. As 0X38 mAb causes little 
in the way of CD4 modulation, perhaps this pathway of p56lck -  CD4 dissociation is not 
utilised in this experimental model.
Exactly how 0X38 pre-treatment leads to altered tyrosine phosphorylation of cytoplasmic 
proteins in the studies described remains unsolved. The anti-CD4 antibody used in the 
experiments described were all bivalent. One can envisage that potential sequestering of 
p56lck via CD4, away from the natural downstream targets could be responsible for the 
observed results. Further experiments utilising monovalent Fab fragments (which do not lead 
to aggregation of CD4) may help to elucidate this point. Another possible mechanism for the 
observed alteration in intracellular signalling could be that, as a result of 0X38 binding to 
CD4, that dephosphorylation or autophosphorylation of p56lck may occur. There were no 
demonstrable changes in tyrosine phosphorylation as a result of CD4 antibody binding 
observed in the present experimental, but further studies looking specifically phosphorylation 
and dephosphorylation at other amino acid residues such as serine moieties would be helpful.
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4.4 KEY POINTS
• The pre-operative anti-CD4 treatment protocol employed in this study results in a 
‘window of opportunity’ for tolerance induction which is not dependent on the 
physical presence of residual antibody: Allograft survival occurs when animals are 
transplanted early after antibody has been cleared from the cell-surface and serum.
• Activation of CD4 T cells using immobilised anti-TCR antibody results in tyrosine 
phosphorylation of a 36-38 kDa protein band which is inhibited by in vitro 0X38  
treatment.
• Cells taken from animals treated with anti-CD4 in vivo during the “window of 
opportunity” for tolerance induction, also display defective TCR activation induced 
tyrosine phosphorylation of the 36-38 kDa protein band.
• Neither in vitro or in vivo anti-CD4 treatment results in significant dissociation of 
p56lck from CD4 molecules.
• Both in vitro and in vivo anti-CD4 treatment affects normal intracellular calcium 
release from CD4 T cells.
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5. The role of the thymus in anti-CD4 monoclonal antibody induced
tolerance
5.1 INTRODUCTION
The role of the thymus in transplantation rejection is well recognised as congenitally athymic 
T cell deficient animals readily accept a variety of allografts, with no evidence of rejection. 
The importance of the thymus in transplantation tolerance is less well understood. Recently, 
there has been much interest in the concept of inducing transplantation tolerance by injection 
of donor alloantigens directly into the thymus gland. A number of experimental studies using 
adult rats [299,300,301,302,303] have shown convincingly that intrathymic injection of donor 
antigen, in most cases together with some form of systemic immunosuppression, can induce 
tolerance to an organ allograft, underscoring the potential importance of the thymus gland as a 
site for tolerance induction. It should be emphasised that it is far form clear, however, how 
introduction of alloantigen directly into the thymic microenvironment in such studies 
promotes the development of transplant tolerance.
Interestingly, the role of the thymus in transplantation tolerance extends beyond the direct 
inoculation of antigen into the thymic gland itself and the thymus gland has been found to be 
important in several models employing different strategies to induce transplantation tolerance 
in both rodents and larger animals. Of particular relevance to the studies described in this 
thesis, Herbert and Roser [160], using 0X38 mAb pre-treatment in ACI (R Tla) recipient rats 
receiving Lewis (RT11) cardiac allografts found that thymectomy of the recipient animal, 
impaired the induction of tolerance in this experimental model. David Sachs and his 
collegues in Boston U.S.A. [304] using inbred miniature swine in which transplant tolerance 
was induced by treatment of recipient animals with a 12 day course of Cyclosporin A, showed
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that thymectomy prior to transplantation (performed 21 and 42 days before transplant) 
abrogated tolerance induction to Class I MHC disparate renal allografts. Interestingly, if 
thymectomy was performed following renal transplantation it did not affect induction or 
maintenance of tolerance in this model.
The thymus is able, in principle, to directly affect the balance between allograft rejection and 
tolerance, by exporting new T cells to the periphery or by re-education of mature T cells 
which circulate within the medulla of the gland. It is likely that the local thymic environment 
which newly exported or re-educated T cells encounter strongly influences the subsequent 
response of these T cells to alloantigen. In a number of elegant experiments using euthymic 
PVG (RT1C) and congenitally athymic T cell deficient PVG (RT1C) nude rats, Bell and his 
group in Manchester U.K. have studied in detail the maturation of re-circulating single 
positive (CD4+ve CD8’ve apTCR+ve) thymocytes, naive and memory like T cells. 
Interestingly, they have shown that RTE (CD4+ve CD8‘ve cx(3TCR+ve CD45RC've Thy-l+ve) 
when injected into euthymic animals, rapidly lose their Thy-1 antigen and express the 
CD45RC+ve high molecular weight isoform by day 7 [305]. Furthermore, presumably after 
antigen contact, by day 14 up to 30% of the transferred cells were found to have reverted back 
to the CD45RC‘ve low molecular weight isoform, showing that expression of the CD45RC 
isoform in vivo in normal animals is dynamic and correlates to the isotype switching of these 
cells observed in vitro [306]. Additionally, when athymic PVG nude animals are 
reconstituted with CD45RC+ve single positive CD4 T cells taken from naive PVG animals, 
they show complete restoration of peripheral T cell function with normal GVH responses, 
allograft rejection and thymus-dependent antibody responses [236]. Conversely, adoptive 
transfer of the CD45RC've Thy-l've subset does not confer normal T cell responses in nude 
recipients. However, if donor PVG (RT1°) animals are given a DA blood transfusion prior to
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cell harvesting, it is the CD45RC've Thy-l‘ve and not CD45RC+ve subset which is responsible 
for initiating DA allograft rejection in the PVG nude rat. Interestingly, however, if PVG nude 
rats are given a DA allogeneic blood transfusion prior to transplantation and cell transfer, then 
the CD45RC"ve subset is prevented from regaining an alloaggressive capacity in these cell 
transfer experiments. Taken together, this data is consistent with the idea that isotypic 
switching of the leukocyte common CD45RC antigen (probably in both RTE and peripheral 
single positive CD4 T cells) reflects a major functional re-programming of CD4 T cells and 
significantly affects the ability of the T cell to respond to antigen.
In the work presented in this section of the thesis, the role of the thymus gland in anti-CD4
mAb induced tolerance induction was further investigated and some of the possible
¥
mechanisms whereby the thymus may contribute to tolerance were explored. Adult 
thymectomy was performed prior to transplanting DA recipients with Lewis cardiac 
allografts, and the effect of thymectomy on anti-CD4 induced tolerance was examined. The 
ability of prior thymectomy to abrogate the capacity of T cells from tolerant animals to 
adoptively transfer tolerance into secondary recipient animals with unmodified primary Lewis 
cardiac allografts was also explored. After examining the residual CD4 T cell subset 
population following anti-CD4 mAb treatment, as discussed earlier in Chapter 3, the role of 
RTE cells was assessed. RTE were found to be preferentially spared from the depleting 
effects of 0X38 mAb treatment. A possible role for RTE in linking the induction and 
maintenance of tolerance in this experimental model was, therefore, sought by a series of 
adoptive transfer experiments in which thymectomised animals were reconstituted with single 
positive (CD4+ve a(3TCR+ve) thymocytes. Finally, because of the observation that RTE were 
preferentially spared following anti-CD4 mAb treatment in this model, and because studies 
using murine thymocytes has found that such cells secrete a mixed pattern of cytokines when
Chapter 5-132
stimulated in vitro [307], the ability of 0X38 mAb to inhibit the proliferation and alter the 
cytokine mRNA profile of single positive CD4+ve a(3TCR+ve thymocytes, following in vitro 
activation using immobilised anti-apTCR mAb was examined.
5.2 RESULTS
5.2.1 Adult thymectomy prevents the ability o f  anti-CD4 mAb to induce tolerance to cardiac 
allografts
The effect of adult thymectomy on the ability of 0X38 mAb to induce tolerance to Lewis 
cardiac allografts in DA rats was examined by thymectomising DA animals and then 
transplanting them with a Lewis heart more than 40 days later, under the cover of anti-CD4 
(0X38) therapy. As expected from the studies of Herbert and Roser [160], adult thymectomy 
prevented the induction of transplant tolerance in this experimental model. All, except one of 
eight thymectomised animals, rejected their heart allografts and the kinetics of rejection were 
similar to those observed for control untreated animals. Table 5.1 below summarises the graft 
survival data of these experiments.
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Table 5.1
Group Pre-Transplant Treatm ent mAb* n Graft Survival (days) MST (days)
1 None 0X21 7 8 ,9 ,10x2 ,11 ,14x2  10
2 None 0X38 7 8 ,>100x6 >100
3 Thymectomy >-40  days (before Transplant) 0X38 8 7 x 2,8,11 x 3,23,>100 11
*mAb was administered by IP injection at a dose o f lOmg/kg (day -3 ) , and 2m g/kg (days -2 , -1 ,  0). DA 
recipient animals received a Lewis cardiac allograft on day 0.
The data for first two experimental groups in Table 5.1, showing the heart allograft survival 
times of euthymic animals treated with either 0X38 or control 0X21 mAb, have been 
described earlier and have only been included here for comparison. The MST in group 3 
(Thymectomised animals) receiving 0X38 mAb was only 11 days. The early graft rejection 
observed in this experimental group implies that either the thymus gland itself, or a recently 
emerged product of the thymus have an important role in the induction phase of anti-CD4 
mAb induced tolerance in this particular model.
5.2.2 Adult thymectomy also abrogates the ability to transfer tolerance using splenocytes 
from tolerant donor animals 
Recent studies have demonstrated that in some rodent transplantation models, transplant 
tolerance can be adoptively transferred from long-standing tolerant animals into new 
recipients bearing primary allografts [179]. Typically, such studies transfer spleen cell from 
the tolerant animal into naive syngeneic secondary recipients at the time of transplantation. 
To determine whether T cell suppression could be observed in the present model of anti-CD4
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induced tolerance, 2 x 108 splenocytes from DA animals bearing long-term Lewis cardiac 
allografts after 0X38 treatment, were adoptively transferred into secondary unmodified DA 
recipients. The secondary animals were then challenged with a Lewis heart allograft the day 
following lymphocyte transfer. Table 5.2 (Group 1) shows the graft survival data following 
such an experiment. Four of six euthymic recipient animals receiving syngeneic splenocytes 
from long-term tolerant donors showed long-term graft survival and the MST for the group 
was greater than 100 days. Cells from tolerant 0X38 mAb treated animals which had only 
had their heart allografts in situ for 21 days were, however, unable to induce tolerance when 
transferred to secondary recipients, as shown in Table 5.2 (Group 2). All 6 animals receiving 
spleen cells from 0X38 mAb treated donors 21 days after heart transplant rejected their grafts 
with a MST of only 10 days. Thus, the ability of spleen cells from tolerant animals to transfer 
tolerance to secondary syngeneic recipients is critically dependent on the length of time the 
tolerant animal has had its heart graft in situ. One interpretation of this result is that the 
cardiac allograft itself promotes the emergence of a regulatory T cell population and the 
development of such regulatory T cells therefore increases with time.
Since the thymus appears important in the induction phase of 0X38 mAb induced transplant 
tolerance, it was of interest to determine whether the presence of the thymus gland facilitated 
the ability of adoptively transferred “tolerant lymphocytes” to induce tolerance in the 
secondary recipients. To address this question, recipient DA animals were thymectomised 
more than 40 days prior to their use as secondary recipients of adoptively transferred T cells. 
Splenocytes were then obtained from long-term (greater than 100 days) 0X38 treated DA 
animals and transferred into the thymectomised secondary recipients. The secondary DA 
recipients were then challenged, the following day, with a Lewis cardiac allograft. 
Intriguingly, adult thymectomy was found to abrogate the ability to transfer tolerance in this
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model. Table 5.2 (Group 3) shows the graft survival data for the thymectomised recipients 
receiving cells from tolerant donors and it can be seen that they rejected their cardiac 
allografts with a MST of only 9.5 days.
Table 5.2.
Group Thym ectomy Splenocytes Transferred* n Graft Survival (days) MST (days)
1 None 2 x 108 Cells (Day >100) 6 11,13,>100x4 >100
2 None 2 x 108 Cells (Day 21) 6 10x5,11 10
3 > -40  days 2 x 108 Cells (Day >100) 6 8,9x2,10,11,12 9.5
*Splenocytes were obtained from 0 X 3 8  treated DA rats bearing a long-standing (>100 or 21 days) Lewis 
cardiac allograft. Secondary syngeneic recipient animals were transplanted with Lewis cardiac allografts 
the day after adoptive transfer o f spleen cells.
The above data demonstrates that the thymus gland plays a role in the induction phase of 
0X38 mAb induced transplant tolerance, and in addition, that the thymus gland (or a product 
thereof) facilitates the ability of tolerant lymphocytes to induce tolerance when adoptively 
transferred into syngeneic recipients of an organ allograft.
5.2.3 Effect o f  0X38 mAb on T cell depletion in thymectomised recipients 
In view of the observation that thymectomy abrogated 0X38 mAb induced transplant 
tolerance, it was of interest to determine the effect of 0X38 mAb treatment on the peripheral 
T cell pool of adult thymectomised DA rats. Euthymic and adult thymectomised DA rats 
were treated with 0X38 mAb, using the standard in vivo protocol, and sacrificed following 
treatment and/or transplant. As a first step to investigate the possible mechanism underlying 
the abrogation of tolerance induction by thymectomy, residual LNC and PBL following 0X38
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treatment were analysed by flow cytometry. PBL and LNC from euthymic and 
thymectomised untreated controls, and animals sacrificed 7 days following the standard in 
vivo 0X38 treatment protocol were examined. To assess the role of exposure to alloantigen 
in these groups of animals, LNC and PBL were also obtained from 0X38 treated euthymic 
and thymectomised animals which had been transplanted with a Lewis cardiac allograft 7 
days earlier. As a first step, the cells which stained double positive for CD4 and aPTCR were 
analysed and the results are depicted in Figure 5.1. It can be seen that thymectomy alone 
reduced the percentage of CD4+ve T cells in both PBL and LNC from 53% and 60% 
respectively in euthymic control animals to 8% and 53% respectively in thymectomised 
animals. Interestingly, the presence of a heart allograft did not affect the relative depletion of 
CD4 T cells observed in either euthymic or thymectomised animals 7 days following 0X38 
treatment.
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Figure 5.1 Depletion of CD4 T cells following 0X38 treatm ent and/or transplant in 
euthymic and thymectomised animals
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Results are expressed as the % mean number of PBL and LNC staining double positive for CD4 
(W3/25 ' e) and aPTCR (R73+ve) from a minimum of 2 rats in each group. Control untreated animals are 
represented by filled columns (C) whereas the Day 7 0X38 treated and transplanted (7Tx) and Day 7 
0X38 treated (7) animals are represented by open columns. Left panels (A) and (C) show results in 
euthymic animals whereas the right panels (B) and (D) show results in thymectomised animals.
5.2.3.1 The relative depletion o fC D 4 5 R C +ve (M RC OX22hlgh) CD4 T cell subset, is sim ilar in 
euthymic and thym ectom ised animals fo llow ing  0 X 3 8  treatment
To further analyse the effect o f  thymectomy on animals treated with 0X 38  mAb, the CD4 T 
cell subsets were analysed by flow cytometry using MRC 0 X 22  to stain the high molecular 
weight isoform o f  the leukocyte common antigen (CD45RC). To allow a direct comparison, 
both euthymic and thymectomised animals were used in each o f  the analysis performed.
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Figure 5.2 shows that untreated thymectomised animals have substantially lower levels o f  
W 3/25+ve OX22hlgh T cells in PBL than euthymic control animals. The figure also shows that 
the reduction in the W3/25+ve OX22hlgh T cell fraction in the PBL and LNC following pre­
treatment o f  euthymic animals with 0 X 3 8  mAb is mirrored by a similar reduction o f  this cell 
population in thymectomised animals.
Figure 5.2 Depletion of the CD45RC ' 1 CD4 T cell subset following 0X 38 treatm ent 
and/or transplant in euthymic and thymectomised animals
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Results are expressed as the %  mean number of PBL and LNC staining double positive for CD4 
(W3/25+ve) and CD45RC+ve (OX22h,gh) from a minimum of 2 rats in each group. Control untreated 
animals are represented by filled columns (C) whereas the Day 7 0X 38 treated and transplanted (7Tx) 
and Day 7 0X 38 treated (7) animals are represented by open columns. Left panels (A) and (C) show 
results in euthymic animals whereas the right panels (B) and (D) show results in adult thymectomised 
rats. Upper panels (A) and (B) are from PBL and lower panels (C) and (D) are LNCs.
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5.23.2 There is no sparing o f the CD4+ve OX22low T cell fraction following anti-CD4 mAb 
treatment in thymectomised animals 
Next, the reciprocal CD4 T cell subset, namely CD4 cells displaying the low molecular 
weight isoform of the leukocyte common antigen, OX22low, were analysed by flow cytometry 
and the results are depicted in Figure 5.3. This figure shows that untreated thymectomised 
animals have far fewer CD4+ve OX22,0W T cells in their PBL than do euthymic animals (3% 
vs. 21% respectively). The data presented in this figure also confirms the previously noted 
observation (Chapter 3 Figure 3.8) that 0X38 treatment does not appear to cause significant 
depletion of the CD4+ve OX22low T cell subset in euthymic animals. In contrast to euthymic 
animals, however, there was no sparing of the CD4+ve OX22low T cells subset in 
thymectomised animals. In both PBL or LNC of thymectomised animals, there was greater 
than 50% depletion of CD4+ve OX22low T cells following 0X38 treatment. To confirm that 
complete thymectomy had been undertaken, and to ascertain the proportion of RTE cells in 
this experimental model, cells were also stained with the antibody to Thy-1 antigen [88], a 
transient marker of naive RTE [305] and of thymocytes in the rat. Interestingly, when the 
CD4+ve OX22low T cells were counter stained with mAb to Thy-1, it could be seen that the 
majority of such cells in euthymic animals were Thy-1 positive (i.e. residual cells were mostly 
RTE). These cells could not, therefore, have been OX22hlgh cells which had reverted back to 
the OX22low phenotype. Cells obtained from the thymectomised animals showed no staining 
with anti-Thy-1 mAb, thereby confirming the completeness of thymectomy in these animals.
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Figure 5.3 Depletion of the CD45RC ' 1 CD4 T cell subset following 0X 38 mAb 
treatm ent and/or transplant in euthymic and thymectomised animals
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Results are expressed as the % mean number of PBL and LNC staining double positive for either CD4 
(W3/25+ve) and CD45RC ' 1 (OX22l<w), or CD4 (W3/25 ve) and Thy-1 (Thy-l+ve) from a minimum of 2 rats 
in each group. The closed columns represent the percentage of W3/25 ve OX221"" cells whereas the open 
columns represent the proportion of these which are also Thy-1 ve. Untreated control animals are 
represented as (C) whereas the Day 7 0X38 treated and transplanted and Day 7 0X 38 treated only 
animals are represented as (7Tx) and (7) respectively. Left panels (A) and (C) show results for euthymic 
animals whereas the right panels (B) and (D) show results for adult thymectomised rats. Upper panels 
(A) and (B) are PBL and lower panels (C) and (D) are LNCs.
5.2.4 The tim ing o f  thymectomy influences tolerance induction using 0 X 5 8  mAb 
Because it takes several days for RTE to become functionally mature and lose their 
expression o f  the Thy-1 antigen [305], the timing o f  thymectomy relative to heart 
transplantation was altered to test, indirectly, whether residual RTE were able, in the absence
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of the thymus gland itself, to facilitate induction of transplant tolerance with 0X38 mAb. 
Thymectomy was performed on days minus 3 and plus 7 relative to cardiac transplantation. 
All animals received 0X38 mAb according to the standard in vivo treatment protocol. The 
results of these experiments are displayed in Table 5.3.
Table 5.3.
Group Timing o f Thym ectom y (relative to Tx) mAb* n Graft Survival (days) MST (days)
1 None 0X 38 7 8 > 1 0 0 x 6 >100
2 > -40 days 0X 38 8 7x2 , 8 , 11  x 3,23,>100 11
3 day -3 0X 38 6 28,>100 x 5 >100
4 day +7 0 X 38 6 > 1 0 0 x 6 >100
*mAb was administered by IP injection at lOmg/kg (day -3 ) , and 2mg/kg (days -2 ,  -1 ,  0). DA recipient 
animals received a Lewis cardiac allograft on day 0.
For comparison, groups 1 and 2 which have already been described earlier (Table 5.1) have 
been included in the Table 5.3. It can be seen from the table that delaying thymectomy to the 
peri-operative period, (day minus 3 and day plus 7 relative to transplant), confers protection 
against the allograft rejection observed when anti-CD4 mAb was given to animals which had 
been thymectomised >40 days before transplantation. These results suggest a role for naive, 
RTE in anti-CD4 induced tolerance induction and indicate that the presence of an intact 
thymus gland is not, therefore, and essential requirement for 0X38 mAb induced transplant 
tolerance.
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5.2.5 Purification o f CD4 single positive thymocytes using negative immuno-magnetic 
beading was monitored by flow  cytometry
Following the demonstration that peri-operative thymectomy in anti-CD4 treated animals did 
not abrogate tolerance induction, and in view of the large numbers of naive thymocytes found 
in the peripheral blood and lymph nodes of 0X38 treated rats, it was decided to determine the 
role of single positive otpTCR+ve CD4+ve thymocytes in tolerance induction, using a series of 
reconstitution experiments and in vitro cell assays.
For these experiments, whole thymus glands were obtained from 6-8 week old adult DA 
donors and thymocytes prepared as described in the Materials and Methods Section 2.10.1. 
Briefly, single positive apTCR+ve CD4+ve thymocytes were fractionated by negative selection 
using anti-CD8 (0X8) mAb and magnetic conjugated Goat-anti-Mouse beads. The purity of 
the fractionated thymocytes was assessed by flow cytometry and the results are depicted in 
Figures 5.4 and 5.5.
The top panel of Figure 5.4 shows the Logio signal for Rabbit-anti-Mouse-FITC (RaMo- 
FITC) verses cell Count, after the addition of 0X8, before and after cell separation using 
magnetic beads. The lower two panels of Figure 5.4 show typical double label flow 
cytometric analysis using anti-CD4 (W3/25-FITC) and anti-CD8 (OX8-PE) antibodies, before 
and after the cell separation. It can be seen that 93% of unseparated rat thymocytes stain 
double positive for CD4 and CD8 (Figure 5.4 panel B). After negative selection, 92% of the 
separated cells express CD4 and only 1% are CD8 positive (Figure 5.4 panel C). It can also 
be seen from Figure 5.4 (panel A), that following cell separation, no cells stained positive 
with RaMo-antibody. This suggests that most 0X8 positive cells have been removed during 
the cell separation process.
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Figure 5.5, the format of which is similar to Figure 5.4, shows typical double label flow 
cytometric profiles of thymocytes before and after immunomagnetic cell separation, except 
that antibodies directed against the rat apTCR (R73) and CD4 (W3/25) and CD8 (0X8) 
molecules were used to stain the separated cells. These profiles confirm that before 
enrichment, the majority of thymocytes wereapTCR've CD4+ve CD8+ve (double positive-TCR 
negative) and following enrichment were 84% single positive apTCR+ve CD4+ve. The 
remaining cell fractions comprised 2-3% single positive apTCR+ve CD8+ve and 8-13% 
W3/25've R73’ve (double negative) cells. These double negative cells were not characterised 
and may represent thymic epithelial and or stromal cells.
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Figure 5.4 Single and two colour flow cytometric analysis of thymocytes before and 
after 0X 8 mAb depletion
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Upper panel (A) shows the single colour fluorescence of thymocytes using FITC-conjugated rabbit-anti- 
mouse after 0 X 8  treatment before and after magnetic cell separation. Single colour fluorescent analysis 
results expressed as count on the y-axis and Log10 of the FITC signal on the x-axis. Middle panel (B) and 
lower panel (C) shows two colour fluorescent analysis of thymocytes using FITC-W3/25 and PE-OX8 
before and after magnetic cell separation respectively. Two colour fluorescent analysis results expressed 
as Log,0 of the FITC signal on the y-axis and Log,0 of the PE signal on the x-axis.
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Figure 5.5 Flow cytometry of thymocytes before and after cell separation using 
negative selection immuno-magnetic beading
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Two colour fluorescent analysis with results expressed as Log10 of the FITC signal on the y-axis and Log|0 
of the PE signal on the x-axis. Left panels (A) and (C) represent analysis of thymocytes after staining 
using FITC-conjugated anti-TCR (y-axis) and PE-conjugated anti-CD8 (x-axis). Right panels (B) and (D) 
depict fluorescent analysis using FITC-conjugated anti-TCR (y-axis) and PE-conjugated anti-CD4 (x- 
axis). Upper panels (A) and (B) shows results when staining before magnetic cell separation whereas the 
lower panels (C) and (D) show the staining after thymocyte separation.
5 .2 .5 .1 Reconstitution o f  adult thym ectom ised 0 X 3 8  treated animals with CD4 single  
positive thymocytes results in prolongation o f  cardiac allograft survival
Single positive CD4 thymocytes purified as described above, were utilised for adoptive 
transfer studies to reconstitute thymectomised anti-CD4 treated DA recipients receiving a
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Lewis cardiac allograft. The CD4 thymocytes were also used in anti-apTCR activation 
assays in vitro, to determine their cytokine repertoire after activation. Table 5.4 shows the 
results obtained after reconstitution of adult thymectomised (>40 days before transplant) anti- 
CD4 treated rats which were given 2-3 x 107 single positive apTCR+ve CD4+ve enriched 
thymocytes on day 2 and day 4 following heart transplantation. The CD4 reconstituted 
thymectomised animals (Group 3), showed prolongation of cardiac allografts survival, when 
compared to the thymectomised but non-reconstituted anti-CD4 treated animals (Group 2). 
The MST of these two groups was 81 and 11 days respectively.
Table 5.4.
Group Thymectom y SP Thym ocytes mAb* n Graft Survival (days) MST (days)
1 None None 0X38 7 8 ,>100x6 >100
2 >-40 days None 0X38 8 7 x 2,8,11 x 3,23,>100 11
3 >-40  days 2-3 x l O7 0X38 6 18,62 x 2,>100 x 3 81
*mAb was administered by IP injection at a dose o f lOmg/kg (day -3 ) , and 2m g/kg (days -2 ,  -1 ,  0). DA 
recipient animals received a Lewis cardiac allograft on day 0. Single positive thym ocytes were given by 
IV injection on days plus 2 and plus 4 relative to transplant.
5.2.5.2 Thymocytes appear resistant to inhibition by 0X38 treatment in vitro and display a 
ThO like cytokine message pattern when stimulated using immobilised anti-TCR mAb
The above data suggests that the absence, in thymectomised animals, of RTE may abrogate 
the ability of 0X38 anti-CD4 mAb to promote transplantation tolerance. The evidence for 
this comes from the observation that in euthymic animals given 0X38 treatment, these cells 
appear to be preferentially spared in contrast to mature CD4+ve T cells, and from 
reconstitution experiments where, in thymectomised recipients, adoptively transferred CD4
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single positive thymocytes confer tolerance. To investigate the effect of 0X38 on CD4 
thymocyte function, the ability of the mAb to inhibit proliferation of CD4+ve ocpTCR+ve 
enriched thymocytes in vitro in response to activation using immobilised anti-TCR was 
assessed. The cytokine repertoire of the thymocytes in response to TCR stimulation in the 
presence and absence of 0X38 mAb was also determined.
Figure 5.6 (upper panel) shows the incorporation of 3H-Thymidine by CD4 thymocytes after 
24 and 48 hrs of culture in the presence of bound anti-apTCR mAb. For comparison, the 
proliferation of CD4 LNC (lower panel), which has been described earlier (Chapter 4 Figure 
4.4) is also shown. In the experiment illustrated, CD4 thymocytes and LNC were treated, 
prior to activation with PBS (Control), 0X38 mAb or 0X38 mAb which was cross linked by 
RaMo-antibody. The cells were added to culture wells in which anti-apTCR mAb (R73) had 
been bound. Cells were then pulsed with 3H-Thymidine, harvested onto microtitration filter 
paper and 3H-Thymidine uptake determined by counting samples on a beta liquid scintillation 
counter. It can be seen from Figure 5.6 that single positive LNCs are far more susceptible to 
inhibition by 0X38 mAb than are single positive CD4 thymocytes. Moreover, this difference 
between CD4 thymocytes and LNC is even more pronounced if the 0X38 mAb was cross- 
linked using RaMo-antibody.
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Figure 5.6 Inhibition of anti-TCR induced proliferation of single positive CD4+Nt 
TCR+' e thymocytes and LNC by 0X38 mAb
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Immunopurified single positive CD4+ve aP T C R +ve thymocytes (upper panel) or CD4 ve T cells (lower 
panel) were treated in vitro using PBS (Control, lightly fdled columns), 0X 38 (0X38, open columns), and 
0X 38 which was cross-linked using Rabbit anti-Mouse antibody (OX38-XL, darker filled columns) and 
were activated using immobilised anti-a(5TCR mAb. Cell cultures were pulsed with 3H-Thymidine at 24 
and 48 hrs, harvested 18 hrs later onto microtitration filter paper, and analysed using a Beta Liquid 
Scintillation counter. The y-axis represents the cpm whereas the x-axis shows the time in hours when the 
cells were pulsed with 3H-Thymidine.
Following TCR activation, thymocyte cell pellets were analysed for cytokine message by RT- 
PCR. Briefly, tissue culture plates were centrifuged at 200 x g for 8 Min and supernatants
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removed so that mRNA could be harvested directly from the cell pellets. Each cell pellet was 
lysed as described in the Materials and Methods (Section 2.17.2) and mRNA extracted using 
Dynabead Oligo (dT)2 5  (DYNAL A.S. Oslo, Norway) direct mRNA kit. Following cDNA 
transcription of mRNA, RT-PCR was performed using primers specific for rat IL-2, INF-y, 
IL-4 and IL-10 cytokines. Figure 5.7 shows Polaroid photographic images obtained after 
stopping each RT-PCR reaction at five different cycle numbers and analysing the RT-PCR 
products by electrophoresis on 1% agarose gels and staining with Ethidium Bromide. The 
RT-PCR results show that anti-TCR activated thymocytes express high levels of both Thl 
(IL-2 and INF-y) and Th2 (IL-4 and IL-10) cytokines and that pre-treatment with 0X38 did 
not preferentially skew this pattern towards either a dominant Thl or Th2 response, 
irrespective of whether the 0X38 antibody was cross-linked or not. The results also show 
that, in keeping with the modest inhibiting effect of 0X38 on thymocyte proliferation, there 
was a small reduction in the cytokine message.
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Figure 5.7 Effect of 0X38 mAb pre-treatm ent on thymocyte cytokine message as 
determined by RT-PCR
Control 0X38 OX38-XL
24 27 30 33 36 24 27 30 33 36 24 27 30 33 36 cycle no.
29 32 35 38 41 29 32 35 38 41 29 32 35 38 41 cycle no.
< ^ 3 7 7  bp
34 37 40 43 46 34 37 40 43 46 34 37 40 43 46 cycle no.
^ - 3 7 2  bp
Immunopurified single positive CD4ne ocPTCR+ve thymocytes pre treated with PBS (Control), 0X38 
(0X38) and 0X38 which was cross-linked using Rabbit anti-IMouse antibody (OX38-XL), were activated 
using immobilised anti-aPTCR antibody. RNA was extracted from the activated cell pellets and RT-PCR 
performed using IL-2, INF-y, IL-4, and IL-10 specific primers. The cycle number for each cytokine are 
show n on the top of each figure and the size in base pairs (bp) shown on the right.
5.3 DISCUSSION
The immuno-regulatory mechanisms involved in the development o f  transplantation tolerance 
can be divided into two phases, namely the induction phase and the maintenance phase o f  
tolerance. During the induction phase, the tolerant state appears somewhat precarious and
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depending on the model employed, can be ‘broken’ by, for example, the administration of 
exogenous cytokines [182,251,308], by depleting CD4+ve [250,308] T cells or by temporarily 
removing alloantigen from the host animal [308]. Conversely, the maintenance phase of 
tolerance appears to be far more robust and is usually resistant to attempts at reversal by 
exogenous administration o f IL-2 or even injection of alloreactive lymphocytes. It is only 
during the maintenance phase of transplant tolerance that cells from tolerant animals are able, 
on adoptive transfer, to confer tolerance to new unmodified recipients [250,308,309], 
(“Infectious Tolerance”).
In the model of anti-CD4 induced tolerance utilised in this thesis, the induction phase of 
transplant tolerance was shown to be thymus dependent; thymectomised animals rejected 
their allografts with a MST of 11 days. This finding was of interest because it underscored 
two important issues concerning the mechanism responsible for tolerance in this experimental 
model. First; because CD4 T cell depletion following 0X38 treatment was no greater in 
euthymic than in thymectomised animals, (which promptly reject their cardiac allografts in 
the presence of 0X38 mAb treatment), it demonstrates that CD4 T cell depletion is unlikely 
to be responsible for tolerance in this model although, of course, CD4 T cell depletion may 
play an important contributory role. Second; because thymectomised, anti-CD4 treated 
animals reject their allografts with kinetics similar to unmodified animals, it indicates that 
residual T cells following 0X38 treatment are sufficient in number and function to initiate 
graft rejection. The results described in this chapter of the thesis also suggest that induction 
of transplant tolerance by 0X38 mAb requires additional events over and above ‘negative 
signalling’ of CD4 T cells. If ‘negative signalling’ occurs, it is clearly reversible.
Following partial depletion of peripheral CD4 T cells with 0X38 mAb, CD4 T cell numbers 
gradually recover and by day 100 following transplantation, T cell numbers have returned to
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near normal. Similarly, in T cell reconstitution experiments using congenitally athymic 
animals, adoptive transfer of mature thoracic duct isolated CD4 and CD8 T cells leads, over 
time, to the expansion of the transferred cells to levels comparable to those found in euthymic 
animals [310]. This underscores the point that the peripheral T cell pool is under strict 
homeostatic regulation, although the mechanisms responsible are not clear.
Following 0X38 treatment, CD4 depletion was far more marked in thymectomised than in 
euthymic animals. It is possible that the pressure to re-expand the peripheral CD4 T cell pool 
following 0X38 induced depletion, imposed on thymectomised anti-CD4 treated animals, is 
sufficient to overcome the ‘inhibitory’ effect of anti-CD4 treatment on residual T cells. Such 
a mechanism is unlikely, however, if one takes into consideration the survival data obtained 
when comparing 0X38 treated animals which were thymectomised on days >minus 40, 
minus 3 or plus 7 relative to transplantation. Altering the timing of thymectomy resulted in 
allograft survival in the two groups of animals undergoing delayed thymectomy groups (days 
minus 3 and plus 7 relative to transplant), and these animals are presumably comparable to 
the early thymectomised (day >minus 40 relative to transplant) anti-CD4 treated animals in 
terms of the pressure on the residual peripheral CD4 T cell pool to proliferate. Although T 
cell depletion was not formally measured and compared in these 3 groups of transplanted 
recipients, it is unlikely that the CD4 depletion observed in the group which had thymectomy 
>40 days before transplant would be significantly different to the other 2 experimental 
groups, with the exception that Thy-l+ve RTE would be absent at the time of transplant in the 
former group.
The thymus has a key role in producing all the apT  cell lineages. During maturation these 
cells develop in a stepwise fashion and are not complete until the single positive CD4+ve or 
CD8+ve stages are reached [311]. The thymus is also critical in the selection of T cells prior to
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exportation to the periphery in that developing thymocytes with TCR which recognise self 
antigens are deleted. It is easy to imagine that following transplantation, foreign antigens 
derived from transplanted organs, either in the form of intact donor cells or antigenic donor 
MHC peptides, could become entrapped within the recipient’s thymus gland, and as both 
CD45RC+ve and RC‘ve CD4+ve T cell subsets are known to re-circulate through the thymus 
[312], re-education of these circulating cells in response to donor antigen could occur and 
result in depletion or anergy of donor reactive clones. This model of tolerance has been 
termed central tolerance and has been shown to be important in several experimental systems, 
including tolerance induction in the rat [313]. Cutler and Bell induced tolerance in euthymic 
neonatal rats by injection of fully allogeneic bone marrow cells from athymic T cell deficient 
nude rats. Adult recipient animals were found to be chimeric, expressing the MHC and 
allotype marker of the donor strain, and accepted donor-specific skin allografts. Thymocytes 
were also shown to be chimeric but failed to respond in vitro to alloantigens of the donor- 
specific haplotype. Additionally, adoptive transfer of peripheral T cells from the tolerant 
euthymic adult animals to T cell deficient nude recipients bearing skin allografts of the same 
donor-specific haplotype, failed to initiate graft rejection in the nude recipients. This data 
suggests that clonal deletion, induced centrally within the thymus was responsible. As 
discussed earlier, thymectomy performed 3 days prior to introduction of graft alloantigen, 
resulted in long-term acceptance of cardiac allografts in the 0X38 mAb treated animals. 
Thus, altering the timing of *thymectomy and removing the thymus gland immediately prior
* All thymectomies were performed using microscopic magnification as described in the Materials and Methods
Section 2.7 and as previously published [314]. After completion of these studies, all thymectomised animals 
were sacrificed and examined by post mortem and none were found to have evidence of incomplete thymectomy.
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to transplantation still allowed 0X38 mAb induced tolerance. Consequently, central 
tolerance as an exclusive mechanism responsible for thymus dependent 0X38 mAb induced 
tolerance in this model can be discounted.
The observation that 0X38 treated recipients bearing a cardiac allograft, displayed marked 
depletion of functionally mature CD4+ve T cells, combined with preferentially sparing of 
RTE, was somewhat surprising. However, preliminary experiments performed in this 
laboratory by Dr. E Bolton, using CD4 enriched LNCs, has found that following 0X38 
treatment, there is a high degree of apoptosis (data not shown). Similar experiments using 
CD4 enriched thymocytes may reveal that thymocytes are less susceptible to anti-CD4 
activation induced apoptosis thus explaining the apparent sparing of RTE in this experimental 
model.
Taken together, these findings suggest a possible role for thymocytes or RTE, as opposed to 
thymic tissue, in 0X38 mAb induced transplant tolerance. Reconstitution of thymectomised 
anti-CD4 treated animals with CD4+ve T cell enriched thymocytes could re-establish 
transplant tolerance. However, the adoptive transfer results must be viewed with some 
caution. Negative selection of CD4 single positive T thymocytes by immuno-magnetic 
negative beading resulted in cell purities of only 84% single positive CD4+ve apTCR+ve cells, 
as measured by flow cytometric analysis. The majority of the ‘contaminating’ cells were 
CD8, CD4 and apTCR negative and may therefore, represent thymic epithelial and/or APCs. 
These cells could theoretically form satellite thymic elements following transfer although this 
seems somewhat unlikely. However, for this reason, future reconstitution experiments should 
include depletion with anti-MHC Class II antibody to minimise this risk and help clarify the 
importance of RTE cells in this system.
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Why should RTE contribute to 0X38 induced transplantation tolerance in the rat? One 
possibility is that RTE may behave as regulatory, or suppressor T cells. It was shown in this 
chapter that purified CD4+ve thymocytes were less susceptible to inhibition by 0X38 mAb 
than CD4+ve lymphocytes when activated using immobilised anti-TCR antibody. 
Additionally, anti-CD4 treated and activated thymocytes were found to produce both Thl and 
Th2 cytokine message, as detected by RT-PCR. This result is comparable with murine 
studies, using single positive (CD4+ve) thymocytes, which were found to secrete a broader 
range of lymphokines than peripheral lymphocytes, including interleukins 4, 5, and 10 andy- 
interferon [307]. Anti-CD4 treated or untreated RTE cells could aggregate to form a T cell 
cluster and, by producing a mixture of cytokines, create a local micro environment which 
favours tolerance and which suppresses potentially alloreactive mature CD4 T cells, in a 
fashion analogous to that proposed by Waldmann’s group. These, workers suggest that naive 
ThO cells aggregate at a cell cluster and produce low levels of IL-2 with moderate secretion of 
IL-4 and INF-y. They propose that this particular combination of cytokines promotes anergy 
in the mature CD4 T cell population, and they have coined the phrase “infectious tolerance” 
to describe it [206].
Another explanation as to why RTE may be important in anti-CD4 induced tolerance, is that 
they (perhaps with or without alloreactive CD8 T cells which on their own are incapable of 
initiating graft rejection) may compete with alloreactive CD4 T cells for locally produced 
growth factors and or costimulatory molecules expressed on the cell-surface of APCs. 
Consequently, the CD4 T cells may be deprived of either appropriate pro-proliferative 
lymphokines and/or second signal costimulation. 0X38 treated alloreactive CD4 T cells 
which would otherwise have been capable of overcoming ‘negative signalling’ and initiating
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graft rejection, may then proceed to a tolerant state and in turn, result in a ‘feedback loop’, 
helping to perpetuate further tolerance induction in other emerging T cells.
The importance of the thymus and/or RTE in adoptive transfer studies where adoptively 
transferred thymectomised animals were found to reject their grafts with kinetics similar to 
control animals was not investigated further here. The role of the thymus in these 
experiments may be a result of any or all of the mechanisms discussed above working either 
independently or together. Further clarification of this complex system will require much 
more experimental work.
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5.4 KEY POINTS
• Adult thymectomy >40 days prior to 0X 38 mAb treatment negates the effectiveness 
of anti-CD4 to induce tolerance to a cardiac allograft and abolishes the ability to 
confer “infectious” tolerance in adoptive transfer studies.
• Thymectomised animals have less circulating CD4 lymphocytes but display the same 
magnitude of CD4 T cell depletion as euthymic treated animals following 0X38  
mAb treatment.
• In thymectomised anti-CD4 mAb treated animals, there is no evidence for 
preferential depletion of the CD45RC+ve T cell subset, and in this respect, they 
contrast with euthymic 0X 38 mAb treated rats.
• Thymectomy on the day of first anti-CD4 treatment (day minus 3 relative to 
transplant), and reconstitution of adult thymectomised anti-CD4 mAb treated 
animals with purified single positive CD4+ve thymocytes results in long-term 
allograft survival, suggesting a role for RTE and not the presence of intact thymic 
tissue in tolerance induction.
• Single positive CD4+ve thymocytes proliferate well in response to immobilised anti- 
TCR stimulation, irrespective of in vitro 0X38 pre-treatment, and produce both Thl 
and Th2 cytokines as measured by RT-PCR.
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6. Final Discussion
Despite many advances in immunosuppression therapy, such as the combined use of 
Azathioprine and Prednisolone in the 1960’s [315], the introduction of Cyclosporin A in the 
late 1970’s [316] and the development and use of newer agents inhibiting T cell activation 
and proliferation such as Tacrolimus [317,318,319], Rapamycin [318,319] and 
Mycophenolate Mophetil [320], in most centres, recipients of first cadaveric renal allografts 
still only display 3 year graft survival rates of 70% [321].
The use of mAb therapy in clinical transplantation, notably the mouse mAb OKT3, (directed 
against the conformational epitope formed between CD3s and either CD36 or CD3y) [322], is 
often effective in reversing acute rejection episodes [323,324,325], but does not induce 
transplantation tolerance. Similarly, other mAb treatments, such as anti-CD4, which 
successfully induce transplantation tolerance in rodents, fail, when applied to human 
transplantation to produce transplant tolerance. One reason why mAb which induce 
transplantation tolerance in rodents are less effective in humans, may be because there are 
differences in the tissue distribution of MHC antigens between the two species. In particular, 
Class II MHC antigens are not expressed constitutively on the vascular endothelium in 
rodents [326,327], whereas in humans, Class II MHC antigens are constitutively found on 
vascular endothelium [328]. Nevertheless, understanding the mechanism of action o f mAb 
induced transplantation tolerance in animal models, such as the one described in this study, 
combined with a better understanding of the physiological differences between the species, 
may lead to more effective application of immunosuppressive therapy in human 
transplantation. Ultimately, this understanding, may help achieve the goal of inducing
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allograft tolerance in the clinic without the need for continuous administration of non-specific 
anti-rejection agents.
The results described in this thesis show that a brief pre-operative course of anti-CD4 mAb, 
(MRC 0X38), leads to donor specific transplant tolerance in the Lewis to DA rat strain 
combination. Transplantation tolerance was associated with partial (50%) depletion o f CD4 
T lymphocytes, with preferential sparing of RTE (CD4+ve CD45RC've Thy-lhlgh). The 
cytokine RT-PCR data obtained from tolerant and rejecting cardiac allografts and the 
alloantibody responses of transplanted animals, did not suggest that tolerance achieved with 
0X38 mAb in this particular experimental model could be explained by a shift from a 
‘detrimental’ Thl to a ‘beneficial’ Th2 type of cytokine response. Anti-CD4 mAb was found 
to influence the residual non-depleted CD4 T cell pool, since cells displayed altered 
intracellular signalling in response to apTCR activation and the alteration observed was 
similar to the signalling defects described previously in anergic T cells [285,286].
The role o f the thymus gland in transplantation tolerance in this experimental model was also 
assessed. Anti-CD4 induced transplantation tolerance and adoptive transfer of tolerance from 
long-term tolerant animals to untreated thymectomised recipient animals were both found to 
be thymus dependent. A possible role for RTE in 0X38 mAb induced tolerance was 
indirectly explored by studies using single positive (CD4+ve oc(3TCR+ve) thymocytes and LNC. 
In reconstitution experiments using thymectomised anti-CD4 treated animals, adoptive 
transfer of single positive thymocytes, restored the ability of 0X38 mAb to prolong allograft 
survival in thymectomised animals. Furthermore, using apTCR proliferation assays, single 
positive thymocytes were found to be less affected by anti-CD4 mAb in vitro than single 
positive LNC and thymocytes still produced both Thl and Th2 cytokine mRNA upon 
activation.
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These data suggest that in the Lewis to DA heterotopic cardiac transplantation model, 0X38 
mAb may preferentially deplete T effector cells capable of initiating allograft rejection and 
render the residual T cell pool transiently incapable of normal activation and in a state which 
may favour anergy induction. RTE may provide the key for lasting tolerance induction in this 
experimental model by producing both Thl and Th2 cytokines when in contact with 
alloantigen. One may speculate that, like the model proposed by Cobbold and collegues 
[206], a cellular collaborative unit may involve competition for the cell-surface of an APC 
between 0X38 mAb treated RTE, 0X38 mAb treated Thl or Th2 CD4+ve T cells and/or 
CD8+ve T cells. In the absence of high levels of IL-2, the RTE, by producing low levels of IL- 
4, may induce the anti-CD4 treated allo-specific mature CD4+ve T cells to become anergic. 
Furthermore, when IL-2 levels are reduced, secretion of INF-y and TGF-p may further 
increase MHC expression and antigen presentation on the surface of the APC, without 
increasing expression of costimulatory molecules. This would make it more likely that 
CD4+ve T cells which had ‘recovered’ from anti-CD4 mAb treatment and/or CD8+ve T cells, 
would encounter antigen on the surface of an APC but fail to receive appropriate 
costimulation, driving them towards the anergic state. One can postulate that, if by 
thymectomy, RTE are removed from this system, then mature CD4+ve T cells which had 
‘recovered’ from anti-CD4 treatment may be the principle cytokine producers at the cell- 
surface of an APC. After antigen contact, these cells could produce high levels of IL-2 in 
conjunction with other cytokines and could initiate allograft rejection. Clearly, this scenario 
entails a considerable degree of speculation, but does provide a possible explanation for the 
observations made in this thesis.
Further studies to ascertain both the qualitative and quantitative nature of cytokine secretion 
by RTE, coupled with a better understanding of the influence of the RTE cytokine profile on
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mature CD4 T cells, are needed to determine the role of RTE in 0X38 mAb induced 
transplantation tolerance. Such data may then provide a rational basis from which to devise 
strategies for manipulating human T cell responses following transplantation. Use for 
example of appropriate anti-CD4 mAb, may allow a ‘favourable’ cytokine profile to be 
produced by cells contacting alloantigen, and lead to lasting tolerance, without the need for 
long-term immunosuppression.
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